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I. Aims 
 
The first aim of the present master thesis is the synthesis of a series of novel chiral 
stationary phases (CSPs) for high performance liquid chromatography (HPLC). In 
particular the focus is placed on weak anion exchange (WAX) type CSPs. Therefore 
two different types of linkers (one allylated and one propargylated), which are 
supposed to serve as immobilization anchor onto preactivated silica, should be 
synthesized. These linkers should be connected to two basic modules derived from 
cinchona alkaloids, namely dihydroquinine and dihydroquinidine, via carbamoyl bond 
with the secondary hydroxylic group. We assume that these reactions would lead to 
four different selectors, from which a series of CSPs should be prepared.   
The second aim is the subsequent evaluation of the synthesized CSPs in terms of 
their chiral separation ability towards chiral acidic compounds, in particular N-
protected amino acids, N-protected aminosulfonic acids, N-protected 
aminophosphonates and carboxylic acids. A small set of basic and zwitterionic 
compounds serves as a proof of principle to ascertain an anion exchange 
mechanism. 
Moreover, the influence of different immobilization strategies, endcapping as well as 
immobilization controllability should be evaluated. Assuming controlled loading of the 
selectors, we aim to evaluate the influence of the selector density on the silica 
surface on the overall performance of the new CSPs. Subsequently, the column with 
the best enantioseparation capabilities should be compared to commercially 
available chiral anion exchangers.  
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1. Introduction 
 
The separation of chiral compounds into single enantiomers is an important aspect 
of analytical and preparative issues including the enantioseparation of chiral drugs 
[1-6], purity determination of pharmaceutical products [7-11], drug development 
[12, 13], separation of chiral synthons [14] or bioactive compounds [15-17] and in the 
flavor and fragrance field [18, 19]. The chiral separation is also required for the 
analysis of food contaminants [20] and environmental pollutants [21-23]. Nowadays, 
all pharmacokinetic profiles of optically active drugs need to be determined 
stereoselectively [14].  
Besides liquid chromatography, various methods such as capillary electrophoresis 
(CE) [11], supercritical fluid chromatography (SFC) [14], gas chromatography (GC) 
[24], simulated moving bed technology (SMB) [25], enzymatic resolution [26] and 
crystallization [27] are used to separate enantiomers either on analytical or 
preparative scale. 
 
1.1. Principles of Chirality 
 
The term chirality is derived from the Greek word χειρ (hand) and means 
handedness. Chiral molecules do have the same atomic composition, they are 
structural isomers, which have the same constitution, but are not superimposable. 
Stereoisomers can be classified into diastereomers and enantiomers. Both differ in 
terms of symmetry and energy level. Diastereomers possess no mirror images in 
terms of symmetry and they have distinct energy content. Enantiomers are 
structurally non-superimposable mirror images with identical level of energy. A left 
and a right hand represent an ideal model of enantiomers. Chiral molecules contain 
no rotation-reflection axis, mirror plane or a center of inversion [14, 28]. 
We cannot distinguish enantiomers in an achiral environment. They have the same 
physical properties (e.g. melting point) except for the behavior towards polarized 
light, which in turn represents a chiral environment. A 1:1 molar mixture of two 
enantiomers is called racemate or racemic mixture. The overall optical rotation for a 
racemic mixture is zero because both of the enantiomers are optical isomers with 
exactly opposite rotation of polarized light [14, 29]. 
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Chirality is grounded in various chiral elements [14, 30]: 
 
• center of chirality (e.g. tetra-coordinated carbon with four different 
substituents) 
• chiral axes (e.g. ortho-substituted biphenyls) 
• chiral planes (e.g. substituted paracyclophanes) 
• chiral helices (e.g. deoxyribonucleic acid - DNA) 
• topologically chiral elements (e.g. iron-sulfur proteins [31]) 
 
Chiral molecules do have a key role in living systems. Almost all natural strains of 
amino acids and sugar molecules consist of only one enantiomer. Naturally occurring 
proteinogenic amino acids largely consist of the (S)-form, while the majority of sugar 
molecules found in living organisms have the (R)-form. Since amino acids are 
building components for proteins and sugars are building blocks of polysaccharides 
like cellulose (helical structure) or starch, chirality can be found throughout all living 
systems [32, 33]. 
 
CH3
H3C CH2
CH3
H3C CH2
(R) (S) 	  
 
Figure 1.1.: The two stereoisomers of limonene; 
left hand side: (R)-limonene, right hand side: (S)-limonene. 
 
Due to the chiral nature of all living systems exogenic chiral compounds like food 
additives (e.g. flavors) and drugs are recognized by sensory organs and metabolized 
by enzymes stereoselectively. One renowned example for the different recognition of 
enantiomers by sensory organs is limonene. In figure 1.1. the structures of the two 
enantiomers are given. The (R)-enantiomer has a fragrant smell of orange, the 
(S)-enantiomer of this flavor has turpentine odour [14]. 
Another prominent examples for the different effect of enantiomers in terms of 
pharmaceutical responses are levopropoxyphen and dextropropoxyphene. The first 
mentioned (2R,3S)-levopropoxyphene has antitussive activity, whereas the 
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(2S,3R)-enantiomer dextropropoxyphene is an analgesic agent. Due to the different 
medical effects of enantiomers it is of utmost importance to administer the right 
stereoisomer [14]. 
The drug Contergan® is probably the most famous and tragic example for the 
importance of chirality in terms of drug effects. The active substance thalidomide (the 
structure is depicted in figure 1.2.) exists in two enantiomeric forms. Thalidomide 
was prescribed in the late 1950s as a sedative with anti-nausea effect for treating 
insomnia and morning sickness of pregnant women. In those days thalidomide was 
administered as racemic mixture. The drug was withdrawn in 1961 due to the terrible 
teratogenic effect [34]. In later investigations it could be shown that only the 
(R)-enantiomer shows beneficial effects (so-called eutomer) and the (S)-enantiomer 
(so called isomeric ballast or distomer [26]) is responsible for the teratogenic 
behavior. However, the administration of the single (R)-enantiomer would not 
contribute to a less teratogenic effect because thalidomide shows rapid in vivo chiral 
inversion and therefore racemization [35].  
 	  
N
O
O
NH
O
O*
 
 
Figure 1.2.: Structure of thalidomide. 
 
1.2. Separation of Enantiomers 
 
As already mentioned above enantiomers do have identical physical and chemical 
properties [30] except their exactly opposite behavior towards polarized light. In an 
achiral environment one cannot distinguish between enantiomers or separate them 
from each other. Basically there are two main strategies for separating enantiomers. 
Both deal with the general approach of forming diastereomers, either via covalent 
bonding or formation of labile diastereomeric associates. Figure 1.3. illustrates these 
two basic concepts. 
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Figure 1.3.: The two basic concepts of enantioseparation; 
adapted and modified from [14]. 
 
In the indirect approach a pair of chemically stable diastereomers with an 
enantiomerically pure auxiliary, a chiral derivatizing agent (CDA), is formed. This 
reaction must proceed quantitatively. Since a covalent bond between selectand (SA) 
and CDA is formed, the separated diastereomers must be cleaved after separation 
to give an enantiomerically pure product. This is one drawback of the indirect 
method. Of course no racemization of the starting compounds and no kinetic 
racemate resolution must happen. For the separation no chiral environment and 
separation system is necessary because diastereomers differ in their 
physicochemical properties. Therefore reversed phase (RP) or normal phase (NP) 
chromatography is often sufficient for the separation of organic molecules 
[14, 30, 36]. 
The direct approach is based on the formation of a diastereomeric pair of molecule 
associates. This formation must be reversible (non-covalent binding). Two 
enantiomeric SAs interact with the enantiomerically pure chiral selector (SO), which 
is e.g. immobilized on a silica surface for chiral stationary phase (CSP) mode in an 
HPLC separation system. If the binding strength differs for both of the SAs (due to 
differences in energy content and therefore unequal thermodynamic complex 
stabilities and equilibrium constants) they are separable due to different retention. 
Another experimental mode for the direct approach would be the chiral additive 
mobile phase mode, which is of little importance nowadays [14, 30]. 
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The interaction of SA with SO in the direct approach for the separation of 
enantiomers can be explained by thermodynamic considerations (van´t Hoff 
analysis) and a basic interaction model called three-point attachment [37]. 
 
1.3. Three-point Interaction Model 
 
This model was proposed in 1952 by K. Dalgliesh [14, 38]. Although this model is not 
free of criticism and its validity is still under debate (e.g. a four-location model was 
proposed by Mesecar and Koshland in 2000 for describing the enantiodiscrimination 
ability of proteins and enzymes [39]), it visualizes the direct approach of 
enantioseparation using liquid chromatography and chiral stationary phases.  
In figure 1.4. the three-point interaction model is illustrated. An enantiomerically pure 
selector (SO) is immobilized on a silica surface representing a chiral stationary 
phase. This selector contains three theoretical interaction sides (A, B and C), which 
can interact with a potential chiral selectand via three binding sites (SA; a, b and c). 
These non-covalent interactions and bonds can be of electrostatic nature like ionic 
interaction, Van der Waals forces like dipole-dipole, dipole-induced dipole and ion-
dipole interactions and/or hydrogen bonding, π-π-interactions, hydrophobic 
interactions and a steric influence as well. The interaction must not be of attractive 
nature; repulsive interaction can also be involved in the three-point interaction [40]. 
In case of an “ideal fit“ all three interactions are complementary and match perfectly. 
One example for a complementary interaction would be e.g. an interaction between 
a hydrogen donating amino group of a SO and a hydrogen accepting carbonyl group 
of a SA. The “ideal fit” situation results in strong non-covalent bonding of SO and SA, 
and therefore high retention for the (S)-SA in the case shown below.  
A “non-ideal fit” situation results in for example just one complementary interaction 
and therefore the interaction strength is weaker in comparison to the “ideal fit”. 
Therefore the (R)-SA is lower retained and elutes before the (S)-SA.  
This result is also indicated by a lower association constant (KS > KR). Due to the 
resulting difference in retention times enantioseparation can be observed [14, 41]. 
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Figure 1.4.: Visualization of the three-point interaction model; 
adapted and modified from [40]. 
 
1.4. Thermodynamic Aspects of Enantioseparation 
 
Enantioseparation is of course influenced by temperature. All chromatographic 
parameters like column efficiency, resolution, enantioselectivity and retention are 
influenced by changes in temperature. Thermodynamic considerations can be 
applied for the reversible formation of a SO--SA complex both for the (R)-SA and the 
(S)-SA. Different affinities of enantiomeric SAs to a chiral SO are described by 
changes of the Gibbs free energy ΔG0(R) and ΔG0(S) in the free and complexed form.  
The equilibrium processes can be described with the equilibrium binding constant Ki 
according to equation [1.1] (subscript i denotes the respective enantiomer), which 
combines the difference in free energy ΔG0(i) and Ki, wherein R is the universal gas 
constant (8.314 J.K-1.mol-1) and T the absolute temperature in Kelvin:  
 Δ𝐺!! = −𝑅𝑇 ∙ 𝑙𝑛𝐾!                     [1.1] 
 
The Gibbs free energy consists of an enthalpic (ΔH(i)) and entropic part (ΔS(i)). This 
fact is represented by the Gibbs-Helmholtz equation (see equation [1.2]): 
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Δ𝐺!! = Δ𝐻!! − 𝑇Δ𝑆!!                    [1.2] 
 
A simple combination of equation [1.1] and [1.2] results in the van´t Hoff equation, 
which is depicted in equation [1.3]: 
 ln𝐾! = − !! !!!!! + !!!!!                     [1.3] 
 
This linear equation can be used for van´t Hoff thermodynamic analysis by simply 
plotting ln Ki vs. 1/T. The intercept reflects the change of entropy ΔS0(i), whereas the 
slope represents the change of entropy ΔH0(i). The enantioselectivity α, which is the 
quotient between the retention factors ki of one pair of enantiomers (see 
equation [3.2] in chapter 3.4. and equation [1.6]), is described as the difference 
between Gibbs free energy changes upon interaction of one SA with the SO over the 
other SO--SA associate. Under the assumption that KS > KR (retention for the 
(S)-enantiomer is higher) one can deduce equation [1.4]: 
 ΔΔ𝐺!,!! = Δ𝐺!! − Δ𝐺!! = −𝑅𝑇 ∙ 𝑙𝑛 !!!! = −𝑅𝑇 ∙ 𝑙𝑛𝛼                [1.4] 
 
This equation can again be combined with the Gibbs-Helmholtz relationship, which 
results in equation [1.5]: 
 lnα = − !! !!!!!! + !!!!!!                    [1.5] 
 
The expression above links the experimentally determinable enantioselectivity 
coefficient α and the absolute temperature with the differential enthalpy ΔΔH0(i) and 
entropy ΔΔS0(i) of enantioseparation. Note that the enantioselectivity coefficient α 
depends on two chromatographic parameters - the retention factor ki and the phase 
ratio Φ (quotient between the volume of the stationary and the mobile phase) - as 
presented in equation [1.6]:  
 α = !!!! = !!⋅!!!⋅!                    [1.6] 
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Based on experimental results one can assume that enantioseparation processes 
are usually controlled by enthalpic contributions [40, 42, 43]. 
 
1.5. Chiral Stationary Phases  
 
For a successful separation of enantiomers two major parameters are important. The 
first is the selection of an appropriate chiral stationary phase (CSP), which is able to 
separate the selected compounds. The second important parameter is the choice of 
the mobile phase conditions to yield retention and separation. In this chapter the 
main groups of CSPs and chiral selectors (SOs), respectively, are briefly described. 
 
In principal one can distinguish between three different types of CSPs: 
 
• Brush type: The chiral selector is immobilized via a spacer on an organic or 
inorganic support like silica. For chiral anion exchange purposes the most 
common type is the brush type CSP.  
• Organic polymer type: Either the pure crosslinked chiral polymer serves as 
CSP or an organic polymer is coated onto the surface of a support material. 
Grafted polymers on a support material are also possible.  
• Molecular imprinted polymer type: In this case either the pure polymer itself is 
imprinted and serves as CSP or the imprinted polymer is surface-grafted onto 
silica [14]. 
 
The chiral selectors can be grouped into low-molecular mass selectors, macrocyclic 
and macromolecular selectors. 
An overview of these chiral selectors is depicted in figure 1.5., for a more detailed 
description also with respect to advantages and disadvantages of every single CSP 
and selector type see [14, 40, 41]. Hereafter only the chiral anion exchange type is 
discussed in a more detailed view because the aim of the thesis was the synthesis 
and evaluation of weak anion exchange (WAX) type CSPs for liquid 
chromatography. 
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Figure 1.5.: Overview of the different types of chiral selectors; data collected from [14]. 
 
1.6. Chiral Ion Exchange  
 
In the field of chiral ion exchangers one can distinguish between anion, cation and 
zwitterionic type CSPs. All three types were developed, among others, in our 
working group. 
 
1.6.1. Cation Exchange type CSPs  
 
For a chiral cation exchange stationary phase a chiral acidic SO has to be 
immobilized on a silica surface. Acidic compounds, which are suitable for cation 
exchange, are e.g. carboxylic acids used as weak cation exchangers (WCXs). 
Strong cation exchangers (SCXs) can be based e.g. on sulfonic acids. Other 
possibilities would be the use of sulfinic, phosphoric, phosphonic or phosphinic 
acids. Hoffmann and Lindner have recently developed a novel type of SCX-CSPs 
[44]. They immobilized a SO based on a chiral 2-aminocyclohexanesulfonic acid 
(ACHSA) derivative and were able to separate basic compounds (chiral organic 
amines) such as common drugs like bupranolol, clenbuterol, quinine, terbutalin and 
others under a polar organic mode mobile phase condition. The structure of one 
SCX-CSP is shown in figure 1.6. with (1R,2R) configuration of the ACHSA residue. 
 Chiral 
Selectors 
Macromolecular 
Selectors 
 
•   Biopolymers (e.g. 
proteins, 
polysaccharides) 
•   Synthetic polymers 
(e.g. polyacrylamides) 
Macrocyclic 
Selectors 
 
•   Cyclodextrins 
•   Macrocyclic antibiotics 
•   Chiral crown ethers 
•   Calixarenes 
Low-molecular 
mass selectors 
 
•   Donor-acceptor 
selectors (Pirkle-type) 
•   Chiral ion exchange 
•  Ligand exchange 
(chelating agents) 
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This selector contains two chiral centers in position 1 and 2. The same selector with 
just opposite configuration (1S,2S) was as well synthesized and immobilized on 
silica by Hoffmann et al. [44] and successfully employed as CSP. Between these two 
CSPs it was possible to achieve reversal of the elution order due to enantiomeric 
behavior of the two selectors. 
 
Cl
Cl
O
O
HN
O3SNH4
(1R)
(2R)
S
 
 
Figure 1.6.: Structure of the SCX-CSP; adapted and modified from [44]. 
 
Under basic mobile phase conditions (e.g. addition of diethylamine DEA or 
diisopropylethylamine DIPEA as a buffer component) the selector is deprotonated 
and therefore cation exchange as a primary retention effect is possible. Further on 
hydrogen bonding via the amide -NH as donor and the amide carbonyl as acceptor is 
possible. The π-acidic dichloro-substituted aromatic moiety is capable of 
π-π-interactions.  
 
1.6.2. Zwitterion type CSPs  
 
This type of CSPs contains both anion exchange type structural motifs as well as 
cation exchange type motifs. The fusion of them results in zwitterionic exchange type 
(ZWIX) CSPs, which were recently developed by Hoffmann et al. [33, 45] in our 
working group. A big advantage of this type of CSPs is the broad applicability in 
terms of separable compounds. Both anions as well as cations can be separated. 
The list can further be extended to zwitterionic SAs such as proteinogenic amino 
acids, drugs like DOPA (3,4-dihydroxyphenylalanine) and aminosulfonic acids (e.g. 
ACHSA).  
In figure 1.7. the structure of a selected ZWIX-CSP invented by Hoffmann et al. in 
2008 [45] is shown. It is a synthetic combination of quinine-type WAX (red colored) 
and ACHSA-type SCX (blue colored). 
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The selector itself is a zwitterion in protonated form of the quinuclidine ring of the 
quinine moiety and deprotonated form of the sulfonic group at the ACHSA moiety. 
 
N
O
O NNH
O
(9R)
(8S)
S
H
H
O3S
(1"S)
(2"S)
 
 
Figure 1.7.: ZWIX-CSP developed by Hoffmann et al. 2008; 
adapted and modified from [45].  
 
The charge state is dependent on the mobile phase conditions. During retention one 
charged moiety can act as an intramolecular counterion and therefore the 
concentration of buffer salts in the mobile phase can be reduced [46]. 
In the case of the ZWIX-CSP shown in figure 1.7. various interactions with a 
potential chiral analyte are possible. Primary ionic interaction due to the charged 
quinuclidine ring and the sulfonic acid group of the ACHSA residue, hydrogen 
bonding via the carbonyl and -NH of the carbamate bridge, π-π-interaction because 
of the aromatic quinoline ring and a sterical influence as well. The overall interaction 
results in a potential ability for chiral recognition and therefore enantioseparation.  
 
1.6.3. Anion Exchange type CSPs  
 
Because of a broad range of chiral acidic compounds used e.g. as drugs or 
agrochemicals (see above) separation of these compounds and analysis of the 
enantiomeric ratio is an important task in analytical chemistry. The enantioseparation 
is possible via anion exchange type CSPs with immobilized selectors containing 
ionizable primary, secondary, tertiary or constantly charged quaternary amines, 
whereas quaternary amines represent the strongest anion exchange type SOs.  
One important group of weak anion exchangers (WAXs), namely O9-tert-butyl 
carbamate derivatives of the cinchona alkaloids quinine and quinidine, were invented 
by Lindner and Lämmerhofer and have been commercialized under the trade name 
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CHIRALPAK® QN-AX and QD-AX by Chiral Technologies [13]. In figure 1.8. the 
structures of these two CSPs are shown.  
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Figure 1.8.: Structures of CHIRALPAK® QN-AX and QD-AX CSPs; 
adapted and modified from [47, 48].  
 
With this type of CSP various interactions are possible which are discussed below 
(see chapter 1.7.). Primary ionic interaction takes place via the protonated tertiary 
amine in the quinuclidine ring under acidic mobile phase conditions. The only 
conformational difference between QN-AX and QD-AX are the centers of chirality in 
position 8 and 9. QN-AX possesses (8S,9R) whereas the pseudoenantiomeric 
QD-AX [13] has (8R,9S) configuration. All the other centers of chirality (located at the 
quinuclidine ring, position 1 = chiral tertiary amine) are of the same absolute 
configuration (1S,3R,4S). 
The selectors in case of QN-AX and QD-AX are immobilized via the vinyl group 
(positions C10, C11) of the quinuclidine ring. One advantage of the naturally 
occurring and relatively cheap quinine (QN) and quinidine (QD) is that immobilization 
is possible without further derivatization. The immobilization is carried out with 
radical thiol-ene addition onto mercaptopropyl-modified silica. 
In former studies, native QN and other cinchona alkaloids have been used as chiral 
selectors with rather inadequate performance [13]. Therefore the secondary alcohol 
group of cinchona alkaloids at position 9 was derivatized with a vast number of 
functional groups resulting in the formation of ethers, amides, esters, sulfonamides 
and hydrazine derivatives. All these selectors where evaluated in terms of their 
applicability for chiral separations, but the carbamate derivatives, especially tButyl 
carbamate of QN and QD, provided high enantioselectivities for a broad range of 
selectands including N-protected amino acids, N-protected aminosulfonic acids, 
N-protected aminophosphonates and carboxylic acids (see chapter 3) [13]. 
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1.7. Retention Mechanism for N-protected amino acids  
 
A retention mechanism for chiral acidic analytes can be explained on the basis of a 
strongly retained compound. As a model CSP in former studies commercially 
available Chiralpak® QN-AX tButyl carbamoylated quinine (the structure is given in 
figure 1.8. above) has been used. This CSP demonstrates extraordinary high 
enantioselectivities, e.g. for N-3,5-dinitrobenzoylated (DNB) amino acids like 
DNB-Leu (α > 15 [13]). In this case the (S)-enantiomer of DNB-Leu shows much 
higher retention compared to the respective (R)-enantiomer.  
Due to the very strong interaction between stationary phase and the above-
mentioned (S)-compound it was possible to elucidate a tentative chiral molecular 
recognition mechanism via a multidisciplinary approach using complementary 
methods like X-ray crystal structure analysis of co-crystallized selector and 
enantiomerically pure DNB-(S)-Leu, molecular modeling approaches, density 
functional theory calculations, FTIR, 1H-NMR, VCD, CD, UV spectroscopy and 
thermodynamic studies [13]. 
The primary driving force for retention is the formation of an ion-pair at the 
quinuclidine ring of the selector. Therefore the bicyclic tertiary amine ring has to be 
positively charged due to protonation under slightly acidic mobile phase conditions 
and the associated SA must be simultaneously deprotonated and therefore 
negatively charged under the same conditions. The protonated amine is then 
capable of forming non-directed, strong and long ranged Coulomb attraction with the 
SA. This ion pairing mechanism is the dominating factor for retention.  
Besides this primary attraction various intermolecular interactions (all of them of non-
covalent nature) stabilize the SO-SA complex:  
 
• Face-to-face π-π-stacking between the electron rich π-basic quinoline 
ring of the SO and the electron poor π-acidic aromatic moiety of the SA. 
• Directed intermolecular hydrogen bonding between the C=O of the SA 
and the carbamoyl -NH of the SO. 
• Van der Waals interactions. 
• A second hydrogen bonding between the amide -NH of the SA and the 
carbonyl of the SO carbamate. 
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• Steric interaction due to the sterically demanding tButyl residue of the 
SO and the flexible leucine moiety of the SA [13, 49, 50]. 
 
All these interactions together with the tight ion pairing primary force result in a high 
degree of enantioselectivity. In figure 1.9. a complexation model for the interaction 
between the carbamoylated QN selector and DNB amino acids as well as 
DNP amino acids is shown.  
 
Figure 1.9.: Tentative chiral recognition model for a carbamoylated QN selector; 
(A) DNB amino acids; (B) DNP amino acids; RSA = 2-methylpropane (Leu); RSO = tButyl; 
adapted and modified from [50]. 
 
The respective DNB-(R)-Leu enantiomer is much less retained in comparison to the 
(S)-enantiomer. The reason for this observation is a steric exclusion process. The 
(R)-enantiomer is not capable of forming a strong SO--SA complex, because of the 
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lack of accommodation in the well-defined binding pocket of the selector. Therefore 
stabilizing secondary interactions like hydrogen bonding and π-π-stacking cannot be 
achieved by the SA and the resulting overall retention is weak [13]. 
The importance of hydrogen bonding for enantioselectivity can be shown with 
DNB-N-methyl leucine. The only structural difference in comparison to DNB-Leu is, 
that the hydrogen of the amide is replaced by a methyl group. For this compound no 
enantioseparation was possible, a result that clearly shows the importance of 
hydrogen bonding in terms of chiral recognition or selectivity [49]. 
Another example for the hydrogen bonding influence is the interaction of the SO with 
a structurally similar compound, namely N-2,4-dinitrophenyl (DNP) leucine (see 
figure 1.9.). The lack of a carbonyl in the protecting group of leucine results in a 
significantly lower enantioselectivity coefficient and a reversal of elution order in 
comparison to the structurally related DNB-Leu compound [50]. 
 
1.8. Stoichiometric Displacement Model 
 
As already mentioned above an ion exchange retention mechanism is reasonable for 
describing the interactions between cinchona based chiral selectors and acidic 
analytes. Besides the interactions taking place between SO and SA the mobile 
phase and its composition contributes to retention in a crucial way. Therefore the 
so-called stoichiometric displacement model allows explaining the dependency of 
retention times on the buffer concentration in the mobile phase, assuming that the 
pH-value stays constant (if one can speak of pH-value in polar organic mode 
consisting for example of MeOH as a bulk phase). A linear relationship between 
log k vs. log [X] (log of the counterion concentration in [mol.L-1]) indicates an ion 
exchange mechanism (equation [1.7]).  
 log 𝑘 = log𝐾! − 𝑍 ∙ log[𝑋]                    [1.7] 
 
This linear relationship demonstrates an important aspect of the stoichiometric 
displacement model. The higher the counterion-concentration, the lower the 
retention is. The counterions are also retained and act as a displacer for SA 
molecules. Due to this equation it is easily possible to adjust the retention times by 
simply diluting the mobile phase or adding buffer in a higher concentration. 
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However, for preparative purposes and mass spectrometric detection high buffer 
concentrations (and especially non-volatile buffers) should be avoided.  
The slope Z in equation [1.7] is an empirical coefficient that contains information on 
how many charges in the ion-exchange process are involved (equation [1.8]): 
 𝑍 = !!                       [1.8]
   
The divisor n is the effective charge number of the mobile phase counterion and the 
dividend m is the effective charge number of the selectand ion. One can see that an 
increase of the charge number of the counterion results in a flatter slope (e.g. citrate 
in comparison to acetate). In terms of elution strength the order citrate > phosphate > 
formate ≥ acetate can be seen as a rule of thumb [13,	  51]. 
If the slope is as steep/flat for both enantiomers, they both respond with the same 
sensitivity to an alteration of the counterion concentration in the mobile phase. 
Therefore the linear regressions are parallel for both stereoisomers. One additional 
aspect is that the selectivity coefficient stays almost constant, independent of the 
counter ion concentration. This allows an easy adjustment of the retention times.  
The intercept KZ in equation [1.7] is a system-specific constant, which is related to 
the mobile phase volume V0 [L], the number of available ion-exchange sites qx 
(representing the surface charge density [mol.m-2], the area of the surface S [m2.g-1] 
and the ion-exchange equilibrium constant K [L.mol-1]. All these parameters are 
expressed in equation [1.9] [40, 51]:   
 𝐾! = !∙!∙ !! !!!                       [1.9] 
 
In the case of cinchona alkaloid based selectors one should not forget that the anion-
exchanger itself is a weak base and therefore acid-base equilibria have to be 
considered. In equation [1.10] the retention factor k is expressed taking these 
dissociation equilibria into account by the mass action model: 
 𝑘 = 𝜙 ∙ !∙[!"!]∙[!"!]!! ∙ !"! ![!"#]                   [1.10] 
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𝜙  phase ratio  
K  ion-exchange equilibrium constant 
[SO+]  concentration of protonated active ion-exchange sites  
[SA-]  ionized, deprotonated SA 
[X-]  concentration of counterions in the mobile phase 
[SAH]  concentration of non-ionized SA 
 
A more simplified version of equation [1.10] is given in equation [1.11], which again 
indicates the inverse proportionality of the retention factor k and the counterion 
concentration [X-].  
 𝑘 = 𝜙 ∙ !!! ∙ 𝐾 ∙ 𝛼!"∗ ∙ 𝛼!"∗ ∙ 𝑆𝑂 !"!                 [1.11] 
 
Please note that in this case α is the degree of dissociation of SA and SO and [SO]tot 
means the total concentration of selector immobilized on the silica support, which is 
equivalent to qx in equation [1.9] [51]. 
 
1.9. Immobilization Strategies  
 
In the present master thesis two different strategies for the immobilization of the 
selectors on silica were employed: 
 
• Radical activated thiol-ene “click” reaction 
• Copper catalyzed azide-alkyne cycloaddition (Huisgen click chemistry) 
 
1.9.1. Radical mediated thiol-ene addition  
 
This reaction is often described as click reaction, although it does not always meet 
the prerequisites for a click reaction. Kolb et al. defined that “the reaction must be 
modular, wide in scope, give very high yields, generate only inoffensive byproducts 
that can be removed by nonchromatographic methods, and be stereospecific (but 
not necessarily enantioselective)”	  [52]. 
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Besides the thiol-ene addition exist several other reactions with “click chemistry” 
characteristics such as metal-free dipolar cycloadditions, Diels-Alder reactions and 
thiol-based reactions like thiol-isocyanate, thiol-bromo and thiol-yne processes. In 
the present case azobisisobutyronitrile (AIBN) has been used as a radical starter for 
mediating the reaction. Apart from the radical pathway the thiol-ene reaction also 
works under a number of different conditions like catalytic processes mediated by 
nuleophiles, bases and acids [53] or supramolecular catalysis using β-cyclodextrin 
[54]. 
 
 
 
Figure 1.10.: Reaction mechanism for the thiol-ene addition; adapted from [53]. 
 
The reaction scheme for the hydrothiolation carried out via radical mediation is 
shown in figure 1.10., in which the photoinitiator (PI) is AIBN and the radicals were 
formed via thermal activation of the radical starter in the present thesis. The reaction 
is a typical chain process consisting of initiation, propagation and termination. First 
the radical starter or photoinitiator decomposes due to heating or irradiation, 
respectively, and forms stable radicals, which treat thiols in order to form thiyl 
radicals. First step of the propagation is the addition of thiyl radical to an alkene 
compound yielding a carbon-centered radical as indicated above. The reaction is 
completed after the chain transfer of radical to another thiol-containing molecule. 
Thereby a new thiyl radical is generated and the reaction cycle is repeated. The third 
step of the radical chain process is the termination, which can be due to coupling 
processes of two radicals. The reaction can be carried out with almost any olefins, 
though terminal enes are more reactive in comparison to internal double bonds [53]. 
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Figure 1.11.: Formation of carbosilane-thioether dendrimers via thiol-ene addition; 
adapted and modified from	  [55]. 
 
Due to the versatile application possibilities of the thiol-ene addition it is also used for 
immobilization of chiral selectors (containing olefins) onto mercaptopropyl-modified 
silica for example by Oberleitner et al. [42].  
Further applications of this type of reaction are the synthesis of films and networks, 
the post-polymerization modification of polymers [53] and the formation of complex 
macromolecules such as dendrimers [56]. An illustrative example for this type of 
macromolecules is the formation of carbosilane-thioether dendrimers via 
photochemical induced hydrothiolation “click” chemistry followed by Grignard 
reaction (see figure 1.11.) [55]. 
 
1.9.2. Azide-alkyne cycloaddition 
 
The copper(I) and base catalyzed Huisgen azide-alkyne click reaction has been 
discovered by Rostovtsev et al. in 2002 [57]. In this 1,3-dipolar cycloaddition 
1,2,3-triazoles are formed from azides and terminal alkyne moieties	   [58]. The 
acceleration rate using a copper catalyst for this click reaction is tremendous in 
comparison to a non-catalyzed reaction (107 to 108) [59].  
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Copper can be used either directly as Cu(I) or as a coupled CuSO4/ascorbate 
system in which Cu(II) as a precatalyst is reduced in situ by the ascorbate to the 
active Cu(I). 
One disadvantage of Cu(I) salts like CuI is that they are sensitive to oxidation, which 
complicates operation and handling. Therefore research is focused on air-stable 
copper(I) complexes or copper(II) precatalysts only (without reducing agent). The 
latter is possible via oxidative homocoupling of alkynes (so-called Glaser reaction), in 
which considerable amounts of active Cu(I) are generated. One advantage of this 
procedure is that no external reductant is necessary [60].  
 
 
Figure 1.12.: Cu(II) precatalyst complex with C186tren ligand; 
adapted and modified from [60]. 
 
One example for a Cu(II) precatalyst with C186tren as a ligand (tren = 
tris(2-aminoethyl)amine), which works without reducing agent at room temperature 
(RT), is presented in figure 1.12. and was developed by Harmand et al. [60]. 
Fortunately this complex is stable towards ambient oxygen. 
In the present thesis Cu(I) iodide was used as a catalyst and acetonitrile as a 
solvent. Under these conditions high immobilization rates could be achieved. Full 
conversion was also observed in previous studies in toluene, dichloromethane, 
N-diisopropylethylamine, tetrahydrofuran and N,N-dimethylformamide as solvents. 
Tornøe et al. observed no reaction in the absence of CuI [58].  
In figure 1.13. a proposed reaction mechanism for the click reaction is shown. In the 
presence of a base the Cu(I) covalently attaches to the terminal alkyne and in a 
stepwise or concerted way to the polarized azide moiety (step 1 and 2). Due to 
rearrangement of the bindings a triazole ring is formed (step 3 and 4) in the non-
regiospecific reaction.  
However, this type of reaction does not work with internal alkynes. As additional 
sources of Cu(I) compounds CuCl, CuBr and CuI can be used [58].  
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Figure 1.13.: Proposed catalytic mechanism for the formation of  
1,2,3-triazoles; adapted from [61]. 
 
Besides the above mentioned copper catalysts it is also possible to use 
ruthenium(II)-based complexes for azide-alkyne cycloaddition catalysis. Boren et al. 
developed several complexes for the reaction of primary and secondary azides with 
both terminal and internal alkynes, whereas tertiary azides were not suitable [59].  
Due to the simple feasibility of click reaction it is used for the immobilization of e.g. 
chiral selectors (containing alkynes) onto azidopropyl-modified silica [62]. 
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2. Synthesis Results 
 
2.1. Synthesis of Selectors and Chiral Stationary Phases 
 
The first aim of the master thesis was the synthesis of new arylcarbamoylated 
cinchona-based chiral selectors (SOs) and chiral stationary phases (CSPs) for liquid 
chromatography. Four different types of chiral weak anion exchange (WAX) SOs 
(SO1-4) have been successfully synthesized. In combination with different SO 
loading on the silica support and different column dimensions, twelve columns 
(containing CSP1-10) have been prepared. 
Therefore two different linkers (L1, L2), which enable the immobilization of the 
selector on the modified silica support were prepared. These isocyanates (L1, L2) 
were subsequently reacted with the hydroxyl group of cinchona alkaloids to afford 
our designed selectors. As building blocks dihydroquinine (DHQN) and 
dihydroquinidine (DHQD) were used. 
The immobilization of the chiral SOs onto preactivated silica surfaces was carried out 
via the carbamoyl moiety implementing either radical addition with alkene thiol group 
or azide-alkyne Huisgen click chemistry, respectively. 
 
2.1.1. Synthesis of Linker 1 
 
Scheme 1 shows the synthetic route to L1. Commercially available 3,5-dichloro-4-
hydroxybenzoic acid 1 was transformed into its 4-allyloxy-3,5-dichlorobenzoic acid 
allyl ester 2a by reaction with allyl bromide. Purification of the product was achieved 
by flash column chromatography on silica. The ester group of the purified 
intermediate was then hydrolyzed with sodium hydroxide. Acidification with 
hydrochloric acid led to the carboxylic acid species 3a. This intermediate was then 
treated with oxalyl chloride (COCl)2 and dry N,N-dimethylformamide (DMF) as a 
catalyst to form the acyl halide 4a. An alternative approach for activating the acid 
would be the reaction with thionyl chloride instead of oxalyl chloride, but (COCl)2 is 
commonly milder [63]. One advantage of both reagents is that they produce only 
gaseous by-products.  
The activated species was then converted into the acyl azide 5a by nucleophilic 
substitution with sodium azide, which could be easily isolated by extraction. Heating 
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up the dry acyl azide led to the respective isocyanate L1 via Curtius-rearrangement. 
The driving force of this reaction is the release of nitrogen. The crude product was 
purified by vacuum distillation and the colorless liquid product was stored at 4°C.  
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Scheme 1: Conditions: (a) allyl bromide, K2CO3, acetone, reflux, 18 h, (b) NaOH, ethanol, water, 
reflux, 1 h, (c) HCl, 0°C, (d) (COCl)2, DMF(catalyst), reflux, 1 h, (e) NaN3, acetone, water, 0°C, 1 h, 
(f) toluene, reflux, 2 h. 
 
2.1.2. Synthesis of Linker 2 
 
Scheme 2 shows the synthetic route to L2. Analogously, commercially available 
3,5-dichloro-4-hydroxybenzoic acid 1 was transformed into its 4-propargyloxy-3,5-
dichlorobenzoic acid propargyl ester 2b by reaction with propargyl bromide. 
Purification of the product was achieved by flash column chromatography on silica. 
The ester group of the purified intermediate was then hydrolyzed with sodium 
hydroxide. Acidification with hydrochloric acid led to the carboxylic acid form 3b. This 
intermediate was then treated with oxalyl chloride and dry DMF as a catalyst 
providing the respective acyl halide 4b, which was subsequently converted into acyl 
azide 5b by reaction with sodium azide, which could be easily isolated by 
precipitation and extraction. The procedure for isolating the acyl azide 5b is slightly 
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different in comparison to the work-up of the acyl azide species described for L1 
above.  
 
OH
Cl Cl
  a
O
Cl Cl
OO
 b
O OH
 c
O
Cl Cl
OHO
O
Cl Cl
 e
O
Cl Cl
N3O
 f
O Cl
NCO
O
Cl Cl
 d
1
3b
4b 5b L2
2b
 
 
Scheme 2: Conditions: (a) propargyl bromide, K2CO3, acetone, reflux, 18 h, (b) NaOH, ethanol, water, 
reflux, 1 h, (c) HCl, 0°C, (d) (COCl)2, DMF (catalyst), reflux, 1 h, (e) NaN3, acetone, water, 0°C, 1 h, 
(f) toluene, reflux, 3 h. 
 
In the case of L2 the acyl azide 5b was first allowed to precipitate in an aqueous 
solution, afterwards filtered and washed in order to remove soluble by-products. The 
filtration cake was then dissolved in EtOAc, washed with water and saturated 
aqueous NaCl solution and dried over MgSO4 to give a fully dry acyl azide 5b after 
evaporation of the solvent. This work-up procedure is much more efficient with 
respect to drying than described above for the acyl azide species of L1.  
Heating up the fully dry acyl azide led to the respective isocyanate L2 via Curtius-
rearrangement. Purification of the product by vacuum distillation was not possible 
due a high boiling point; hence the crude product was used directly for 
carbamoylation of cinchona derivatives.  
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2.1.3. Synthesis of Selector 1 
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Scheme 3: Conditions: toluene, dibutyltin dilaurate (catalyst), reflux, N2, 18 h. 
 
Scheme 3 shows the synthetic route to generate SO1 (DHQN-type SO). 
Commercially available DHQN was dissolved in toluene and dried via azeotropic 
distillation. The carbamoylation of dihydroquinine was carried out under nitrogen 
atmosphere with isocyanate L1 and dibutyltin dilaurate (DBTDL) as a catalyst [64]. 
Purification of the product SO1 was achieved by flash column chromatography on 
silica. 
 
2.1.4. Synthesis of Selector 2 
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Scheme 4: Conditions: toluene, DBTDL (catalyst), reflux, N2, 18 h. 
 
Scheme 4 shows the synthetic route to generate SO2 (DHQD-type). Analogously to 
the procedure mentioned above, DHQD and L1 were mixed together with the 
catalyst, the product was formed and afterwards purified by flash column 
chromatography on silica. SO2 was then recrystallized from EtOH. 
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2.1.5. Synthesis of Selector 3 
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Scheme 5: Conditions: toluene, DBTDL (catalyst), reflux, N2, 18 h. 
 
Scheme 5 shows the synthetic route to generate SO3 (DHQN-type). Commercially 
available DHQN was dissolved in toluene and dried via azeotropic distillation. The 
carbamoylation of DHQN was carried out under nitrogen atmosphere with purified 
isocyanate L2 and DBTDL as a catalyst. Purification of the product was achieved by 
flash column chromatography on silica. Crystallization of SO3 was not possible.  
 
2.1.6. Synthesis of Selector 4 
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Scheme 6: Conditions: toluene, DBTDL (catalyst), reflux, N2, 18 h. 
 
Scheme 6 shows the synthetic route to generate SO4 (DHQD-type). Analogously to 
the procedure mentioned above, DHQD and L2, which was prepared in situ via 
Curtius rearrangement of acyl azide 5b, were mixed, catalyst was added, the product 
was formed and afterwards purified by flash column chromatography on silica. 
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2.1.7. Immobilization of SO1 onto MP-Silica 
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Scheme 7: Conditions: methanol, azobisisobutyronitrile (AIBN), reflux, N2, 18 h. 
 
Scheme 7 shows the immobilization step for CSP1 (DHQN-type) via radical thiol-ene 
addition. Mercaptopropyl-modified silica (MP-Silica, loading of thiol groups 
app. 650 µmol/g silica), SO1 and AIBN as a radical starter were suspended in MeOH 
under nitrogen atmosphere. When AIBN is heated, it decomposes and forms two 
stable 2-cyanoprop-2-yl radicals and one molecule of nitrogen is released. The 
suspension was mechanically stirred in order to not damage the silica particles and 
heated under reflux. After 18 h the silica was filtered with a frit and washed. After 
drying under vacuum SO loading of CSP1 was determined by elemental analysis 
(EA). 
 
2.1.8. Immobilization of SO2 onto MP-Silica 
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Scheme 8: Conditions: methanol, AIBN, reflux, N2, 18 h.  
 
Scheme 8 shows the synthetic route to CSP2 (DHQD-type) via radical addition. The 
reaction was carried out in the same manner as mentioned above for the 
immobilization of SO1. The reagents were suspended in MeOH, heated and after 
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18 h the modified silica was filtered, washed, dried and SO loading of CSP2 was 
determined by elemental analysis. 
 
2.1.9. Synthesis of AzP-Silica 
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Scheme 9: Conditions: (a) toluene, p-toluenesulfonic acid (catalyst), reflux, 18 h, (b) NaN3, 
dimethylsulfoxide (DMSO), tetrabutylammonium iodide (catalyst), 80°C, 72 h.  
 
Scheme 9 shows the two-step synthetic route to azidopropyl-modified silica 
AzP-Silica. The synthesis was carried out similarly to a procedure published by 
Kacprzak et al. [62]. 
Silica and the catalyst were suspended in toluene and dried via azeotropic 
distillation. For surface-preactivation the haloalkylsilane was added to the reaction 
mixture and the mixture was stirred under reflux. The suspension was then filtered 
and washed with toluene and methanol. Chloropropyl-modified silica (CP-Silica) was 
dried under vacuum and chloropropyl-loading was determined by elemental analysis. 
CP-Silica was treated with NaN3 in DMSO and tetrabutylammonium iodide as a 
catalyst to substitute the chloro-group by an azide group via nucleophilic halide/azide 
exchange. AzP-Silica was filtered, washed and dried under vacuum. Azide-loading 
of AzP-Silica was determined by elemental analysis. The analysis results showed a 
successful conversion of 85% from CP-Silica (740 µmol/g) to AzP-Silica with an 
azide-alkylsilane loading of 630 µmol/g.  
 
2.1.10. Immobilization of SO3 onto AzP-Silica 
 
Scheme 10 shows the synthetic route to CSP3 (DHQN-type) linked via 1,2,3-triazole 
group. The described procedure can be considered as a general synthetic pathway 
valid for CSP5 (DHQN-type) as well. All azide click reactions were carried out in a 
way similar to the procedure published by Kacprzak et al. [47, 62, 65]. 
 
	   - 39 - 
N
O
O NNH
O
Cl
Cl
O
N
O
O NNH
O
Cl
Cl
ONSi
O
Si
CSP3+5 (DHQN-type)
+
OMe
OMe
N3
AzP-Silica
SO3
N N
O
OMe
OMe
(9R)
(9R)
(8S)
(8S)
H
H
 
 
Scheme 10: Conditions: ACN, CuI (catalyst), N,N-diisopropylethylamine (DIPEA), room temperature 
(RT), 72 h. 
 
ACN was degassed together with AzP-Silica, SO3 and DIPEA (Hünig´s base) in a 
resealable glass bottle. Catalyst was added under N2 flushing and the sealed glass 
bottle was shaken for 72 h on an overhead shaker at room temperature. The 
reaction mixture was then filtered, washed and dried under vacuum. SO loading was 
determined by elemental analysis. 
 
2.1.11. Immobilization of SO4 onto AzP-Silica 
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Scheme 11: Conditions: ACN, CuI (catalyst), DIPEA, RT, 72 h.  
 
Scheme 11 shows the synthetic route to CSP4 (DHQD-type) via azide-alkyne 
Huisgen cycloaddition. This synthetic procedure was also applied for 
CSP6+7+8+9+10 (all of them are DHQD-type CSPs). Analogously to the procedure 
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mentioned above, the reagents were mixed, degassed, shaken for 72 h and 
afterwards worked up. SO loading was again determined by elemental analysis. 
 
2.2. Summary of all synthesized CSPs  
 
In combination with different SO loading of SO1-4 onto silica, 12 different columns 
were prepared. Table 2.1. shows a summary of all synthesized CSPs together with 
dimensions of the packed columns, type and loading of the SO.  
SO loading for the radical thiol-ene addition was 144 and 179 µmol/g for CSP1 
(DHQN-type) and CSP2 (DHQD-type), respectively. In comparison to the 
immobilization via Huisgen azide alkyne click reaction the SO loading achieved via 
thiol-ene addition was approximately three times lower. This could be due to the 
π-acidic character of the dichloro-substituted aromatic ring from the linker and the 
resulting radical scavenging property [66]. However, in former experiments of our 
working group the SO loading of about 200 µmol/g showed good enantioseparation 
properties for N-protected amino acids [65]. 
 
Table 2.1.: Summary of synthesized CSPs and the corresponding packed columns. 
Column CSP 
SO 
Type of Dimensions Dimensions SO loading 
Number Number SO of the column of Silica [µmol/g] 
1 CSP1 SO1 DHQN 
150x4 mm ID 5 µm, 120 Å 
179 
2 CSP2 SO2 DHQD 140 
3 CSP3 SO3 DHQN 477 
4 CSP4 SO4 DHQD 490 
5 CSP5 SO3 DHQN 214 
6 CSP6 SO4 DHQD 232 
7 CSP7 SO4 DHQD 238 
8 CSP8 SO4 DHQD 314 
9 CSP9 SO4 DHQD 150 
10 CSP10 SO4 DHQD 138 
11 CSP3 SO3 DHQN 
75x4 mm ID 5 µm, 120 Å 
477 
12 CSP4 SO4 DHQD 490 
 
CSP7 and CSP10 (both of them DHQD-type) do have slightly different chemical and 
physical properties in comparison to the other synthesized CSPs. CSP7 is almost a 
one to one physical mixture of CSP4 and pure AzP-Silica. This CSP was made for 
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comparative purposes to CSP6 (DHQD-type) because of similar overall SO loading 
per gram silica. 
CSP10 is a modified version of CSP9. The only difference is that the free azido-
groups of CSP9 – after immobilizing SO4 – were endcapped with propargyl alcohol 
to give CSP10. The reaction scheme for endcapping is shown in scheme 12. 
 
OH OHNSiO
Si +
OMe
OMe
N3
AzP-Silica
N N
O
OMe
OMe
 
 
Scheme 12: Conditions: ACN, CuI (catalyst), DIPEA, RT, 72 h.  
 
All columns were packed “in-house” into stainless steel columns with 150 mm length 
and 4 mm inner diameter, except for columns 11 and 12, which were packed into 
75x4 mm ID columns for comparative purposes and a loading study. Packing of the 
columns was carried out using the conventional slurry packing method with iPrOH as 
slurry solvent and MeOH as packing solvent at a pressure of approximately 
650 bars. 
After packing the columns were flushed with aqueous EDTA solution to remove 
remaining CuI catalyst (column 3-12), water and MeOH.  
 
2.3. Properties of the SOs  
 
All four SOs (SO1-4) are derived from well-established cinchona alkaloid weak anion 
exchange (WAX) type SOs, namely QN-AX and QD-AX [67] and thus they are 
potentially suitable for the separation of acidic chiral compounds. Due to the 
pseudoenantiomeric behavior of the building blocks DHQN and DHQD [13, 49, 68, 
69].  
reversal of the elution order is possible. The immobilization can be carried out via 
two different strategies, either radical thiol-ene addition with AIBN or V65 as radical 
starter or copper(I)-catalyzed Huisgen alkyne-azide click chemistry. 
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There are multiple interactions with potential analytes (selectands, SAs) possible: 
 
• Primary ionic interaction via the ionizable bicyclic tertiary amine in the 
quinuclidine ring at acidic mobile phase conditions (pK app. 9.8, entirely 
protonated at pH-values lower than 7.8 [70]). The quinoline amine (pK is 
app. 3.9) is mainly deprotonated under weakly acidic mobile phase conditions 
[70]. 
• Hydrogen-bonding via the carbamate -NH as donor and the carbonyl as an 
acceptor. 
• Intermolecular π-π interactions via the aromatic π-basic quinoline ring and the 
aromatic ring of the linker.  
• Steric interaction because of the sterically demanding aromatic dichloro-
substituted linker. 
 
All these interactions result in a potential ability for chiral recognition and make the 
SOs suitable for enantiomeric separation of chiral acidic SAs. 
 
2.4. Immobilization Efficiency  
 
In table 2.2. and figure 2.1. the dependency of the immobilization efficiency of 
offered SO is shown. All immobilizations were carried out using the same conditions 
for Huisgen click chemistry. 
 
Table 2.2.: Dependency of immobilization efficiency of offered SO. 
CSP 
Offered SO Actual Loading Loading 
[µmol/g Silica] [µmol/g Silica] Efficiency [%] 
3 1044 477 /// 
4 1014 490 /// 
8 360 314 87 
6 250 232 93 
5 230 214 93 
9 150 150 100 
 
 
For CSP3 (DHQN-type) and CSP4 (DHQD-type) no selector loading efficiency is 
shown, because the SOs (SO3 for CSP3 and SO4 for CSP4) were offered in 
app. 1.5 times molar excess referring to azidopropyl-loading on AzP-Silica with 
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629 µmol/g silica. For CSP5+6+8+9 the SOs were offered in deficit. With higher 
amount of offered SO the loading efficiency decreases. At a very low level of offered 
SO (150 µmol/g for CSP9) immobilization can be regarded as quantitatively. In 
average 93% of the offered SO were immobilized.  
The maximum of practical loading is approximately 500 µmol/g silica, achieved with 
excess offer of SO. The stoichiometric maximum of loading capacity at 629 µmol/g 
was never reached, even with a considerable excess of SO. This result reflects the 
impact of sterical hindrance. 
 
 
Figure 2.1.: Actual loading vs. offered SO3 or SO4; 
blue line: stoichiometric maximum (629 µmol/g). 
 
Similar effects have been observed by Marshall et al. [71]. In the present case, the 
sterically demanding cinchonan derived SO leads to saturation phenomena at 
surface densities higher 500 µmol/g, rendering the preparation of more densely 
loaded CSP surfaces elusive.  
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3. Evaluation of the WAX-CSPs 
 
3.1. Reference CSPs and Columns 
 
For comparative purposes and the loading study as well, four additional columns 
were used (see table 3.1.). Three columns were packed with commercially available 
Chiralpak® QN-AX and QD-AX selector type silica materials [13]. In figure 3.1. the 
structures of these cinchona-derivatives-based weak anion exchange CSPs are 
depicted. These two quinine and quinidine derived carbamoylated reference 
materials show high capabilities in terms of resolution of chiral acidic compounds 
[49, 50, 67, 72, 73]. 
To further discover the influence of free azido-groups on the retention of analytes 
(selectands, SAs), one 150x4 mm ID column was packed with pure AzP-Silica as a 
non-chiral stationary phase (SP1).  
 
Table 3.1.: Further used columns for Evaluation. 
Column Type of Dimensions Dimensions Selector loading 
Number Selector of the column of Silica [µmol/g] 
13 QN-AX 150x4 mm ID 
5 µm, 120 Å app. 340 14 QD-AX 150x4 mm ID 
15 QD-AX 75x4 mm ID 
16 AzP 150x4 mm ID 5 µm, 120 Å 629 
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Figure 3.1.: Structures of CHIRALPAK® QN-AX and QD-AX CSPs; 
adapted and modified from [47, 48]. 
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3.2. Analytes 
 
For the evaluation of the CSPs a broad set of chiral SAs was used. Since all the 
synthesized CSPs are weak anion exchange type CSPs based on cinchona 
alkaloids and the retention is primarily driven by an ion exchange mechanism 
[42, 49, 67], the majority of the SAs consists of chiral organic acids and acid 
derivatives including 31 N-protected amino acids (BOC-Gly and DNZ-Gly as achiral 
compounds), 17 carboxylic acids, nine N-protected aminophosphonates and three 
N-protected aminosulfonic acids. For determining the elution order single 
enantiomers were used if they were available. To further proof the concept of anion 
exchange four zwitterionic and three basic compounds, which should stay non-
retained [42], were also used for the evaluation of the CSPs. In figures 3.2. to 3.9. 
the structures of all SAs used for evaluation are shown. The SAs were commercially 
available, synthesized earlier in the working group of Prof. Lindner or were kind gifts 
of other working groups [74, 75]. 
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Figure 3.2.: N-protected amino acids (leucine derivatives). 
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Figure 3.3.: N-protected amino sulfonic acids. 	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Figure 3.4.: Basic compounds. 
 
 
O
OH
HN O
Ac-Phe
O
OH
HN O
O
O
OH
HN O
O
BOC-Phe
O
OH
HN
FMOC-beta-Phe
O
OH
HN
OO
Bz-Phe
O
OH
HN
O
Bz-beta-Phe
Z-Phe DNZ-Phe
Z-beta-Phe
O
OH
HN O
O
O2N NO2
O
OH
HN O
OO
 
 
Figure 3.5.: N-protected amino acids (phenylalanine derivatives). 
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Figure 3.6.: N-protected aminophosphonates. 
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Figure 3.7.: Zwitterionic compounds. 
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Figure 3.8.: Carboxylic acids (including profens). 
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Figure 3.9.: N-protected amino acids. 
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3.3. Materials and Methods for Evaluation 
 
The chromatographic screening of the columns was carried out on a 1290 series 
Infinity HPLC system from Agilent Technologies (Waldbronn, Germany) consisting of 
an automated sampler, solvent tray, a binary pump with two channels, a degasser, a 
thermostated column compartment for six columns and a diode array detector 
(DAD). All SAs were detected at a wavelength of 254 nm. The columns were 
thermostated at 25.0 ± 0.1°C. Data processing was carried out with a ChemStation 
chromatographic data software from Agilent Technologies and Excel spreadsheet 
software from Microsoft Corporation. 
The loading studies were carried out on an 1100 series HPLC system from Hewlett 
Packard (Waldbronn, Germany) consisting of an automated sampler, solvent tray, a 
binary pump with two channels, a degasser, a thermostated column compartment 
and a multiple wavelength detector (MWD). The SAs were detected at a wavelength 
of 270 nm. The columns were thermostated at 25 ± 0.1°C. Racemic Ac-Phe 
(obtained from Sigma) was dissolved in pure MeOH at a sample concentration of 
100 ± 0.1 mg/mL. The injection volume was 5 to 100 µL. Elution was performed in 
isocratic mode with a flow rate of 0.5 mL/min for 15 min. As a starting mobile phase 
the same composition as for screening was used (see below).  
For screening purposes 5 µL of each SA-solution with a concentration of 
1.0 ± 0.1 mg/mL in MeOH were injected. For determining the elution order in a 
racemic mixture a single enantiomer was – if available – measured as well. Elution 
was performed in isocratic mode with a flow rate of 1.0 mL/min at 25.0 ± 0.1°C. The 
composition of the mobile phase used for screening was MeOH/AcOH/NH4OAc 
(99/1/0.25 v/v/w). The mobile phase was degassed by sonication prior to use. This 
mobile phase composition is a diluted version of a commonly and successfully used 
mobile phase in polar organic (PO) mode used e.g. by Kacprzak et al. [47].  
The acetic acid in the mobile phase is necessary to provide weakly acidic conditions 
in the chromatographic system for protonation of the selector. The acidic additive 
and buffer salt also act as co- and counterion that determines the electrostatic 
interactions between SA and CSP [76]. Because buffer salts also act as competitors 
to the SAs and are therefore displacers for the SAs, the retention time is highly 
dependent on an ion strength and ion charge in the mobile phase. 
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3.4. Chromatographic Parameters 
 
For evaluation of the different CSPs it is necessary to define the main 
chromatographic parameters:  
 
• Retention Factor ki:  
 𝑘! = !!!!!!!                     [3.1] 
 
The retention factor ki reflects the binding strength between a SA or single 
enantiomer of the SA and the SO immobilized on the surface of a CSP. The 
larger the value of ki, the stronger is the interaction. The retention factor is 
calculated by dividing the difference between the retention time and the void 
time by the void time.  
 
• Selectivity coefficient α: 
 𝛼 = !!!!                     [3.2] 
 
The selectivity coefficient or separation factor α describes the ratio of the 
retention factors of two separated SAs or enantiomers. It is calculated by 
dividing the retention factor of the second eluted enantiomer (k2) by the 
retention factor of the first eluted enantiomer (k1). If separation takes place, 
the α-value is higher 1. For preparative purposes high selectivity is one 
important prerequisite. 
 
• Resolution R: 
 𝑅 = !!"! ∙ !!!! ∙ !!!!!!"                   [3.3] 
 
The resolution R indicates the quality of separation and consists of three 
terms (efficiency, selectivity and retention). The first term includes the average 
number of theoretical plates for separation Nav (see equation [3.4]). This term 
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describes the separation performance. The resolution is directly proportional 
to the square root of Nav. The higher the number of plates, the higher is the 
resolution. The second term includes the selectivity coefficient α. The 
retention factor of the second eluted enantiomer (k2) and the average 
retention factor for both enantiomers are described in the third term. 
  
• Number of theoretical plates Ni: 
 𝑁! = 5.54 ∙ !!!!! !                    [3.4] 
 
The number of theoretical plates Ni indicates the separation performance. Ni 
informs on the number of equilibrium settings of the SA between the mobile 
and stationary phase. It is dependent on the quality of packing of the column 
and the SO density on the surface of the silica material. Ni is calculated by 
dividing the retention time by the width of the peak at half maximum wi1/2. 
Please note that in the following discussion Ni always refers to the respective 
column length. 
 
3.5. Influence of immobilization strategy 
 
In figures 3.10. to 3.12. one can see the influence of the immobilization strategy on 
the performance of the same selector. CSP2 (DHQD-type) in column 2 was prepared 
by the radical thiol-ene addition, while CSP9 (DHQD-type) in column 9 was 
immobilized by alkyne-azide click chemistry. This is the only structural difference 
between the two CSPs, because the remaining structures of the SOs are the same. 
SO loading of CSP2 was 144 µmol/g and for CSP9 150 µmol/g, so they both are 
comparable in terms of the SO density on the surface. The chromatographic 
conditions used were the same for both measurements. 
The acidic compounds are at least partially separated; the elution order for amino 
acid derivatives is always L before D, except for DNB-Pro, which was observed for 
any other DHQD-type CSP as well. DNB-N-Me-Leu was not separated on the 
column 9, and the alpha-value on the column 2 was very low. Basic compounds like 
QN, QD, clenbuterol hydrochloride and zwitterionic compounds are neither retained 
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nor separated; they all had a k-value below 0.3. Figure 3.10. shows that the k-values 
are comparable for both columns. Column 9 exhibits an increased selectivity for the 
aminophosphonic compound PI-2-15-1 (α = 1.71) in comparison to column 2 
(α = 1.16). The alpha-values for the other SAs are comparable (see figure 3.11.). 
These results demonstrate that both types of CSPs are capable of separating a 
variety of chiral acidic compounds, independently on structural variations and acidity. 
 
 
Figure 3.10.: Dependency of retention of the immobilization strategy; 
column 2: DHQD-type, 140 µmol/g; column 9: DHQD-type, 150 µmol/g. 
 
In terms of resolution the behavior is different (see figure 3.12.). R is always higher 
for the radical thioether like CSP. One example is DCB-Leu: Resolution is about 13 
for column 2 and 8 for column 9. This is based on the different number of theoretical 
plates for each column, because k and alpha-values are comparable. 
For column 2 Nav is about 5300 (all measured samples), for column 9 the number of 
theoretical plates is a factor of 2.3 lower (Nav = 2300, all measured samples). One 
reason for different resolution-values could be a different packing density of the two 
columns, because packing also influences the number of plates and therefore the 
resolution. 
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Figure 3.11.: Dependency of selectivity of the immobilization strategy; 
column 2: DHQD-type, 140 µmol/g; column 9: DHQD-type, 150 µmol/g. 
 
The same results and trends were observed when comparing columns 1 and 5, the 
corresponding DHQN-type CSPs with 179 µmol/g and 214 µmol/g SO loading, 
respectively. 
 
 
Figure 3.12.: Dependency of resolution of the immobilization strategy; 
column 2: DHQD-type, 140 µmol/g; column 9: DHQD-type, 150 µmol/g. 
 
3.6. Influence of free Azide groups on Retention 
 
The influence of free azide-groups on silica is shown in figure 3.13. The effect of 
free azide-groups could be important for low loaded CSPs, because there are free 
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azide groups not-clicked with an alkyne residue. The azide itself is highly polarized 
and therefore it can potentially interact with polarized groups of SAs. This study was 
performed with pure AzP-Silica as a non-chiral stationary phase (SP1, column 16). 
The influence of pure AzP-Silica is low. There is – of course – no enantioselectivity 
and no retention as well, except a very low retention value for QN and QD. The other 
SAs used for this study eluted before t0. The overall effect is quite limited and there 
is almost no contribution with regard to retention. 
The average k-value is below zero (kav = -0.1). Furthermore, Franco et al. carried out 
retention studies with pure MP-Silica as a reference material and they documented 
that there is also no substantial contribution of the carrier material with respect to 
retention [42]. They have observed average k-values below 0.1 for a variety of 
N-protected amino acids as well. 
 
 
Figure 3.13.: Influence of free azide-groups on silica; column 16: AzP-type, 629 µmol/g. 
 
3.7. Influence of Endcapping 
 
In figures 3.14. and 3.15. the influence of endcapping in terms of selectivity and 
resolution is shown. For this study CSP9 (DHQD-type) was used, part of which was 
endcapped with propargyl alcohol to give CSP10. SO loading is almost the same 
after endcapping (138 µmol/g for CSP10 in comparison to 150 µmol/g for CSP9), 
12 µmol (8%) of SO per gram silica have been cleaved off during immobilization and 
the work-up procedure. The average number of theoretical plates for column 9 was 
Nav = 2324, for column 10 Nav = 3486 (factor of 1.5).  
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Even with this low amount of immobilized SO at least partial separation of the SAs 
was possible. Only hydroxyphenyllactic acid was not separated on column 10, on the 
other hand, partial separation on column 9 was achieved (α = 1.07).  
The k1- and k2-values (not shown here, see appendix) were generally lower for the 
endcapped material. This can be explained by the slightly lower SO loading. The 
aminophosphonate derivative PI-2-15-1 exhibits, however, slightly higher retention 
on column 10.  
 
 
Figure 3.14.: Influence of endcapping in terms of selectivity; 
column 9: DHQD-type, 150 µmol/g; column 10: DHQD-type, 138 µmol/g (endcapped). 
 
DCB-Leu and the two aminosulfonic acid derivatives P-DML-ACHSA and P-DCL-
ACHSA do have higher k2-values on column 10 compared to column 9.  
There is a trend that alpha-values for N-protected amino acid derivatives are slightly 
increased for the encapped material, so selectivity is better. On the other hand, the 
resolution is lower. For the tested aminophosphonate and the aminosulfonic acid 
derivatives resolution is increased, which is in agreement with the trend observed for 
selectivity coefficient α. 
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Figure 3.15.: Resolution-influence of endcapping; 
column 9: DHQD-type, 150 µmol/g; column 10: DHQD-type, 138 µmol/g (endcapped). 
 
3.8. Reversal of the Elution Order  
 
Referring to the pseudoenantiomeric behavior of the building blocks DHQN (8S,9R) 
and DHQD (8R,9S; both of them 1S,2R,3S) [13, 49, 67-69], reversal of the elution 
order was observed for every single separated racemic SA, without any exception. 
The DHQN and DHQD derived CSPs show exactly opposite behavior in terms of 
enantioselectivity as indicated in figure 3.16. for the separation of P-DCL-ACHSA 
(S,S > R,R) on column 1 (DHQN-type) and column 2 (DHQD-type). For the 
N-protected amino acid derivatives elution order was always D before L for DHQN-
type CSPs except for DNB-Pro (L before D). The DHQD-type SOs behaved just the 
opposite way. This indicates an equal separation mechanism for all 
N-protected amino acid derivatives except for DNB-Pro.  
Maier et al. reported that “the absolute configuration of the C9 stereogenic center in 
the cinchonan backbone determines the elution order of these analytes. SOs having 
(9R)-configuration, i.e., QN- […] derived CSPs, show stronger retention for 
N-acylated (S)-amino acids, whereas their (R)-enantiomers interact more strongly 
with QD- […] based selectors” [67]. 
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Figure 3.16.: Reversal of the elution order on changing from DHQN to DHQD-type CSPs; 
column 1: DHQN-type, 179 µmol/g, column 2: DHQD-type, 140 µmol/g.  
 
3.9. Comparison of DHQN and DHQD-type CSPs 
 
Column 5 (DHQN-type) and column 6 (DHQD-type) are well suited for the 
comparison of DHQN and DHQD-type CSPs because they have approximately the 
same amount of SO immobilized on the surface via Huisgen alkyne-azide click 
chemistry. CSP 5 in column 5 has a SO loading of 214 µmol/g in comparison to 
CSP6 in column 6 with a loading of 232 µmol/g silica. 
In figure 3.17. the ratio of partial separation, baseline separation and no separation 
for 58 acidic chiral SAs for columns 5 and 6 is shown. In case of the DHQD-type 
CSP (column 6) 53% of the 58 acidic SAs were baseline separated and 19% were 
partially separated. All together separation was observed for 72% of the acidic SAs. 
The percentage of baseline separated SAs for the DHQN-type CSP (column 5) is 
lower (50%), but all together 72% of the SAs were at least partially separated. The 
value for not separated compounds is equal for both columns (28%). The observed 
partial separation of Trp on the DHQN-type CSP5 (α = 1.14, R = 0.48) is not 
included in the calculation. This separation was not observed for CSP6. The other 
three zwitterionic compounds and the three basic compounds were not separated. 
For the DHQD-type CSP no zwitterionic and basic compound was separated. 
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Figure 3.17.: Ratio of partial separated (0 < R < 1.5), baseline separated (R ≥ 1.5) and 
not separated acidic SAs (R = 0) observed for column 5 (DHQN-type, 214 µmol/g) 
and column 6 (DHQD-type, 232 µmol/g). 
 
However, one should consider that these results were observed for just one mobile 
phase (polar organic mode, MeOH/AcOH/NH4OAC 99/1/0.25 v/v/w). Variation of the 
mobile phase could of course alter the percentages for partial, baseline and no 
separation.  
 
3.9.1. Selectivity 
 
In figure 3.18. the average values of the selectivity coefficients for the different 
groups of acidic SAs are shown. A general trend for all the groups of SAs is that 
selectivity is increased for the DHQD-type CSP6. The N-protected phenylalanine 
derivatives represent an exception in two aspects:  
 
1. Both for DHQN and for DHQD-type CSP the average alpha-value is the 
highest compared to the other groups of chiral acidic SAs.  
2. The behavior, in terms of selectivity, is exactly the opposite in comparison to 
the other groups of acidic compounds – the DHQN-type CSP has an 
increased selectivity by a factor of 1.67. This is because the selectivity for 
DNZ-Phe is doubled in case of the DHQN-type CSP (21.4 for DHQN-type and 
10.4 for DHQD-type CSP).  
 
Alpha-values of other N-protected phenylalanine derivatives are increased for the 
DHQD-type CSP (column 6). 
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Figure 3.18.: Average α-values for the different groups of acidic SAs; 
column 5: DHQN-type, 214 µmol/g; column 6: DHQD-type, 232 µmol/g. 
 
The carboxylic acid derivatives, in particular profens (representing aryl propionic 
acids) are hard to separate. In this regard Lämmerhofer et al. noticed that this type of 
carboxylic acids is not capable of forming additional dipole interaction or hydrogen 
bonding due to the absence of an additional polar unit between the aromatic group 
and the chiral center [49]. 
 
3.9.2. Resolution 
 
A comparison between CSP5 and 6 in terms of average resolution shows a clear 
trend for higher resolution for the DHQD-type CSP. Figure 3.19. represents a 
graphical illustration of this behavior. Generally, the resolution is increased for every 
group of SA by a factor of 1.27. The resolution dependent average number of 
theoretical plates Nav is increased by a factor of 1.14 for the DHQD-type CSP as 
well.  
In combination with the observed increase of selectivity (see chapter 3.9.1.), one 
can conclude that the DHQD-type SO is generally more suitable for the separation of 
chiral acids. 
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Figure 3.19.: Average resolution-values for the different groups of acidic SAs 
column 5: DHQN-type, 214 µmol/g; column 6: DHQD-type, 232 µmol/g. 
 
3.10. Separation capability compared between Columns 1 to 6 
 
For comparing structural influences on the separation behavior it is reasonable to do 
that with the results obtained for the column with the highest separation capability. In 
table 3.2. the results of the separation studies between columns 1 to 6 are 
summarized for the 58 chiral acidic SAs. Please note that BOC-Gly and DNZ-Gly are 
non-chiral acidic compounds and therefore are not included in the calculation below. 
Because all the CSPs represent weak anion exchange type CSPs, the set of non-
acidic SAs is excluded from the considerations as well. 
The results obtained for columns 7 to 12 are not included in this study because in 
this case a smaller set of samples was used for screening and therefore it is not 
possible to do systematic comparative studies on the structural influence of the SAs.  
The largest part of baseline separated chiral acidic compounds was observed for 
column 2 (55%, DHQD-type CSPs). The smallest part of not separated compounds 
was observed for column 5 and 6 (both 28%). 
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Out of these results column 6 is the column with the highest separation capability 
and therefore the results observed for column 6 were used for comparing structural 
influences of the SAs on the separation behavior. 
 
Table 3.2.: Overall separation capabilities of columns 1 to 6; 
partial separation 0 < R < 1.5; baseline separation R ≥ 1.5; no separation R = 0. 
Column 
CSP SO loading Baseline Partial No 
Type [µmol/g] Separation [%] Separation [%] Separation [%] 
Column 1 DHQN 179 52 17 31 
Column 2 DHQD 140 55 16 29 
Column 3 DHQN 477 29 33 38 
Column 4 DHQD 490 34 31 34 
Column 5 DHQN 214 50 22 28 
Column 6 DHQD 232 53 19 28 
 
 
3.11. Influence of analyte structure on Separation 
 
In chapter 3.10. the column with the highest separation capability turned out to be 
column 6. In this case the largest part of chiral acidic compounds was at least 
partially separated (72%). CSP6 in column 6 has got a SO loading of 232 µmol of 
SO4 (DHQD-type) per gram CSP.  
 
3.11.1. N-protected leucine derivatives 
 
DNB-N-Me-Leu was not separated on column 6 (see figure 3.20.). On the other 
side, the enantioselectivity is dramatically increased for the structurally related 
DNB-Leu, which shows the highest values of enantioselectivity and resolution for the 
N-protected leucines. The only difference between these two SAs is that the amido 
hydrogen of DNB-Leu is alkylated and replaced by a methyl group for DNB-N-Me-
Leu. Evidently this amido hydrogen is essential for chiral recognition and 
enantioselectivity, respectively. Lämmerhofer et al. observed the same result when 
comparing these two SAs [49]. This behavior is also in agreement with the results 
previously found by Mandl et al. [50]. 
Without the capability of forming a hydrogen bond between the amido hydrogen as a 
donor and the carbonyl of the SO carbamate as an acceptor, enantioseparation is 
not possible for the DNB-Leu derivatives. The k2-value for the methylated derivative 
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is 4.93 in comparison to 14.88 for the non-methylated compound, so there is much 
stronger interaction between the cinchona based carbamoylated SO and the non-
methylated DNB-Leu due to hydrogen bonding. Since the amido hydrogen of 
DNB-Leu is close to the center of chirality, enantiodiscrimination between L and D is 
possible.  
 
 
Figure 3.20.: Comparison of selectivity α and resolution R between 
N-protected leucine derivatives; column 6: DHQD-type, 232 µmol/g.  
 
When comparing DCB-Leu and A-DCL-Leu, the structural difference is based on the 
para-allyloxy substitution at the protecting benzoyl group. Both of them are 
analogously meta-substituted with two chloro atoms at the benzoyl protecting group. 
The k2-values are slightly increased for A-DCL-Leu (k2 = 5.09) compared to DCL-Leu 
(k2 = 4.67). The retention factors for the first eluted enantiomers are almost equal. 
Substitution with an allyloxy group also increases the enantioselectivity and 
resolution – this effect could be either due to the increased sterical demand of the 
rotating allyloxy group or due to different polarization of the aromatic system 
because of the introduction of an oxygen atom.  
Complete substitution of all aromatic H-atoms with five fluorine atoms results in 
descending enantioselectivity and resolution. It has to be noted that fluoro-
substitution generally results in special behavior. Of course no fluorophilic interaction 
with the SO can take place and therefore retention is low. The opposite result was 
observed e.g. by Kohout et al. when using trifluoromethyl substituted SOs based on 
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mefloquine as a basic module [77]. They observed that the trifluoromethyl groups of 
the SO are capable of promoting the recognition of PFB-Leu. 
The separation parameters observed for Z-Leu are similar to those observed for 
PFB-Leu. Introducing an oxycarbonyl with a flexible CH2 spacer instead of carbonyl 
for Bz-Leu results in decreased selectivity and resolution. One can conclude that the 
carbamate is less interacting with the SO in comparison to the amide. 
For disubstituted Bz-Leu the selectivity coefficient decreases in the order 
DNB-Leu > BTFMB-Leu > DCB-Leu. In terms of resolution the behavior is slightly 
different, just BTFMB-Leu and DCB-Leu are exchanged in the order. Compared to 
the other leucine derivatives DNB-Leu shows extraordinary high values for α and R. 
The retention time of the stronger retained D enantiomer is approximately four times 
higher than for the corresponding D enantiomer of DCB-Leu. Due to the negative 
mesomeric effect of the nitro groups the aromatic ring is a stronger π-acid compared 
to DCB-Leu and the other benzoyl-substituted leucines. This of course leads to the 
stronger interaction with the π-basic SO. 
 
3.11.2. N-protected phenylalanine derivatives  
 
Concerning N-protected phenylalanine derivatives the selectivity coefficient and 
resolution-value are strikingly increased for DNZ-Phe (α = 10.43 and R = 20.01). The 
same result was observed for DNB-Leu (see chapter 3.11.1.). The average α-value 
for all the other N-protected phenylalanine derivatives is about 8 times lower 
(αav = 1.32, n = 6). 
In figure 3.21. the selectivity coefficients and resolution-values for the N-protected 
phenylalanine derivatives are shown with the exception of DNZ-Phe. The highest 
resolution was observed for Bz-Phe, followed by Ac-Phe. These two compounds are 
both baseline separated on column 6. In case of Ac-Phe - which is the smallest 
compound of the phenylalanine derivatives - no interaction with the SO is possible 
for the protecting group except hydrogen acceptation via the carbonyl group and of 
course hydrogen donation via the amido hydrogen. Switching from α-Phe to β-Phe 
derivatives resulted in a decrease in both selectivity and resolution.  
Introducing benzyloxycarbonyl instead of benzoyl results in decreased selectivity and 
resolution. Hence the carbamate may be less interacting with the SO. The same 
result was observed for Bz-Leu and Z-Leu (see chapter 3.11.1.) This result indicates 
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that the distance between the center of chirality and the aromatic moiety of the 
α-amino acid derivative including flexibility and conformation are of great importance 
for optimal interaction. This conclusion was also drawn by Maier et al.	  [67]. 
 
 
Figure 3.21.: Comparison of selectivity α and resolution R among 
N-protected phenylalanine derivatives; column 6: DHQD-type, 232 µmol/g.  
 
3.11.3. N-protected amino sulfonic acids  
 
In figure 3.22. the effect of substitution for three N-protected aminosulfonic acids is 
shown. All three of them are comparable according to selectivity (1.10 ≤ α ≤1.19). 
The non-substituted Bz-ACHSA gives the lowest value for resolution (R = 1.44). 
P-DML-ACHSA and P-DCL-ACHSA are sterically more demanding in comparison to 
Bz-ACHSA. In combination with the influence of the oxygen of the propargyloxy-
substituent on the electron distribution this may result in a higher resolution for 
substituted Bz-ACHSA derivatives. Exchanging the methoxy-substituents by chlorine 
results in an increase of resolution. 
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Figure 3.22.: Comparison of selectivity α and resolution R within the series of 
N-protected aminosulfonic acids; column 6: DHQD-type, 232 µmol/g.  
 
3.11.4. N-protected aminophosphonates 
 
For structure comparative studies a number of different aminophosphonate 
derivatives was also employed. In figure 3.23. the summarized results in terms of 
selectivity coefficients and resolution are shown for column 6 (DHQD-type, 
232 µmol/g). 
One can clearly see that PI-2-4-3 (N-FMOC-protected α-phenylphosphonic acid 
methyl ester) shows the largest value both for selectivity and resolution. Both values 
are slightly decreased when exchanging the α-phenyl by a butyl residue as it was 
observed for PI-2-15-1. Exchanging the α-phenyl by a benzyl residue results in a 
drop of the two chromatographic parameters.  
The only structural difference between PI-2-15-1 and PI-2-87-1 is the protecting 
group (Z in case of PI-2-87-2 instead of FMOC). In this case the FMOC-protected 
aminophosphonate shows much higher resolution and a selectivity coefficient that is 
almost a factor of 1.4 higher in comparison to Z-protection. Exchanging the methyl 
ester by a benzyl ester in case of PI-2-87-1 and PI-3-67-1, respectively, slightly 
increases the resolution, wherein the α-values are almost equal. Hydrolysis of the 
ester results in compound PI-2-56-2. There was just a very slight separation 
observed for the free phosphonic acid derivative compared to the methyl ester. The 
shorter the backbone alkyl chain, the higher selectivity was observed, although there 
is almost no difference between ethyl and propyl side chain for compound PI-2-38-1 
and PI-2-34-1.  
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Figure 3.23.: Comparison of selectivity α and resolution R among 
N-protected aminophosphonates; column 6: DHQD-type, 232 µmol/g.  
 
The aminophosphonate derivative PI-1-89-1 was not separated on column 6 (DHQD-
type CSP). This compound could never be separated on DHQD-type CSPs (column 
2, 4 and 6). Exactly the opposite was observed for DHQN-type CSPs (column 1, 3 
and 5), where at least partial separation could be observed. On column 13 and 14, 
which are standard QN-AX and QD-AX CSPs for comparative purposes, compound 
PI-1-89-1 could be separated on both QN and QD type CSP. 
 
3.11.5. FMOC-protected amino acids 
 
Because of the larger number of FMOC-protected amino acids present in the set of 
SAs, it is also possible to compare them with respect to the amino acid residue. 
Lämmerhofer et al. observed that these aryloxycarbonyl as well as the 
alkyloxycarbonyl amino acid derivatives behave in a similar way to their amido 
congeners because they are also capable of hydrogen donation and acceptation 
[49]. Since the elution order is the same when comparing DHQN and DHQD-type 
CSPs, an analogous mechanism for chiral separation can be assumed. 
No separation was observed for FMOC-Gln. The retention factor for the FMOC-Gln 
is k = 0.14, so almost no interaction with the SO was possible. Glutamine is an 
amino acid with a polar side chain, namely a primary amide. Hence a competitive 
hydrogen bonding of the primary amide group could be possible.  
Separation could be possible with a different mobile phase composition, but this has 
not been investigated so far. 
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Figure 3.24.: Comparison of selectivity α and resolution R  
within the series of N-protected amino acids; column 6: DHQD-type, 232 µmol/g.  
 
Interestingly, FMOC-Asn was partially separated on column 6. This observation 
cannot be explained without further experiments and mobile phase variations, 
because the behavior should be similar to FMOC-Gln (both amino acids contain a 
primary amide). When comparing FMOC-Aze and FMOC-Pro (both containing a 
heterocyclic ring consisting four or five atoms), one can observe no significant 
difference in terms of α and R.  
 
3.12. Comparison of Columns with the same total amount of SO 
 
Column 6, 7 and 12 do almost have the same total amount of immobilized SO per 
column (SO4, DHQD-type SO), but with different properties. The CSP in column 6 
has a SO loading of 232 µmol/g (column dimensions: 150x4 mm ID), column 12 is a 
short 75x4 mm ID column with a SO loading of 490 µmol/g and column 7 is a 
homogenous physical mixture made prepared from the same material used for 
packing column 12 and pure AzP-Silica (column dimensions: 150x4 mm ID). All in all 
almost the same total amount of SO is in all three columns. In figure 3.25. a model 
for these three columns is shown. 
When comparing all three columns with the same flow rate (1.0 mL/min), the 
retention times t1 of the first eluted enantiomers are similar for most of the SAs, but 
retention time of column 6 is in most cases the longest (see figure 3.26.).  
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This result indicates that the overall retention is predominantly dependent on the 
total amount of SO per column. 
 
 
 
Figure 3.25.: Model for the compared columns in terms of SO density 
distribution and column dimensions; light orange: 232 µmol/g (DHQD-type SO4); 
dark orange: 490 µmol/g (DHQD-type SO4); colorless: AzP-Silica particles.  
 
Column 7 and 12 behave more similar to each other compared to column 6, which 
behaves a bit different. For the aminosulfonic acids retention time t1 is significantly 
higher, as well as for the aminophosphonates. The same results were observed for 
the retention times of the second eluted enantiomer (not shown here, for the data 
see appendix). 
There was no separation observed for PFB-Leu and DNB-N-methyl leucine for 
columns 7 and 12. On the other hand, PFB-Leu was partially separated on column 6 
(α = 1.09). The retention factors (see figure 3.27.) are comparable but slightly lower 
for most of the SAs for column 7 compared to column 6. This reflects the 
expectation. The CSP in column 7 is a physical mixture prepared from CSP4 and 
pure AzP-Silica to give an average SO density of 238 µmol/g. The distribution of the 
SO density is locally inhomogenous. Figure 3.25. can be seen as a model for the 
SO density distribution.  
As one can imagine, the retention strength along the column is always the same for 
column 6 and 12 because of homogenous SO-concentration along the whole 
column. 
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Figure 3.26.: Comparison of the retention times of the first eluted enantiomer; 
flow rate always 1.0 mL/min; column 6: DHQD-type, 232 µmol/g; 
column 7: DHQD-type, 238 µmol/g; column 12: DHQD-type, 490 µmol/g.  
 
The different properties are also reflected in the selectivity coefficient alpha, the 
resolution R and the average number of theoretical separation plates Nav: For this 
comparative purpose the flow rates are different to ensure a fair comparison. The 
flow rate for the two 150 mm long columns is 1.0 mL/min in comparison to the half of 
the flow rate (0.5 mL/min) for the column with the half of the length (75 mm). The 
selectivity coefficients are comparable for the high loaded short column 12 and the 
physical mixture CSP in column 7 with the same total amount of SO (see 
figure 3.28.).  
There was no separation observed for PFB-Leu and DNB-N-Me-Leu both for 
columns 7 and 12, as already mentioned above.  
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Figure 3.27.: Comparison of the retention factors k1; flow rate for columns 6 and 7: 
1.0 mL/min.; column 6: DHQD-type, 232 µmol/g; column 7: DHQD-type, 238 µmol/g. 	  
 
 
 
 
 
 
 
 	  
 
Figure 3.28.: Comparison of the selectivity coefficients; flow rate for columns 6 and 7 
1.0 mL/min, for column 12 0.5 mL/min.; column 6: DHQD-type, 232 µmol/g; 
column 7: DHQD-type, 238 µmol/g; column 12: DHQD-type, 490 µmol/g.  
 
The resolution R for column 6 is always higher compared to 7 and 12 (see 
figure 3.29.). Columns 7 and 12 are – in terms of resolution – more similar. This 
leads to the conclusion that a high-loaded CSP like in the case of the 75x4 mm ID 
column 12 (490 µmol/g) is not as efficient as a middle-loaded CSP like in the case of 
column 6 (150x4 mm ID, 232 µmol/g). They both include the same total amount of 
SO, but the average efficiency is almost doubled (factor of 1.9) for column 6 in 
comparison to column 12. The difference between column 6 and 7 is even higher 
(average factor of 2.3 in terms of resolution).  
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Figure 3.29.: Comparison of the resolution; flow rate for columns 6 and 7 1.0 mL/min, 
for column 12 0.5 mL/min.; column 6: DHQD-type, 232 µmol/g; column 7: DHQD-type, 
238 µmol/g; column 12: DHQD-type, 490 µmol/g.   
 
The average numbers of theoretical plates Nav are compared in figure 3.30.. One 
can clearly see that in the case of column 6 the number of theoretical plates is higher 
in comparison to the two other columns. Columns 7 and 12 do have almost the same 
number of theoretical plates (Nav = 1473 and 1443, n = 20, all measured 
compounds). Compared to column 6 Nav (4691, n = 67, all measured compounds) is 
decreased for both of them by an average factor of 3.2. 
 
 
 
Figure 3.30.: Comparison of average number of theoretical plates Nav; flow rate for columns 6 
and 7 1.0 mL/min, for column 12 0.5 mL/min.; column 6: DHQD-type, 232 µmol/g; column 7: 
DHQD-type, 238 µmol/g; column 12: DHQD-type, 490 µmol/g.   
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3.13. Effects of different SO loading 
 
Because a large number of CSPs with different SO loading was prepared, it was 
possible to determine the effect of SO loading with regards to retention, selectivity, 
resolution and efficiency. The columns used for this study were all packed with 
DHQD-type CSPs based on the same SO (SO4), but with different SO density on the 
surface. In table 3.3. a summary of all used columns for determining the effects of 
different SO loading including their properties is given. 
 
Table 3.3.: Summary of all used columns for determining 
the effects of different SO loading (all SOs DHQD-type). 
Column CSP Type of Dimensions Dimensions SO loading 
Number Number SO of the columns of Silica [µmol/g] 
4 CSP4 
SO4 150x4 mm ID 5 µm, 120 Å 
490 
8 CSP8 314 
6 CSP6 232 
9 CSP9 150 
 
Of course retention time and k-values are increasing with higher SO loading as 
depicted in figure 3.31. (see below). An almost linear relationship for example was 
observed for the aminosulfonic acid derivative P-DML-ACHSA. CSP8 with 
314 µmol/g slightly differs from the other CSPs in terms of k-values. 
 
Figure 3.31.: Dependency of k2 of the SO loading (DHQD-type).  
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In figure 3.32. a more detailed diagram of the k2 dependency on the SO loading for 
N-protected amino acid derivatives is shown. The overall effect of increasing 
retention factors among higher SO loading was observed for every single acidic SA, 
including N-protected aminosulfonic acids, carboxylic acids and N-protected 
aminophosphonates. 
 
Figure 3.32.: Dependency of k2 of the SO loading (DHQD-type) shown for 
a series of N-protected amino acid derivatives.  
 
A different behavior was observed for the selectivity coefficient alpha. The selectivity 
drops with increasing SO loading for every single acidic SA. This trend is close to 
linear behavior.  
 
Figure 3.33.: Dependency of the selectivity of the SO loading (DHQD-type).  
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The corresponding resolution has a maximum value at a SO loading of 314 µmol/g, 
higher loading results in rapid loss of resolution. This result indicates a blockage of 
the silica pores due to high SO loading which leads to the limited conformational 
freedom of the immobilized SOs, and thus hindered interactions with SAs. Before 
this threshold of about 310 µmol/g the resolution-values increase with increasing SO 
loading. A SO concentration of about 310 µmol/g seems to be an optimal coverage. 
 
 
Figure 3.34.: Dependency of the resolution of the SO loading (DHQD-type). 
 
Exactly the same behavior was observed for the resolution-dependent number of 
theoretical plates for separation. After exceeding the limit value at 314 µmol/g N 
drops rapidly and efficiency is actually decreased below the value obtained for a SO 
loading of 150 µmol/g.  
 
 
Figure 3.35.: Dependency of the number of theoretical plates of the SO loading (DHQD-type). 
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Since a lower loading also results in higher selectivity values and lower retention 
times, a quite low selector-loaded CSP (e.g. 150 µmol/g) has to be preferred relative 
to a CSP with saturated SO density, which of course is more economic as well. 
 
3.14. Comparison of Column 8 to QD-AX  
 
Regarding the effects of different SO loading column 8 is well suited for a 
comparison to the standard QD-AX CSP packed column 14. Both these columns are 
quinidine derived CSPs and contain a similar amount of immobilized SO per gram 
silica (column 8 314 µmol/g; column 14 app. 340 µmol/g). The QD-AX SO has been 
immobilized via radical thiol alkene addition using the vinyl residue at position 3 of 
the quinuclidine ring as immobilizing anchor. The two CSPs are therefore not only 
different in the structure of the SO, but also immobilized via different immobilization 
strategies at different positions, because CSP8 in column 8 has been immobilized 
via Huisgen alkyne-azide click chemistry with the propargyl moiety of the aromatic 
linker as an immobilizing anchor. For the structure of the CSP in column 14 see 
figure 3.1., the structure of CSP8 is shown in the experimental part of the thesis. 
 
 
Figure 3.36.: Comparison of the selectivities of column 8 and column 14; column 8: 
DHQD-type, 314 µmol/g; column 14: QD-AX type, app. 340 µmol/g.  
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Figure 3.37.: Comparison of the resolution-values of column 8 and column 14; 
column 8: DHQD-type, 314 µmol/g; column 14: QD-AX type, app. 340 µmol/g. 
 
First of all, the two columns differ in the general separation capability for chiral acidic 
compounds. DNB-Pro was not separated on QD-AX, whereas flurbiprofen was not 
separated on column 8 under the given mobile phase composition. All the other 
samples shown in figure 3.36. and 3.37. were at least partially separated.  
The alpha-values obtained with QD-AX are generally higher compared to column 8. 
The difference for example for DCB-Leu is striking, also for the two aminosulfonic 
acids P-DML-ACHSA and P-DCL-ACHSA. The same results were observed in terms 
of resolution. Solvophobic effects and different binding increments in terms of 
relative strength and position could make the difference in this case. 
One exception is DBTAMME (dibenzoyltartaric acid monomethyl ester), where the 
behavior is exactly the opposite.  
 
3.15. Loading Study  
 
The loadability of the highest-loaded CSP in terms of a possible preparative 
application was another topic for the evaluation. Therefore an SA that meets several 
criteria has to be used:  
 
• Solubility in methanol or mobile phase should be high. 
• Retention time should be short. 
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• Selectivity coefficient and resolution-value should be reasonably large. 
• The SA must be available in larger quantities than analytical amounts.  
 
This loading study was performed with racemic Ac-Phe as an SA of choice. Ac-Phe 
was not the SA with the best prerequisites, but it was a compromise between all the 
criteria. In order to avoid long retention time a 75x4 mm ID column with 490 µmol/g 
SO loading (CSP4, column 12) and a SA solution with a concentration of 100 mg/mL 
in MeOH were used. Further chromatographic conditions that were used were 
0.5 mL/min flow rate, 15 min run time and a detection wavelength of 270 nm. 
  
Figure 3.38.: Absorption spectra of Ac-Phe. 
 
The wavelength was chosen higher than the usual 254 nm for screening, because 
sensitivity is lower and therefore the detector does not reach its limit at higher 
concentrations. In figure 3.38. an absorption spectrum of Ac-Phe from 210 to 
310 nm is shown. As an initial mobile phase the same phase composition as used 
for screening was applied (MeOH/AcOH/NH4OAc 99/1/0.25 v/v/w).  
 
 
 
Figure 3.39.: Chromatogram for Ac-Phe (α = 1.37); column 12 (75x4 mm ID, 
490 µmol/g, DHQD-type CSP); injection volume: 5 µL (= 0.5 mg); sample concentration: 
100 mg/mL Ac-Phe in MeOH; flow rate: 0.5 mL/min; detection wavelength: 270 nm; mobile 
phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C. 
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Figure 3.40.: Chromatogram for Ac-Phe (α = 1.58); column 15 (75x4 mm ID, app. 340 µmol/g, 
QD-AX type CSP); injection volume: 5 µL (= 0.5 mg); sample concentration: 100 mg/mL Ac-Phe 
in MeOH; flow rate: 0.5 mL/min; detection wavelength: 270 nm; mobile phase composition: 
MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C. 
 
In figure 3.39. one chromatogram for a 5 µL injection volume (0.5 mg total amount 
of injected SA) is shown. Retention time is 6.26 min for the first eluted enantiomer (L) 
and 8.05 min for the second eluted enantiomer (D) at a void time of 1.46 min; 
selectivity coefficient of 1.37 and a resolution of 1.96. Both enantiomers are baseline 
separated according to the chromatogram.  
For comparative purposes another loading study was carried out with a 75x4 mm ID 
standard QD-AX column (column 15). For a better comparison of the two columns, 
retention time for QD-AX had to be adjusted and therefore extended, because it was 
not the same as for column 12 (see figure 3.40.). It was easily possible to adjust the 
k2-value via modification of the buffer concentration (counter-ion concentration) by 
diluting the standard mobile phase with pure MeOH [67]. This behavior follows the 
well-established stoichiometric displacement model [13, 78].  
Alternative possibilities would be to vary the flow rate, pH-value, temperature and the 
content of organic modifier like ACN. In previous studies by Mandl et al. it has been 
shown that according to an anion-exchange mechanism the retention times are 
decreasing with increasing buffer salt concentration in the mobile phase [50]. 
However, enantioselectivity remains almost constant and therefore it is not 
significantly affected by the buffer concentration [13]. 
 
4.223 
5.762 
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Table 3.4.: Adjustment of k2 by variation of the buffer concentration. 
k2 log(k2) Bufferconc. [%] log(1/Bufferconc.) 
5.762 0.761 0.250 0.602 
7.706 0.887 0.125 0.903 
9.841 0.993 0.063 1.204 
8.049 0.906 0.107 0.971 
 
 
In figure 3.41. and table 3.4. the results for the adjustment of the buffer 
concentration are shown. Using the linear equation it was easily possible to adjust 
the k2-value for column 15 (QD-AX type) without a significant loss of 
enantioselectivity. In reality the adjusted k2-value was slightly higher than the 
calculated k2-value, because the mobile phase was freshly prepared and not diluted 
from the concentrated version used for the mobile phase variation.  
 
Figure 3.41.: Linear correlation between log(k2) vs. log(bufferconcentration-1); 
column 15: QD-AX type, app. 340 µmol/g. 
 
 
In figure 3.42. one can see the overlaid chromatograms for column 12. The retention 
is shifted to lower retention times the higher the amount of injected sample is, 
because the higher retained enantiomer (Ac-D-Phe) acts as a displacer for the lower 
retained enantiomer (Ac-L-Phe). Furthermore, overloading-effects of the column are 
involved in the retention.  
 
y = 0.3861x + 0.5314         R² = 0.99753 
0.4 
0.6 
0.8 
1.0 
1.2 
1.4 
1.6 
1.8 
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 
lo
g 
(k
2)
 o
r α
   
 
log (bufferconcentration-1) 
 
   α 
	   - 81 - 
 
Figure 3.42.: Overlaid chromatograms for Ac-Phe; column 12 (75x4 mm ID, 490 µmol/g, DHQD-
type CSP); injection volume: 5-100 µL (0.5-10 mg); sample concentration: 100 mg/mL Ac-Phe in 
MeOH; flow rate: 0.5 mL/min; detection wavelength: 270 nm; mobile phase composition: 
MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C. 
 
The selectivity is almost constant (column 12 αav = 1.36, n = 9; QD-AX αav = 1.57, 
n = 12), as well as the end of the second peak at about 10 minutes. The resolution 
and plate numbers are of course decreasing rapidly with higher amount of injected 
sample (data not shown here, see appendix). In figure 3.43. the overlaid 
chromatograms for QD-AX column 15 are shown. One can clearly see that the 
sample contains impurities, which are retained exactly in between the two 
enantiomers of Ac-Phe. However, for a possible preparative purpose this would not 
be a problem because one can easily cut impurity-containing fractions out of the 
fractions with the pure enantiomer as the product. 
With the assumption that approximately 0.7 g of CSP are packed in a 75x4 mm ID 
column, the calculated theoretical productivity for column 12 is about 0.4 kg pure 
enantiomer per kg CSP per day. For QD-AX the productivity is about 0.6 kg/kg/day, 
so 50% higher. Please note that the selectivity coefficient for the separation on 
QD-QX is higher in comparison to column 12 (see above), so therefore the 
productivity has to be better.  
The calculated productivities are just approximate calculations for one mobile phase 
system. There are many parameters, which can be optimized to achieve higher 
productivities. 
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Figure 3.43.: Overlaid chromatograms for Ac-Phe; column 15 (75x4 mm ID, app. 340 µmol/g, 
QD-AX type CSP); injection volume: 5-100 µL (0.5-10 mg); sample concentration: 100 mg/mL 
Ac-Phe in MeOH; flow rate: 0.5 mL/min; detection wavelength: 270 nm; mobile phase 
composition: MeOH/AcOH/NH4OAc 99.46/0.43/0.11 (v/v/w); temperature: 25°C. 
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4. Experimental Part 
 
4.1. Materials and Methods 
 
1H-NMR and 13C-NMR spectra were measured with a Bruker DRX 400 spectrometer 
(Karlsruhe, Germany) at 400 MHz and 100 MHz, respectively, at room temperature. 
Either CDCl3 or CD3OD (both 99.8%, Deutero GmbH, Kastellaun, Germany) were 
used as solvents and the solvent signals were used as reference signals. The raw 
data were processed with SpinWorks 2.5 software. 
The IR-measurements were carried out on a Bruker Tensor 27 Diamond ATR FTIR 
spectrometer (Ettlingen, Germany) with Opus 4.2 software.  
Mass spectrometric measurements of the selectors (SOs) were performed using a 
4000 QqLIT mass spectrometer with an ESI ion source from Applied Biosystems 
(Foster City, USA). All mass spectrometric measurements were carried out in 
positive ionization mode. For data processing the software Analyst 1.5 was used. 
The mass spectrometer was coupled with a 1200 series HPLC system from Agilent 
Technologies (Santa Clara, USA). The chromatographic runs for LC/MS were done 
using reversed phase mode chromatography. 
CHNS elemental analyses of the CSPs were operated on a EURO EA 3000 
CHNS-O instrument from HEKAtech (Wegberg, Germany). Determination of the 
chlorine content of the CSPs was performed using potentiometric titration with a 
Mettler DL 21 titrator (Greifensee, Switzerland). 
For thin layer chromatography TLC Silica gel 60 F254 from Merck was used. Flash 
column chromatography was carried out using Normasil 60 Silica Gel from VWR. 
Daisogel SP-120-5P from Daiso (Japan) was used as a basis for AzP-Silica and 
MP-Silica (both 5 µm, 120 Å). MP-Silica was prepared by modification and 
endcapping in house. 
The solvents for synthesis were purchased from VWR, ROTH, DonauChem, Sigma-
Aldrich, Merck and FLUKA. As reagents and catalysts the following chemicals were 
used: 3,5-dichloro-4-hydroxybenozic acid (97%, Sigma-Aldrich), allyl bromide (99%, 
Aldrich), propargyl bromide (80% in toluene, FLUKA), (COCl)2 (98%, Aldrich), 
anhydrous DMF (99.8%, Sigma-Aldrich), NaN3 (>99%, Aldrich), DHQN and 
DHQD.HCl (both >97%, Buchler), dibutyltin dilaurate (95%, Aldrich), AIBN (≥98%, 
Merck), p-toluenesulfonic acid monohydrate (98.5%, Sigma-Aldrich), 3-chloropropyl-
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trimethoxysilane (97%, ABCR), tetrabutylammonium iodide (98%, Merck), 
diisopropylethylamine (98%, FLUKA), CuI (98%, Aldrich), EDTA disodium salt (99%, 
FLUKA) and propargyl alcohol (99%, AcrosOrganics). 
As mobile phase compounds the following chemicals were used: MeOH (HPLC 
grade quality, 99.8%, VWR), AcOH (≥ 99%, Sigma-Aldrich) and NH4OAc (≥ 97%, 
p.a., Fluka). 
 
4.2. Synthesis of Linker 1 
 
4-Allyloxy-3,5-dichlorobenzoic acid allyl ester (2a) 
33.88 g of 3,5-dichloro-4-hydroxybenzoic acid 1 (158.8 mmol), 32 mL allyl bromide 
(369.8 mmol) and 64.85 g of potassium carbonate (447.5 mmol) were suspended in 
300 mL of acetone and refluxed for 16 h. The orange suspension was cooled to 
room temperature and poured into 600 mL of water. After extraction with EtOAc 
(3x100 mL), the combined organic phases were washed with 100 mL of H2O and 
50 mL of saturated aqueous NaCl solution. The combined organic solution was dried 
with anhydrous MgSO4, filtered and evaporated under reduced pressure. The 
obtained orange crude 4-allyloxy-3,5-dichlorobenzoic acid allyl ester was then 
purified by flash column chromatography on silica (250 g of silica, PE/EtOAc 20:1). 
The fractions with pure intermediate (control on TLC with the same mobile phase as 
used for flash column chromatography) were collected, filtered and evaporated 
under reduced pressure.  
Yield: 40.55 g (141.2 mmol, 89%) of a colorless transparent oil. 
1H-NMR [CD3OD]: δ = 7.87 (s, 2H), 6.03 (m, 1H), 5.94 (m, 1H), 5.32 (m, 2H), 
5.19 (m, 2H), 4.72 (m, 2H), 4.54 (m, 2H). 
13C-NMR [CD3OD]: δ = 172.6 (C=O), 154.1 (Car-O), 134.7 (CarCl), 134.3 (CarH), 
131.6 (CH), 131.6 (CH), 130.4 (Car), 120.7 (CH2=), 120.4 (CH2=), 76.3 (CH2), 
68.0 (CH2). 
IR: 3074 cm-1 (ν=CH2), 1719 cm-1 (νC=O). 
 
4-Allyloxy-3,5-dichlorobenzoic acid (3a) 
The 4-allyloxy-3,5-dichlorobenzoic acid allyl ester 2a (40.55 g, 141.2 mmol) was 
diluted with 60 mL of EtOH and a solution of 12.15 g NaOH (303.8 mmol) in 60 mL 
H2O was added. The reaction mixture was refluxed for 1 h. After cooling to 0°C the 
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orange-brown solution was diluted with 30 mL EtOH and 50 mL of H2O. After 
acidification with concentrated HCl to pH~2 the 4-allyloxy-3,5-dichlorobenzoic acid 
3a immediately precipitated as a white solid. The suspension was filtered, the 
filtration cake was washed with cold H2O (2x100 mL) and afterwards dried under 
reduced pressure at 60°C for 48 h. 
Yield: 34.80 g (140.9 mmol, quantitative yield) of a white solid. 
1H-NMR [CD3OD]: δ = 7.97 (s, 2H), 6.15 (m, 1H), 5.35 (dd, 2H), 4.89 (s, 1H), 
4.64 (d, 2H). 
13C-NMR [CD3OD]: δ = 167.7 (C=O), 156.5 (Car-O), 134.5 (CarH), 131.8 (CH), 
131.3 (CarCl), 130.0 (Car), 119.7 (CH2=), 76.0 (CH2). 
IR: 3077 cm-1 (ν=CH2), 1690 cm-1 (νC=O). 
 
4-Allyloxy-3,5-dichlorobenzoyl chloride (4a) 
Dry 4-allyloxy-3,5-dichlorobenzoic acid 3a (10.83 g, 43.8 mmol) was slowly 
suspended in 50 mL of (COCl)2 and four drops of dry DMF as a catalyst were added 
slowly. The suspension was refluxed for 1 h while it turned into an orange clear 
solution with a small amount of brown precipitate. The main part of unreacted oxalyl 
chloride was distilled off and 70 mL of petroleum ether (PE) were added to the 
reaction mixture together with a spatula tip of activated carbon (app. 200 mg) for 
adsorption of side products and impurities. After refluxing for three min the still 
boiling reaction mixture was filtered and evaporated under reduced pressure. No 
further purification was carried out. Characterization of the product by NMR and IR 
spectroscopy was not carried out, because the product is not very stable and 
therefore it was directly converted into the corresponding acyl azide.  
Yield: 11.04 g (41.6 mmol, 95%) of an orange-brown liquid acyl halide. 
 
4-Allyloxy-3,5-dichlorobenzoyl azide (5a) 
The acyl halide 4a (11.04 g, 41.6 mmol) was dissolved in 70 mL of cold acetone and 
cooled to 0°C. A solution of 12.55 g NaN3 (193.0 mmol) in 40 mL of H2O was then 
added dropwise to the acyl halide solution under vigorous stirring during 1 h at 0°C. 
After a while a white precipitate appeared in the red-brown solution. The reaction 
mixture was then diluted with 100 mL of water and extracted with EtOAc (3x75 mL). 
The combined organic phases were washed with 30 mL of saturated aqueous NaCl 
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solution, dried with MgSO4, filtered and evaporated under reduced pressure at room 
temperature. No further purification was carried out. 
Yield: 9.83 g (36.1 mmol, 87%) of an orange-brown oil. 
1H-NMR [CD3OD]: δ = 7.88 (d, 2H), 6.05 (m, 1H), 5.35 (d, 1H), 5.23 (d, 1H), 
4.57 (d, 2H). 
13C-NMR [CD3OD]: δ = 170.4 (C=O), 156.2 (Car-O), 132.8 (CarH), 130.6 (CarCl), 
130.4 (CH), 127.9 (Car), 119.9 (CH2=), 75.1 (CH2). 
IR: 3073 cm-1 (ν=CH2), 2162 cm-1 (νN3), 1686 cm-1 (νC=O). 
 
4-Allyloxy-3,5-dichlorophenylisocyanate (L1) 
The last step of the synthesis of L1 was the formation of isocyanate via Curtius-
rearrangement of the acyl azide. The acyl azide 5a (9.83 g, 36.1 mmol) was 
dissolved in 100 mL of azeotropically dried toluene and refluxed for 3h. Emerging 
nitrogen indicated the successful rearrangement. After 3 h no nitrogen bubbles were 
visible in the bubble counter, so the reaction was completed. After evaporation of the 
solvent under reduced pressure, the transparent liquid isocyanate L1 was obtained 
by vacuum distillation (boiling point: 99°C at 0.10 mbar). The purified liquid product 
was stored in the freezer with air-exclusion, because the isocyanate is highly water 
sensitive. 
Yield: 7.22 g (29.6 mmol, 82%) of a colorless liquid L1. 
1H-NMR [CDCl3]: δ = 6.90 (s, 2H), 5.97 (m, 1H), 5.20 (dd, 2H), 4.39 (d, 2H). 
13C-NMR [CDCl3]: δ = 149.7 (Car-O), 133.0 (CH), 130.6 (CarCl), 130.5 (Car), 
125.4 (CarH), 119.6 (CH2=), 74.9 (CH2).  
IR: 2250 cm-1 (νN=C=O). 
 
4.3. Synthesis of Linker 2 
 
3,5-Dichloro-4-propargyloxybenzoic acid propargyl ester (2b) 
7.29 g of 3,5-dichloro-4-hydroxybenzoic acid 1 (34.2 mmol), 15.35 mL of propargyl 
bromide (80% in toluene, 118.7 mmol) and 8.35 g of potassium carbonate 
(60.4 mmol) were suspended in 40 mL of DMF and heated up to 60°C for 18 h. The 
orange-brown suspension was cooled to room temperature and poured into 150 mL 
of water. After extraction with EtOAc (3x75 mL), the combined organic phases were 
washed with 50 mL of H2O and 30 mL of saturated aqueous NaCl solution. The 
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combined organic solution was dried with MgSO4, filtered and evaporated under 
reduced pressure. The obtained orange-brown solid crude product was then purified 
by flash column chromatography on silica (150 g of silica, CH2Cl2 as a mobile phase 
for flash column chromatography and fraction control on TLC). The fractions with 
pure intermediate were collected, filtered and evaporated under reduced pressure.  
Yield: 9.23 g (32.6 mmol, 95%) of a white solid. 
1H-NMR [CDCl3]: δ = 8.02 (s, 2H), 4.89 (dd, 4H), 2.54 (t, 2H). 
13C-NMR [CDCl3]: δ = 163.7 (C=O), 154.5 (Car-O), 130.8 (CarCl), 130.7 (CarH), 
127.5 (Car), 77.7 (C4), 76.0 (CH), 61.0 (CH2), 53.5 (CH2). 
IR: 3298 cm-1 (ν≡CH), 3257 cm-1 (ν≡CH), 2125 cm-1 (νC≡C), 1710 cm-1 (νC=O). 
 
3,5-Dichloro-4-propargyloxybenzoic acid (3b) 
The 3,5-dichloro-4-propargyloxybenzoic acid propargyl ester 2b (9.23 g, 32.6 mmol) 
was dissolved in 70 mL of EtOH and a solution of 2.94 g NaOH (73.5 mmol) in 
40 mL H2O was added. The reaction mixture was refluxed for 1 h. The yellowish 
clear solution was diluted with 20 mL of EtOH and 20 mL of H2O and cooled down to 
0°C with an ice-bath. After acidification with concentrated HCl to pH~2, the 
3,5-dichloro-4-propargyloxybenzoic acid immediately precipitated as a white solid. 
The suspension was filtered and the filtration cake was washed with 2x100 mL of 
cold H2O and afterwards dried under reduced pressure at 60°C for 48 h. 
Yield: 7.30 g (29.8 mmol, 91%) of a white solid. 
1H-NMR [CD3OD+CDCl3]: δ = 7.97 (s, 2H), 4.85 (d, 2H), 2.79 (t, 1H). 
13C-NMR [CD3OD+CDCl3]: δ = 166.2 (C=O), 153.9 (Car-O), 130.6 (CarH), 
130.3 (CarCl), 129.0 (Car), 78.2 (CH), 77.9 (C4), 60.9 (CH2). 
IR: 3294 cm-1 (ν≡CH), 2131cm-1 (νC≡C), 1698 cm-1 (νC=O). 
 
3,5-Dichloro-4-propargyloxybenzoyl chloride (4b) 
7.30 g of the acid 3b (29.8 mmol) were slowly suspended in 50 mL of (COCl)2 at 0°C 
and four drops of dry DMF as a catalyst were added slowly. The suspension was 
stirred at 0°C for 15 min and then heated up to 30°C for 45 min. The suspension 
turned into a yellowish clear solution with little brown drops. The bulk of unreacted 
oxalyl chloride was then distilled off and 120 mL of PE were added to the reaction 
mixture together with a spatula tip of activated carbon (app. 200 mg) for adsorption 
of side products and impurities. After refluxing for 3 min the still boiling reaction 
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mixture was filtered and evaporated under reduced pressure. No further purification 
was carried out. Characterization of the product by NMR and IR spectroscopy was 
not carried out, because the product is not very stable. The acyl chloride was then 
directly converted into acyl azide. 
Yield: 7.16 g (27.2 mmol, 91%) of a slightly yellowish solid acyl halide. 
 
3,5-Dichloro-4-propargyloxybenzoyl azide (5b) 
7.16 g of the acyl chloride 4b (27.2 mmol) were dissolved in 70 mL of cold acetone 
and cooled to 0°C with an ice-bath. A solution of 5.48 g NaN3 (84.3 mmol) in 30 mL 
of H2O was then added dropwise to the acyl halide solution under vigorous stirring 
during 1 h at 0°C. After a while a voluminous white precipitate appeared in the 
orange solution. The precipitate was filtered and washed with cold H2O (2x50 mL). 
For an effective drying the filtration cake was dissolved in 150 mL of EtOAc and the 
organic solution was washed with 20 mL of H2O, 20 mL of saturated aqueous NaCl 
solution and afterwards dried with anhydrous MgSO4. Evaporation of the solvent and 
drying under vacuum at room temperature yielded a fully dry product.  
Yield: 6.43 g (23.8 mmol, 88%) of a white solid. 
1H-NMR [CDCl3]: δ = 7.91 (s, 2H), 4.81 (d, 2H), 2.47 (t, 1H). 
13C-NMR [CDCl3]: δ = 170.3 (C=O), 155.2 (Car-O), 130.9 (CarCl), 130.4 (CarH), 
128.6 (Car), 77.7 (CH), 77.0 (C4), 61.1 (CH2).  
IR: 3297 cm-1 (ν≡CH), 2166 cm-1 (νN3), 1686 cm-1 (νC=O). 
 
3,5-Dichloro-4-propargyloxyphenylisocyanate (L2) 
5.21 g of the acyl azide 5b (19.3 mmol) were dissolved in 200 mL of azeotropically 
dried toluene and refluxed for 3 h. After evaporation of the solvent under reduced 
pressure a white solid was obtained by vacuum distillation, but implementation of the 
distillation was difficult and only 1.41 g of L2 (5.8 mmol, 30%) could be isolated. 
Therefore the formation of L2 was carried out in azeotropically dried toluene as 
described above. The reaction solution was then cooled to room temperature and L2 
was directly used in solution without further purification, because isolation by vacuum 
distillation resulted in large losses of the product.  
1H-NMR [CDCl3]: δ = 7.10 (s, 1H), 6.91 (s, 1H), 4.60 (dd, 2H), 2.37 (m, 1H). 
13C-NMR [CDCl3]: δ = 125.4 (CarCl), 119.2 (Car), 76.6 (C4), 61.0 (CH), 53.1 (CH2). 
IR: 3294 cm-1 (ν≡CH), 2263 cm-1 (νN=C=O). 
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4.4. Synthesis of Selector 1 
 
9-(4-Allyloxy-3,5-dichlorophenylcarbamoyl)dihydroquinine (SO1) 
1.84 g of commercially available DHQN (5.6 mmol) were dissolved in 100 mL of 
toluene. After flushing the apparatus with nitrogen, 50 mL of toluene were distilled off 
under nitrogen atmosphere. After finishing the drying process 1.51 g of L1 
(6.2 mmol) and 40 µL of DBTDL as a catalyst were added with nitrogen flushing of 
the apparatus. The reaction mixture was refluxed for 16 h. Due to several by-
products visible on TLC the clear brownish solution was evaporated to dryness and 
the crude product was purified by flash column chromatography on silica (150 g of 
silica, CH2Cl2/MeOH 10:1). The fractions with pure product (monitored by TLC using 
the same eluent) were collected, filtered and evaporated under reduced pressure. 
The obtained solid was dried under vacuum at room temperature. 
Yield: 2.85 g (5.0 mmol, 89%) of a white solid. 
1H-NMR [CDCl3]: δ = 8.67 (d, 1H), 7.99 (d, 1H), 7.48 (d, 1H), 7.35 (d, 1H), 
7.33 (s, 2H), 7.26 (d, 1H), 6.54 (d, 1H), 6.11 (m, 1H), 5.38 (dd, 1H), 5.25 (dd, 1H), 
4.49 (d, 2H), 3.96 (s, 3H), 3.34 (q, 1H), 3.15-2.95 (broad, 2H), 2.63 (m, 1H), 
2.36 (d, 1H), 1.89-1.78 (broad, 2H), 1.77-1.64 (broad, 1H), 1.59-1.39 (broad, 3H), 
1.39-1.22 (broad, 2H), 0.86 (t, 3H).  
13C-NMR [CDCl3]: δ =158.6 (Car-O), 152.4 (C=O), 147.3 (CarH), 144.7 (Car), 
143.4 (Car), 134.4 (Car), 132.9 (CH=), 131.7 (CarH), 129.7 (Car), 127.2 (Car), 
121.9 (CarH), 118.8 (CH2=), 118.8 (CarH), 118.7 (CarH), 101.4 (CarH), 74.4 (CH), 
74.4 (CH2), 58.9 (CH), 58.0 (CH2), 55.7 (CH3-O), 42.6 (CH2), 37.3 (CH), 28.3 (CH2), 
27.7 (CH2), 25.2 (CH), 24.2 (CH2), 12.1 (CH3). 
IR: 2930 cm-1, 2865 cm-1, 1730 cm-1 (νC=O). 
MS [ESI, positive]: 570 [M+H]+, 286 [M+2H]2+. 
 
4.5. Synthesis of Selector 2 
 
DHQD free base 
5.0 g of commercially available DHQD.HCl (13.8 mmol) were dissolved in 800 mL of 
H2O and alkalized with NaHCO3 to pH 8. The solution was stirred for 18 h at 50°C. 
DHQD as free base was extracted with CH2Cl2 (3x75 mL) and the combined organic 
phases were washed with 30 mL of H2O and 30 mL of saturated aqueous NaCl 
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solution. After drying with MgSO4 the solvent was evaporated. The obtained white 
crystals were dried under vacuum for 24 h. 
Yield: 4.50 g (quantitative yield).  
 
9-(4-Allyloxy-3,5-dichlorophenylcarbamoyl)dihydroquinidine (SO2) 
1.88 g of DHQD free base (5.8 mmol) were suspended in 100 mL of toluene. After 
flushing the apparatus with nitrogen 50 mL of toluene were distilled off under 
nitrogen atmosphere. After finishing the drying process 1.61 g of L1 (6.7 mmol) and 
40 µL of DBTDL as a catalyst were added. The reaction mixture was then refluxed 
for 16 h. Due to several by-products visible on TLC the clear brownish solution was 
evaporated to dryness and the crude product was purified by flash column 
chromatography on silica (150 g of silica, CH2Cl2/MeOH 10:1). The fractions with 
pure product monitored by TLC were collected, filtered and evaporated under 
reduced pressure. The obtained crystals were dried under vacuum. 
Yield: 2.12 g (3.7 mmol, 64%) of a white solid. 
1H-NMR [CDCl3]: δ = 8.70 (d, 1H), 8.01 (d, 1H), 7.48 (d, 1H), 7.38 (s, 2H), 
7.36 (d, 1H), 7.32 (d, 1H), 6.54 (d, 1H), 6.13 (m, 1H), 5.40 (dd, 1H), 5.27 (dd, 1H), 
4.53 (d, 2H), 3.97 (s, 3H), 3.73 (q, 2H), 3.31 (q, 1H), 2.95-2.56 (broad, 3H), 
1.77 (m, 1H), 1.65-1.41 (broad, 4H), 1.23 (t, 2H), 0.92 (t, 3H). 
13C-NMR [CDCl3]: δ = 158.4 (Car-O), 153.0 (C=O), 147.7 (CarH), 145.1 (Car), 
144.3 (Car), 134.9 (Car), 133.3 (CH=), 132.0 (CarH), 130.2 (Car), 127.8 (Car), 
122.3 (CarH), 119.4 (CH2=), 119.3 (CarH), 119.2 (CarH), 102.0 (CarH), 74.8 (CH), 
74.2 (CH2), 59.8 (CH), 58.8 (CH2), 56.0(CH3-O), 50.1 (CH2), 37.7 (CH), 27.6 (CH2), 
26.3 (CH), 25.9 (CH2), 24.4 (CH2), 12.4 (CH3). 
IR: 2933 cm-1, 2870 cm-1, 1729 cm-1 (νC=O). 
MS [ESI, positive]: 592 [M+Na]+, 570 [M+H]+, 286 [M+2H]2+. 
 
4.6. Synthesis of Selector 3 
 
9-(3,5-Dichloro-4-propargyloxyphenylcarbamoyl)dihydroquinine (SO3) 
1.85 g of commercially available DHQN (5.7 mmol) were dissolved in 100 mL of 
toluene. After flushing the apparatus with nitrogen 50 mL of toluene were distilled off 
under nitrogen atmosphere. After finishing the drying process 1.41 g of purified solid 
L2 (5.8 mmol) and 30 µL of DBTDL as a catalyst were added. The reaction mixture 
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was refluxed for 18 h. The clear dark green solution was then evaporated to dryness 
and because of several by-products visible on TLC the crude product was purified by 
flash column chromatography on silica (150 g silica, CH2Cl2/MeOH 10:1). The 
fractions with product were collected, filtered and evaporated under reduced 
pressure. The pre-purified not fully dry greenish solid was then coated onto 7.50 g of 
silica and further purified by flash column chromatography on silica (150 g silica, 
CH2Cl2/MeOH 10:1). The fractions with the pure product monitored by TLC were 
collected, filtered, evaporated and the obtained solid product was dried under 
reduced pressure.  
Yield: 2.10 g (3.7 mmol, 65%) of a slightly greenish solid. 
1H-NMR [CDCl3]: δ = 8.60 (d, 1H), 7.91 (d, 1H), 7.41 (d, 1H), 7.30 (d, 1H), 
7.20 (s, 2H), 7.19 (d, 1H), 6.46 (d, 1H), 4.64 (d, 2H), 3.89 (s, 3H), 3.27 (q, 1H),  
3.08-2.89 (broad, 2H), 2.56 (m, 1H), 2.43 (t, 1H), 2.29(d, 1H), 1.83-1.71 (broad, 2H), 
1.69-1.59 (broad, 1H), 1.51-1.32 (broad, 3H), 1.32-1.21 (broad, 2H), 0.80 (t, 3H). 
13C-NMR [CDCl3]: δ = 158.6 (Car-O), 152.8 (C=O), 147.7 (CarH), 146.4 (Car), 
145.2 (Car), 143.7 (Car), 135.4 (Car), 132.1 (CarH), 130.4 (CarCl), 127.6 (Car), 
122.4 (CarH), 119.2 (CarH), 101.8 (CarH), 78.3 (CH≡), 76.6 (C4), 60.9 (CH2), 
59.3 (CH), 58.5 (CH2), 56.2 (CH3-O), 43.0 (CH2), 37.7 (CH), 28.7 (CH2), 28.1 (CH2), 
25.6 (CH), 24.7 (CH2), 12.5 (CH3). 
IR: 3298 cm-1 (ν≡CH), 2930 cm-1, 2868cm-1, 1730 cm-1 (νC=O). 
MS [ESI, positive]: 1158 [2M+Na]+, 568 [M+H]+, 284 [M+2H]2+. 
 
4.7. Synthesis of Selector 4 
 
3,5-Dichloro-4-propargyloxyphenylisocyanate (L2) 
80 mL of toluene were dried via azeotropic distillation (30 mL of the solvent were 
removed). After addition of 2.38 g of dry acyl azide 5b (8.8 mmol), the yellowish 
solution was refluxed for 3 h to get the isocyanate L2 via Curtius-rearrangement. 
Then the solution was cooled to room temperature. An infrared spectrum of the 
solution confirmed the successful quantitative acyl azide conversion to isocyanate. 
IR: 2261 cm-1 (νN=C=O). 
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9-(3,5-Dichloro-4-propargyloxyphenylcarbamoyl)dihydroquinidine (SO4) 
2.10 g of DHQD (6.4 mmol) were suspended in 80 mL of toluene. After flushing the 
apparatus with nitrogen 40 mL of toluene were distilled off under nitrogen 
atmosphere. The suspension was cooled below the boiling point of toluene and then 
the previously prepared solution of L2 in dry toluene was added under nitrogen. 
Additional 30 mL of solvent were distilled off before adding 40 µL of DBTDL as a 
catalyst. The reaction mixture was then refluxed for 18 h. The initially white 
suspension became gradually turbid yellowish and a slightly brownish precipitate 
was formed at the bottom of the flask. 
After 18 h the reaction mixture was evaporated to dryness. The crude product was 
coated onto 15 g of silica and purified by flash column chromatography (200 g silica, 
CH2Cl2/MeOH 10:1). The fractions with pure product monitored by TLC were 
collected, filtered and evaporated to dryness. 
Yield: 2.07 g (3.6 mmol, 56%) of slightly brownish crystals. 
1H-NMR [CDCl3]: δ = 8.68 (d, 1H), 7.99 (d, 1H), 7.45 (d, 1H), 7.37 (s, 2H), 
7.34 (d, 1H), 7.30 (d, 1H), 6.53 (d, 1H), 4.71 (d, 2H), 3.95 (s, 3H), 3.28 (q, 1H), 
2.93-2.85 (broad, 1H), 2.82-2.54 (broad, 3H), 2.50 (t, 1H), 1.80-1.72 (broad, 2H), 
1.61-1.53 (broad, 2H), 1.50-1.38 (broad, 2H), 1.27-1.21 (broad, 2H), 0.90 (t, 3H).  
13C-NMR [CDCl3]: δ =158.5 (Car-O), 152.9 (C=O), 147.7 (CarH), 146.4 (Car), 
145.1 (Car), 144.2 (Car), 135.5 (Car), 132.1 (CarH), 130.4 (CarCl), 127.8 (Car), 
122.3 (CarH), 119.2 (CarH), 101.9 (CarH), 78.2 (CH≡), 76.6 (C4), 74.2 (CH), 
60.9 (CH2), 59.8 (CH), 56.0 (CH3-O), 51.2 (CH2), 37.7 (CH), 27.6 (CH2), 26.3 (CH), 
25.9 (CH2), 24.4 (CH2), 12.4 (CH3). 
IR: 3296 cm-1 (ν≡CH), 2932 cm-1, 2870 cm-1, 1728 cm-1 (νC=O). 
MS [ESI, positive]: 568 [M+H]+, 284 [M+2H]2+. 
 
4.8. Immobilization of SO1 onto MP-Silica = CSP1 
 
2.57 g of mercaptopropyl-modified silica (5 µm, 120 Å, endcapped with hexamethyl-
disilazane, 650 µmol thiol-groups per gram modified silica, corresponding to 
1.67 mmol thiol-groups), 1.76 g of SO1 (3.09 mmol) and 228 mg of AIBN as a radical 
starter were suspended in 25 mL of MeOH under nitrogen atmosphere. The 
suspension was mechanically stirred and heated under reflux. After 18 h the reaction 
mixture was cooled to room temperature and the modified silica was filtered with a 
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frit and washed with MeOH and CH2Cl2 (each 3x50 mL). After drying under vacuum 
at 60°C SO loading was determined by elemental analysis (EA). 
Yield: 2.56 g. 
EA: C: 10.93 w-%; H: 1.75 w-%; N: 0.749 w-%; S: 1.94 w-%; Cl: 0.960 w-%. 
SO loading calculated according to the nitrogen content: 179 µmol/g. 
 
4.9. Immobilization of SO2 onto MP-Silica = CSP2 
 
2.49 g of MP-Silica (5 µm, 120 Å, endcapped with hexamethyl-disilazane, 660 µmol 
thiol-groups per gram modified silica, corresponding to 1.64 mmol thiol-groups), 
1.76 g SO2 (3.10 mmol) and 212 mg of AIBN as a radical starter were suspended in 
30 mL of MeOH under nitrogen atmosphere. The suspension was mechanically 
stirred and heated under reflux. After 18 h the reaction mixture was cooled to room 
temperature and the silica was filtered with a frit and washed with MeOH and CH2Cl2 
(each 3x50 mL). After drying under vacuum at 60°C SO loading was determined by 
elemental analysis.  
Yield: 2.64 g. 
EA: C: 9.41 w-%; H: 1.64 w-%; N: 0.59 w-%; S: 1.92 w-%; Cl: 0.91 w-%. 
SO loading calculated according to the nitrogen content: 144 µmol/g. 
 
4.10. Synthesis of AzP-Silica 
 
Chloropropyl-modified silica (CP-Silica) 
15.78 g of silica (Daisogel for HPLC; Grade SP-120-5P, 5 µm, 120 Å) were 
suspended in 200 mL toluene and dried via azeotropic distillation. During the 
distillation 20 mg of p-toluenesulfonic acid were added to the suspension and also 
dried together with toluene and silica. After distilling off 100 mL of the solvent, the 
descending condenser was replaced by a dry reflux condenser and 4.6 mL of 
3-chloropropyltrimethoxysilane (25 mmol) were added to the suspension. The 
reaction mixture was mechanically stirred and heated under reflux for 18 h. The 
suspension was then cooled to room temperature, filtered with a frit, washed with 
toluene and methanol (each 2x100 mL) and resuspended in 100 mL toluene again. 
This suspension was mechanically stirred for 0.5 h and heated under reflux.  
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Afterwards the suspension was filtered and washed the same way as before. 
CP-Silica was then dried under vacuum at 60°C and chloropropyl-loading was 
determined by elemental analysis. 
Yield: 17.19 g. 
EA: C: 3.61 w-%; H: 1.01 w-%; N: < 0.03 w-%; S: < 0.01 w-%; Cl: 2.63 w-%. 
Chloropropyl-loading calculated according to the chlorine content: 742 µmol/g. 
 
Azidopropyl-modified silica (AzP-Silica) 
17.19 g of CP-Silica were suspended in 110 mL 0.5 M NaN3 in warm DMSO 
(55 mmol) and 60 mg of tetrabutylammonium iodide as a catalyst were added. This 
reaction mixture was then mechanically stirred for 72 h at 80°C. AzP-Silica was then 
filtered with a frit, washed with 500 mL H2O and 250 mL MeOH and dried under 
vacuum. Azide-loading was determined by elemental analysis. 
Yield: 16.07 g. 
EA: C: 3.64 w-%; H: 0.92 w-%; N: 2.64 w-%; S: < 0.01 w-%; Cl: 0.18 w-%. 
Azidopropyl-loading calculated according to the nitrogen content: 629 µmol/g (85% 
conversion from chloropropyl to azidopropyl). 
 
4.11. Immobilization of SO3 onto AzP-Silica = CSP3 
 
3.00 g of AzP-Silica (corresponding to 1.89 mmol -N3) and 1.78 g SO3 (3.13 mmol) 
were suspended in 60 mL of ACN in a glass bottle. 1.06 mL (6.25 mmol) of 
N,N-diisopropylethylamine were added and the suspension was sealed with a 
septum and degassed by flushing with N2 through a syringe needle for 10 min. 
25 mg of CuI (0.13 mmol, 6.9 mol% according to -N3) as a catalyst were added 
under nitrogen flushing and the glass bottle was closed and sealed with Parafilm®. 
The sealed glass bottle was shaken for 72 h on an overhead shaker at room 
temperature. After 48 h additional 22 mg of catalyst (0.12 mmol, 6.3 mol%) were 
added under nitrogen flushing, the glass bottle was closed and the reaction 
continued under given conditions. After 72 h the ocher reaction mixture was filtered 
with a frit and washed with ACN, MeOH, 2 w-% EDTA in H2O, MeOH/H2O 1:1 v/v, 
10 v-% AcOH in MeOH and pure MeOH (each 150 mL). CSP3 was then dried under 
vacuum at 60°C for 72 h. SO loading was determined by elemental analysis.  
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Yield: 4.07 g. 
EA: C: 19.20 w-%; H: 2.16 w-%; N: 4.24 w-%; S: < 0.02 w-%; Cl: 3.38 w-%. 
SO loading calculated according to the chlorine content: 477 µmol/g (76% 
conversion of azido-groups). 
 
4.12. Immobilization of SO4 onto AzP-Silica = CSP4 
 
3.00 g of AzP-Silica (corresponding to 1.89 mmol -N3) and 1.73 g of SO4 
(3.04 mmol) were suspended in 60 mL of ACN in a glass bottle. 1.06 mL of DIPEA 
(6.25 mmol) were added and the suspension was degassed for 10 min as described 
above. 25 mg of CuI (0.13 mmol, 6.9 mol% according to -N3) as a catalyst were 
added under nitrogen flushing and the glass bottle was closed and sealed with 
Parafilm®. The sealed glass bottle was shaken for 72 h on an overhead shaker. After 
48 h additional 21 mg of catalyst (0.11 mmol, 5.8 mol%) were added under nitrogen 
flushing and the reaction continued under given conditions. After additional 24 h the 
ocher reaction mixture was filtered with a frit and washed with ACN, MeOH, 2 w-% 
EDTA in H2O, MeOH/H2O 1:1 v/v, 10 v-% AcOH in MeOH and pure MeOH (each 
150 mL). CSP4 was then dried under vacuum at 60°C for 72 h. SO loading was 
determined by elemental analysis.  
Yield: 4.13 g. 
EA: C: 19.04 w-%; H: 2.19 w-%; N: 4.18 w-%; S: < 0.02 w-%; Cl: 3.48 w-%. 
SO loading calculated according to the chlorine content: 490 µmol/g (78% 
conversion of azido-groups). 
 
4.13. Immobilization of SO3 onto AzP-Silica = CSP5 
 
3.50 g of AzP-Silica (corresponds to 2.20 mmol -N3) and 458 mg of SO3 
(0.81 mmol) were suspended in 60 mL of ACN in a glass bottle. 1.24 mL of DIPEA 
(7.31 mmol) were added and the suspension was degassed by flushing with N2 for 
10 min as described above. 28 mg of CuI (0.15 mmol, 7.4 mol% according to -N3) as 
a catalyst were added under nitrogen flushing and the glass bottle was closed and 
sealed with Parafilm®. The sealed glass bottle was shaken for 72 h on an overhead 
shaker. After 48 h additional 25 mg of catalyst (0.13 mmol, 6.0 mol%) were added 
under nitrogen flushing and the reaction continued under given conditions. After 
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additional 24 h the greenish reaction suspension was filtered with a frit and washed 
with ACN, MeOH, 2 w-% EDTA in H2O, MeOH/H2O 1:1 v/v, 10 v-% AcOH in MeOH 
and pure MeOH (each 150 mL). CSP5 was then dried under vacuum at 60°C for 
three days. SO loading was determined by elemental analysis.  
Yield: 3.90 g.  
EA: C: 10.04 w-%; H: 1.41 w-%; N: 3.42 w-%; S: < 0.02 w-%; Cl: 1.52 w-%. 
SO loading calculated according to the chlorine content: 214 µmol/g (93% of SO3 
immobilized). 
 
4.14. Immobilization of SO4 onto AzP-Silica = CSP6 
 
2.40 g of AzP-Silica (corresponding to 1.51 mmol -N3) and 341 mg of SO4 
(250 µmol/g silica) were suspended in 50 mL of ACN in a glass bottle. 886 µL of 
DIPEA were added (5.21 mmol) and the suspension was degassed by flushing with 
N2 for 10 min. 36 mg of CuI (189 µmol, 12.5 mol% according to -N3) as a catalyst 
were added under nitrogen flushing and the glass bottle was closed and sealed with 
Parafilm®. The sealed glass bottle was shaken for 72 h on an overhead shaker. The 
ocher suspension was filtered with a frit and washed with ACN, MeOH, 2 w-% EDTA 
in H2O, MeOH/H2O 1:1 v/v, 10 v-% AcOH in MeOH and pure MeOH (each 150 mL). 
CSP6 was then dried under vacuum at 60°C for 24 h. SO loading was determined by 
elemental analysis.  
Yield: 2.68 g.  
EA: C: 9.90 w-%; H: 1.38 w-%; N: 3.11 w-%; S: < 0.02 w-%; Cl: 1.83 w-%. 
SO loading calculated according to the chlorine content: 232 µmol/g (93% of SO4 
immobilized). 
 
4.15. Preparation of CSP7 
 
1.23 g of CSP4 (490 µmol SO4 per gram silica) were combined with 1.28 g of 
AzP-Silica (azidopropyl-loading of 629 µmol/g) and suspended in 250 mL of MeOH 
to result in a calculated final selector-concentration of 240 µmol/g. This suspension 
was mechanically stirred at room temperature for 4 h. Afterwards the homogenously 
mixed silica material was filtered and washed with 50 mL of MeOH. CSP7 was dried 
under vacuum at 60°C for 24 h. SO loading was determined by elemental analysis. 
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Yield: 2.50 g. 
EA: C: 11.14 w-%; H: 1.54 w-%; N: 3.34 w-%; S: < 0.02 w-%; Cl: 1.69 w-%. 
SO loading calculated according to the chlorine content: 238 µmol/g (99% of the 
expected value). 
 
4.16. Immobilization of SO4 onto AzP-Silica = CSP8 
 
2.50 g of AzP-Silica (corresponding to 1.57 mmol -N3) and 512 mg of SO4 
(0.90 mmol) were suspended in 60 mL of ACN in a glass bottle. 1.0 mL of DIPEA 
was added (5.88 mmol) and the suspension was degassed by flushing with N2 for 
10 min. 50 mg of CuI (263 µmol, 17 mol% according to -N3) as a catalyst were added 
under nitrogen flushing and the glass bottle was closed and sealed with Parafilm®. 
The sealed glass bottle was shaken for 72 h on an overhead shaker. The yellow 
suspension was filtered with a frit and washed with ACN, MeOH, 2 w-% EDTA in 
H2O, MeOH/H2O 1:1 v/v, 10 v-% AcOH in MeOH and pure MeOH (each 150 mL). 
CSP8 was then dried under vacuum at 60°C for 24 h. SO loading was determined by 
elemental analysis.  
Yield: 2.79 g. 
EA: C: 12.96 w-%; H: 1.65 w-%; N: 3.28 w-%; S: < 0.02 w-%; Cl: 2.23 w-%. 
SO loading calculated according to the chlorine content: 314 µmol/g (87% of SO4 
immobilized). 
 
4.17. Immobilization of SO4 onto AzP-Silica = CSP9 
 
10.0 g of AzP-Silica (corresponding to 6.29 mmol -N3) and 853 mg of SO4 
(1.50 mmol) were suspended in 200 mL of ACN in a glass bottle. 10 mL of DIPEA 
were added (58.8 mmol) and the suspension was degassed by flushing with N2 for 
15 min. 200 mg of CuI (1.05 mmol, app. 17 mol% according to -N3) as a catalyst 
were added under nitrogen flushing and the glass bottle was closed and sealed with 
Parafilm®. The sealed glass bottle was shaken for 72 h on an overhead shaker. The 
yellow suspension was filtered with a frit and washed with ACN, MeOH, 2x2 w-% 
EDTA in H2O, MeOH/H2O 1:1 v/v, 10 v-% AcOH in MeOH and pure MeOH (each 
300 mL). CSP9 was then dried under vacuum at 60°C for 24 h. SO loading was 
determined by elemental analysis.  
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Yield: 10.46 g.  
EA: C: 7.75 w-%; H: 1.24 w-%; N: 2.82 w-%; S: < 0.02 w-%; Cl: 1.24 w-%. 
SO loading calculated according to the chlorine content: 150 µmol/g (SO4 
quantitatively immobilized). 
 
4.18. Endcapping of CSP9 resulting in CSP10 
 
2.5 g of CSP9 (SO4 loading of 150 µmol/g) were suspended in 60 mL of ACN in a 
glass bottle. 1.0 mL of DIPEA was added (5.88 mmol) and the suspension was 
degassed by flushing with N2 for 10 min. 50 mg of CuI (0.26 mmol, app. 22 mol% 
according to free -N3) as a catalyst and 100 µL of propargyl alcohol (1.73 mmol) 
were added under nitrogen flushing and the glass bottle was closed and sealed with 
Parafilm®. The sealed glass bottle was shaken for 72 h on an overhead shaker. The 
yellow suspension was filtered with a frit and washed with ACN, MeOH, 2 w-% EDTA 
in H2O, MeOH/H2O 1:1 v/v, 10 v-% AcOH in MeOH and pure MeOH (each 150 mL). 
CSP10 was then dried under vacuum at 60°C for 24 h. SO loading was determined 
by elemental analysis.  
Yield: 2.49 g of a slightly yellowish modified silica.  
EA: C: 8.98 w-%; H: 1.33 w-%; N: 2.72 w-%; S: < 0.02 w-%; Cl: 1.16 w-%. 
SO loading calculated according to the chlorine content: 138 µmol/g (92% of CSP9, 
8% of SO4 have been splitted off during endcapping and the work-up process). 
 
4.19. Column-packing 
 
Column-packing was carried out in the same way for every single CSP and the 
AzP-Silica-Column using standard slurry-method. The modified silica was sieved 
through a 40 µm sieve and 2.30 g of it were suspended in 20 mL of iPrOH and 
1.0 mL AcOH. 
The suspension was homogenized in an ultrasonic bath for 20 min and the silica 
material was packed in house under high pressure (app. 650 bar) into a 
150x4 mm ID Bischoff stainless steel HPLC column followed by rinsing with 
methanol (columns 1 to 10, 13, 14 and 16). 
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When packing 75x4 mm ID columns only 1.80 g of CSP were used for packing 
(columns 11, 12 and 15). Before using the packed columns they were rinsed with 
100 mL 1.0 w-% aqueous EDTA solution (except columns 1, 2 and 13 to 16), 50 mL 
bidistilled H2O and 100 mL of MeOH. 
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II. List of Abbreviations 
 
/// no value, no data MeOH methanol 
αi selectivity coefficient min minute 
ACHSA aminocyclohexanesulfonic acid MP-Silica mercaptopropyl-modified silica 
ACN acetonitrile MS mass spectrometry 
AcOH acetic acid MWD multiple wavelength detector 
AIBN 2,2'-azobis(2-methylpropionitrile) n number 
AzP-Silica azidopropyl-modified silica Ni number of theoretical plates 
ATR attenuated total reflection NMR nuclear magnetic resonance spectroscopy 
av average NP normale phase 
CD circular dichroism Φ phase ratio 
CDA chiral derivatizing agent PE petroleum ether 
CE capillary electrophoresis PI photoinitiator 
CP-Silica chloropropyl-modified silica PO polar organic mode 
CSP chiral stationary phase QD quinidine 
DAD diode array detector QN quinine 
DBTDL dibutyltin dilaurate QqLIT hybrid quadrupole linear ion trap 
DEA diethylamine R residue 
DHQD dihydroquinidine Ri resolution 
DHQN dihydroquinine RP reversed phase 
DIPEA diisopropylethylamine, Hünig base RT room temperature 
DMF N,N-dimethylformamide SA selectand 
DMSO dimethylsulfoxide SCX strong cation exchange 
DNA deoxyribonucleic acid SFC supercritical fluid chromatography 
DOPA 3,4-dihydroxyphenylalanine SMB simulated moving bed technology 
e.g. exempla gratia, for example SO selector 
EA elemental analysis T temperature 
EDTA ethylenediaminetetraacetic acid tButyl tert-butyl 
EO elution order, first eluted enantiomer THF tetrahydrofuran 
ESI electrospray ionization ti retention time 
et al. et alii, and others TLC thin layer chromatography 
EtOAc ethyl acetate tren tris(2-aminoethyl)amine 
EtOH ethanol UV ultraviolet 
FTIR fourier transform infrared spectroscopy v-% volume percent 
GC gas chromatography v/v volume to volume ratio 
h hour v/v/w volume to volume to mass ratio 
HPLC high performance liquid chromatography V65 2,2'-azobis(2,4-dimethyl valeronitrile) 
ID internal diameter VCD vibrational circular dichroism 
iPrOH isopropanol w-% mass percent 
IR infrared spectroscopy WAX weak anion exchange 
ki retention factor WCX weak cation exchange  
L linker wi peak width at half maximum  
LC liquid chromatography ZWIX zwitterionic exchange type  
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III. Abbreviations of the Analytes  
 
A-DCL-Leu  N-4-allyloxy-3,5-dichlorobenzoyl leucine 
Ac-Phe  N-acetyl phenylalanine 
Ac-Trp  N-acetyl tryptophane 
Acetylmandelic acid  O-acetylmandelic acid 
Atrolactic acid  2-phenyl-2-hydroxypropionic acid 
BOC-Gly N-tert-butyloxycarbonyl glycine 
BOC-Phe  N-tert-butyloxycarbonyl phenylalanine 
BOC-Tyr  N-tert-butyloxycarbonyl tyrosine 
BTFMB-Leu  N-3,5-bis-(trifluoromethyl)benzoyl leucine 
Bz-ACHSA  N-benzoyl-2-aminocyclohexanesulfonic acid 
Bz-Leu  N-benzoyl leucine 
Bz-Phe N-benzoyl phenylalanine 
Bz-β-Phe  N-benzoyl β-phenylalanine 
Carprofen  2-(6-chloro-9H-carbazol-2-yl)propanoic acid 
Clenbuterol  1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol 
DBTAMME  dibenzoyltartaric acid monomethyl ester 
DCB-Leu  N-3,5-dichlorobenzoyl leucine 
Dichlorprop  2-(2,4-dichlorophenoxy)propanoic acid 
DNB-Leu  N-3,5-dinitrobenzoyl leucine 
DNB-N-Me-Leu  N-3,5-dinitrobenzoyl-N-methyl leucine 
DNB-Pro  N-3,5-dinitrobenzoyl proline 
DNP-Mandelic acid  O-(3,5-dinitrophenylcarbamoyl)mandelic acid 
DNZ-Gly N-3,5-dinitrobenzoyloxycarbonyl glycine 
DNZ-Phe N-3,5-dinitrobenzoyloxycarbonyl phenylalanine 
DNZ-Val  N-3,5-dinitrobenzoyloxycarbonyl valine 
Fenoprofen  2-(3-phenoxyphenyl)propanoic acid 
Flurbiprofen  2-(2-fluorobiphenyl-4-yl)propanoic acid 
FMOC-Abu  N-fluorenylmethoxycarbonyl-α-aminobutyric acid 
FMOC-Asn  N-fluorenylmethoxycarbonyl asparagine 
FMOC-Aze  N-fluorenylmethoxycarbonyl azetidine 
FMOC-Gln  N-fluorenylmethoxycarbonyl glutamine 
FMOC-Ile  N-fluorenylmethoxycarbonyl isoleucine 
FMOC-Pro  N-fluorenylmethoxycarbonyl proline 
FMOC-β-Phe  N-fluorenylmethoxycarbonyl β-phenylalanine 
Hydroxymandelic acid  4-hydroxymandelic acid 
Hydroxyphenyllactic acid  3-(4-hydroxyphenyl)lactic acid 
Ibuprofen  2-(4-(2-methylpropyl)phenyl)propanoic acid 
MFQ.HCl  mefloquine hydrochloride 
	   - 102 - 
Naproxen  2-(6-methoxynaphthalen-2-yl)propanoic acid 
Nitrophenylpropionic acid  2-(4-nitrophenyl)propionic acid 
P-DCL-ACHSA  
N-(3,5-dichloro-4-propargyloxybenzoyl)-2-
aminocyclohexanesulfonic acid 
P-DML-ACHSA  
N-3,5-dimethoxy-4-propargyloxybenzoyl-2-
aminocyclohexanesulfonic acid 
PFB-Leu  N-2,3,4,5,6-pentafluorobenzoyl leucine 
Phe  phenylalanine 
Phenyl-Gly  α-phenylglycine 
Phenylbutyric acid  2-phenylbutyric acid 
QD quinidine 
QN quinine 
TMB-Ala  N-3,4,5-trimethoxybenzoyl alanine 
Trolox  6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 
Tropic acid  3-hydroxy-2-phenylpropanoic acid 
Trp  tryptophane 
Tyr  tyrosine 
Vanillylmandelic acid  4-hydroxy-3-methoxymandelic acid 
Z-Arg  N-benzoyloxycarbonyl arginine 
Z-Leu  N-benzoyloxycarbonyl leucine 
Z-Phe  N-benzoyloxycarbonyl phenylalanine 
Z-Ser  N-benzoyloxycarbonyl serine 
Z-β-Phe  N-benzoyloxycarbonyl β-phenylalanine 
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IV. Conclusion and Outlook 
 
The focus of the present master thesis was the synthesis and evaluation of novel 
arylcarbamoylated cinchona-based weak anion exchange type chiral stationary 
phases for liquid chromatography.  
Commercially available dihydroquinine and corresponding pseudoenantiomeric 
dihydroquinidine as the building blocks were carbamoylated with two different 
linkers. In total four different selectors were successfully synthesized, wherein each 
two of them are pseudoenantiomers. Due to the protonation of the quinuclidine ring 
of the building blocks under weakly acidic mobile phase conditions anion exchange 
takes place.  
On the basis of two differently substituted linkers (one allylated and one 
propargylated) it was possible to use two different immobilization strategies – radical 
mediated thiol-ene addition or Cu(I) and base catalyzed Huisgen alkyne-azide click 
chemistry. The radical addition onto mercaptopropyl-modified silica yielded low 
immobilization efficiencies; on the other hand, it was possible to control the amount 
of immobilized selector via alkyne-azide click chemistry, which yielded saturated 
selector densities in case the selector was offered in excess. Altogether ten CSPs 
with different selector loadings were synthesized through immobilization of the four 
selectors.  
All CSPs were then evaluated in terms of their capability for enantioseparation with a 
set of 67 analytes; most of them were chiral acidic compounds. For comparative 
purposes two commercially available CSPs (QN-AX and QD-AX) were used as well. 
As a trend it was observed that the immobilization via radical thiol-ene addition 
results in higher resolution values (taking into account that the selector densities are 
equal), but this behavior could also be caused by packing phenomena. Free azido 
groups on modified silica show no contribution to retention. Endcapping of the free 
azido groups results in higher selectivity and lower resolution. A 1:1 physical mixture 
prepared from a high loaded CSP and pure azidopropyl-modified silica behaves 
similarly to a half-length column containing the high loaded material. The elution 
order changes from DHQN to DHQD type CSPs, whereas DHQD type CSPs exhibit 
higher selectivity and resolution. The higher the selector loading, the higher the 
retention. The maximum resolution and selectivity were observed at a selector 
density of app. 310 µmol/g.  
	   - 104 - 
All CSPs are well suitable for the separation of N-protected aminophosphonates, 
which is an advantage in comparison to the commercially available QN-AX and QD-
AX anion exchangers.  
A loading study confirmed an ion exchange mechanism for the retention of acidic 
analytes under polar organic mode mobile phase conditions. The stoichiometric 
displacement model was proved to be valid as well. 
In summary the synthesis of novel weak anion exchange type CSPs based on 
carbamoylated cinchona alkaloids was carried out successfully. New findings were 
achieved employing different immobilization strategies and selector densities. By the 
usage of the present synthesis protocols and immobilization strategies in 
combination with a derivatization of the substituted linker it is possible to perform 
further investigations in the field of enantioseparation in the future.   
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V. Zusammenfassung 
 
Der Schwerpunkt der vorliegenden Masterarbeit war die Synthese und Evaluierung 
neuartiger Chinin-basierter chiraler Anionenaustauschermaterialien für die Trennung 
chiraler organischer Säuren mittels Hochleistungs-Flüssigkeitschromatographie. 
Kommerziell erhältliches Dihydrochinin und das entsprechende pseudoenantiomere 
Dihydrochinidin wurden als chirale Grundbausteine mit zwei verschiedenen 
Isocyanaten carbamoyliert. Insgesamt konnten vier verschiedene Selektoren 
erfolgreich synthetisiert werden, wobei jeweils zwei davon als pseudoenantiomere 
Paare angesehen werden können. Durch Protonierung des Chinuclidinrings der 
Selektoren unter leicht sauren Bedingungen ist in weiterer Folge Anionenaustausch 
möglich. 
Aufgrund von zwei unterschiedlich substituierten Isocyanaten als Linker (allyliert und 
propargyliert) war es möglich, zwei verschiedene Strategien für die Immobilisierung 
der Selektoren zu verwenden - radikale Thiol-En Addition oder Cu(I) und 
basenkatalysierte Huisgen Alkin-Azid Klick-Chemie. Die radikalische Immobilisierung 
auf Mercaptopropyl-modifiziertem Kieselgel ergab einerseits eine niedrige 
Immobilisierungseffizienz, andererseits war es möglich, die Menge an 
immobilisiertem Selektor über Alkin-Azid Klick-Chemie zu steuern. 
Zusammenfassend konnten zehn CSP mit unterschiedlicher Selektorbeladung 
synthetisiert werden. 
Alle CSP wurden bezüglich ihrer Fähigkeit zur Trennung von Enantiomeren mit 
einem Set von 67 Analyten untersucht, wobei die meisten davon chirale saure 
Verbindungen waren. Zu Vergleichszwecken wurden zwei kommerziell erhältliche 
CSP (QN-AX und QD-AX) verwendet. 
Als Trend wurde beobachtet, dass die Immobilisierung über radikalische Thiol-En-
Addition bei gleicher Selektordichte höhere Auflösungen ergibt, was allerdings auch 
auf Packungsphänomene zurückzuführen sein könnte. Freie Azidogruppen auf 
modifiziertem Kieselgel liefern keinen Beitrag zur Retention der Analyten. 
Endcapping der freien Azidogruppen führt einerseits zu höherer Selektivität, 
andererseits zu geringerer Auflösung. Eine 1:1 physikalische Mischung hergestellt 
aus einer hoch belegten CSP und Azidopropyl-modifiziertem Kieselgel verhält sich 
ähnlich wie eine Säule, welche mit hoch belegtem Material gepackt wurde und nur 
die halbe Länge aufweist.  
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Eine Umkehr der Elutionsreihenfolge von DHQN zu DHQD Typ CSP konnte bei allen 
Analyten beobachtet werden, wobei die DHQD Typ CSP generell eine höhere 
Selektivität und Auflösung zeigten. Je höher die Selektordichte, desto größer war die 
Retention, jedoch begleitet von einer Abnahme der Selektivität. Das Maximum an 
Auflösung und Selektivität wurde bei einer Selektordichte von zirka 310 µmol/g 
beobachtet. 
Die synthetisierten chiralen stationären Phasen waren sehr gut für die Trennung von 
N-geschützten Aminophosphonaten geeignet, was ein Vorteil im Vergleich zu den im 
Handel erhältlichen QN-AX und QD-AX Anionenaustauschermaterialien ist. 
Eine Beladungsstudie bestätigte einen Ionenaustausch-Mechanismus für die 
Retention von sauren Analyten. Die Gültigkeit des stöchiometrischen Verdrängungs-
Modells konnte ebenfalls erwiesen werden. 
Zusammenfassend konnte die Synthese neuer Anionenaustauscherphasen für 
Hochleistungsflüssigkeitschromatographie auf der Basis von arylcarbamoylierten 
Chinin-Derivaten erfolgreich durchgeführt werden. Neue Erkenntnisse konnten durch 
den Einsatz unterschiedlicher Immobilisierungs-Strategien und Selektordichten auf 
der Kieselgeloberfläche gewonnen werden. Durch diese Erkenntnisse und die 
Verwendung der vorliegenden Syntheseprotokolle und Immobilisierungsstrategien in 
Kombination mit einer Derivatisierung des substituierten Linkers ist es möglich, 
weitere Untersuchungen auf dem Gebiet der Enantiomerentrennung durchzuführen. 
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VIII. Appendix  
 
Table I: Column 1 (150x4 mm ID, 179 µmol/g, DHQN-type CSP; injection volume: 5 µL; sample 
concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; mobile 
phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C): different t0-
values derive from different positions of the column in the column compartment. 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
Bz-Leu (L>D) 1.441 3.612 4.440 D 1.51 2.08 1.38 3.53 4671 4771 
PFB-Leu (rac.) 1.441 3.512 3.512 /// 1.44 1.44 1.00 0.00 2273 2273 
A-DCL-Leu (rac.) 1.441 4.729 9.698 D 2.28 5.73 2.51 11.39 4421 4330 
DNB-Leu (rac.) 1.441 6.098 17.473 D 3.23 11.13 3.44 16.34 4645 4522 
DCB-Leu (rac.) 1.441 4.547 8.540 D 2.16 4.93 2.29 10.34 4659 4529 
BTFMB-Leu (rac.) 1.441 2.928 5.117 D 1.03 2.55 2.47 9.04 4451 4374 
DNB-N-Me-Leu (rac.) 1.441 6.907 7.434 D 3.79 4.16 1.10 1.10 3874 3352 
Ac-Phe (rac.) 1.441 3.707 4.579 D 1.57 2.18 1.38 3.70 4999 4898 
Z-Phe (rac.) 1.441 6.148 6.553 D 3.27 3.55 1.09 1.03 4049 4297 
Phe (rac.) 1.441 1.640 1.640 /// 0.14 0.14 1.00 0.00 2034 2034 
DNZ-Phe (D>L) 1.441 10.395 17.845 D 6.21 11.38 1.83 9.16 4782 4873 
BOC-Phe (rac.) 1.441 4.136 4.517 D 1.87 2.13 1.14 1.55 4991 4867 
FMOC-β-Phe (rac.) 1.441 5.103 5.730 D 2.54 2.98 1.17 1.94 4472 4475 
Z-β-Phe (rac.) 1.441 3.575 3.575 /// 1.48 1.48 1.00 0.00 4432 4432 
Bz-Phe (D>L) 1.441 5.299 6.855 D 2.68 3.76 1.40 4.49 4937 4883 
Phenyl-Gly (rac.) 1.441 1.649 1.649 /// 0.14 0.14 1.00 0.00 907 907 
DNZ-Val (D>L) 1.441 6.828 10.742 D 3.74 6.45 1.73 7.61 4766 4578 
BOC-Tyr (rac.) 1.441 3.996 4.233 D 1.77 1.94 1.09 0.98 4645 4526 
Ac-Trp (rac.) 1.441 4.841 5.819 D 2.36 3.04 1.29 3.13 4746 4552 
FMOC-Asn (rac.) 1.441 7.120 7.990 D 3.94 4.54 1.15 1.92 4465 4447 
DNB-Pro (rac.) 1.441 6.382 6.382 /// 3.43 3.43 1.00 0.00 1739 1739 
FMOC-Ile (L>D) 1.441 5.573 7.170 D 2.87 3.98 1.39 3.16 4581 501 
FMOC-Gln (rac.) 1.441 1.686 1.686 /// 0.17 0.17 1.00 0.00 3004 3004 
Z-Ser (rac.) 1.441 4.494 4.494 /// 2.12 2.12 1.00 0.00 4522 4522 
FMOC-Pro (L>D) 1.441 5.960 5.960 /// 3.14 3.14 1.00 0.00 2836 2836 
FMOC-Aze (rac.) 1.441 6.743 7.090 D 3.68 3.92 1.07 0.87 4927 4779 
DBTAMME (rac.) 1.441 6.951 7.805 S,S 3.82 4.42 1.15 2.00 4741 4839 
Trolox (rac.) 1.441 3.738 4.062 S 1.59 1.82 1.14 1.42 4695 4644 
Ibuprofen (rac) 1.441 2.623 2.623 /// 0.82 0.82 1.00 0.00 2608 2608 
Naproxen (rac.) 1.441 3.497 3.497 /// 1.43 1.43 1.00 0.00 3936 3936 
DNP-Mandelic acid (rac.) 1.775 29.004 39.736 R 15.34 21.39 1.39 5.10 4202 4325 
Acetylmandelic acid (rac.) 1.441 4.924 5.286 S 2.42 2.67 1.10 1.26 5293 4880 
Phenylbutyric acid (rac.) 1.441 2.370 2.370 /// 0.64 0.64 1.00 0.00 4550 4550 
TMB-Ala (rac.) 1.441 3.893 5.209 /// 1.70 2.61 1.54 4.98 4775 4713 
Bz-ACHSA (rac.) 1.441 5.289 5.678 /// 2.67 2.94 1.10 1.27 5107 5224 
MFQ.HCl (rac.) 1.441 1.401 1.401 /// -0.03 -0.03 1.00 0.00 1792 1792 
BOC-Gly 1.441 3.999 /// /// 1.78 /// /// /// 254 /// 
DNZ-Gly 1.441 8.081 /// /// 4.61 /// /// /// 5041 /// 
Vanillylmandelic acid (rac.) 1.441 5.583 5.583 /// 2.87 2.87 1.00 0.00 2105 2105 
Nitrophenylpropionic acid (rac.) 1.441 3.894 3.952 /// 1.70 1.74 1.02 0.32 7324 7672 
Hydroxyphenyllactic acid (rac.) 1.441 5.269 5.829 /// 2.66 3.05 1.15 1.73 4742 4618 
Tropic acid (rac.) 1.441 2.766 2.766 /// 0.92 0.92 1.00 0.00 4943 4943 
Fenoprofen (rac.) 1.441 3.187 3.187 /// 1.21 1.21 1.00 0.00 4000 4000 
Dichlorprop (rac.) 1.441 6.718 6.718 /// 3.66 3.66 1.00 0.00 4224 4224 
Hydroxymandelic acid (rac.) 1.441 5.494 5.494 /// 2.81 2.81 1.00 0.00 3455 3455 
Atrolactic acid (rac.) 1.441 4.875 4.875 /// 2.38 2.38 1.00 0.00 3243 3243 
Carprofen (rac.) 1.441 4.034 4.149 /// 1.80 1.88 1.04 0.54 6356 5591 
FMOC-Abu (rac.) 1.441 5.474 6.250 /// 2.80 3.34 1.19 2.07 3133 4656 
Flurbiprofen (rac.) 1.441 3.622 3.622 /// 1.51 1.51 1.00 0.00 2709 2709 
Bz-β-Phe (rac.) 1.441 3.682 4.138 /// 1.56 1.87 1.20 1.91 4246 4319 
Z-Leu (rac.) 1.441 3.867 3.867 /// 1.68 1.68 1.00 0.00 4627 4627 
Z-Arg (L>D) 1.441 2.053 2.053 /// 0.42 0.42 1.00 0.00 2335 2335 
Trp (rac.) 1.441 1.840 1.840 /// 0.28 0.28 1.00 0.00 1187 1187 
Tyr (rac.) 1.441 1.654 1.654 /// 0.15 0.15 1.00 0.00 2153 2153 
QN/QD (2:1) 1.441 1.585 1.585 /// 0.10 0.10 1.00 0.00 1578 1578 
Clenbuterol.HCl (rac.) 1.441 1.281 1.281 /// -0.11 -0.11 1.00 0.00 2025 2025 
PI-2-56-2 1.441 7.971 11.040 /// 4.53 6.66 1.47 4.54 3408 2912 
PI-2-4-3 1.441 11.452 11.596 /// 6.95 7.05 1.01 0.19 4375 2714 
PI-2-25-1 1.441 8.206 9.050 /// 4.69 5.28 1.12 1.59 4363 4104 
PI-2-34-1 1.441 4.369 5.477 /// 2.03 2.80 1.38 3.44 3851 3622 
PI-3-67-1 1.441 7.032 9.853 /// 3.88 5.84 1.50 5.68 4601 4631 
PI-1-89-1 1.441 7.342 8.181 /// 4.10 4.68 1.14 1.84 4673 4613 
PI-2-15-1 1.441 6.827 7.708 /// 3.74 4.35 1.16 2.00 4330 4340 
PI-2-38-1 1.441 4.165 5.314 /// 1.89 2.69 1.42 4.14 4753 4576 
PI-2-87-1 1.441 4.599 5.845 /// 2.19 3.06 1.39 4.06 4748 4517 
P-DML-ACHSA (S,S>R,R) 1.775 6.812 7.427 R,R 2.84 3.18 1.12 1.59 5480 5381 
P-DCL-ACHSA (S,S>R,R) 1.775 9.517 10.991 R,R 4.36 5.19 1.19 2.70 5692 5571 
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Table II: Column 2 (150x4 mm ID, 144 µmol/g, DHQD-type CSP; injection volume: 5 µL; sample 
concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; mobile 
phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C): different t0-
values derive from different positions of the column in the column compartment. 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
Bz-Leu (L>D) 1.441 3.612 4.440 D 1.51 2.08 1.38 3.53 4671 4771 
PFB-Leu (rac.) 1.441 3.512 3.512 /// 1.44 1.44 1.00 0.00 2273 2273 
A-DCL-Leu (rac.) 1.441 4.729 9.698 D 2.28 5.73 2.51 11.39 4421 4330 
DNB-Leu (rac.) 1.441 6.098 17.473 D 3.23 11.13 3.44 16.34 4645 4522 
DCB-Leu (rac.) 1.441 4.547 8.540 D 2.16 4.93 2.29 10.34 4659 4529 
BTFMB-Leu (rac.) 1.441 2.928 5.117 D 1.03 2.55 2.47 9.04 4451 4374 
DNB-N-Me-Leu (rac.) 1.441 6.907 7.434 D 3.79 4.16 1.10 1.10 3874 3352 
Ac-Phe (rac.) 1.441 3.707 4.579 D 1.57 2.18 1.38 3.70 4999 4898 
Z-Phe (rac.) 1.441 6.148 6.553 D 3.27 3.55 1.09 1.03 4049 4297 
Phe (rac.) 1.441 1.640 1.640 /// 0.14 0.14 1.00 0.00 2034 2034 
DNZ-Phe (D>L) 1.441 10.395 17.845 D 6.21 11.38 1.83 9.16 4782 4873 
BOC-Phe (rac.) 1.441 4.136 4.517 D 1.87 2.13 1.14 1.55 4991 4867 
FMOC-β-Phe (rac.) 1.441 5.103 5.730 D 2.54 2.98 1.17 1.94 4472 4475 
Z-β-Phe (rac.) 1.441 3.575 3.575 /// 1.48 1.48 1.00 0.00 4432 4432 
Bz-Phe (D>L) 1.441 5.299 6.855 D 2.68 3.76 1.40 4.49 4937 4883 
Phenyl-Gly (rac.) 1.441 1.649 1.649 /// 0.14 0.14 1.00 0.00 907 907 
DNZ-Val (D>L) 1.441 6.828 10.742 D 3.74 6.45 1.73 7.61 4766 4578 
BOC-Tyr (rac.) 1.441 3.996 4.233 D 1.77 1.94 1.09 0.98 4645 4526 
Ac-Trp (rac.) 1.441 4.841 5.819 D 2.36 3.04 1.29 3.13 4746 4552 
FMOC-Asn (rac.) 1.441 7.120 7.990 D 3.94 4.54 1.15 1.92 4465 4447 
DNB-Pro (rac.) 1.441 6.382 6.382 /// 3.43 3.43 1.00 0.00 1739 1739 
FMOC-Ile (L>D) 1.441 5.573 7.170 D 2.87 3.98 1.39 3.16 4581 501 
FMOC-Gln (rac.) 1.441 1.686 1.686 /// 0.17 0.17 1.00 0.00 3004 3004 
Z-Ser (rac.) 1.441 4.494 4.494 /// 2.12 2.12 1.00 0.00 4522 4522 
FMOC-Pro (L>D) 1.441 5.960 5.960 /// 3.14 3.14 1.00 0.00 2836 2836 
FMOC-Aze (rac.) 1.441 6.743 7.090 D 3.68 3.92 1.07 0.87 4927 4779 
DBTAMME (rac.) 1.441 6.951 7.805 S,S 3.82 4.42 1.15 2.00 4741 4839 
Trolox (rac.) 1.441 3.738 4.062 S 1.59 1.82 1.14 1.42 4695 4644 
Ibuprofen (rac) 1.441 2.623 2.623 /// 0.82 0.82 1.00 0.00 2608 2608 
Naproxen (rac.) 1.441 3.497 3.497 /// 1.43 1.43 1.00 0.00 3936 3936 
DNP-Mandelic acid (rac.) 1.775 29.004 39.736 R 15.34 21.39 1.39 5.10 4202 4325 
Acetylmandelic acid (rac.) 1.441 4.924 5.286 S 2.42 2.67 1.10 1.26 5293 4880 
Phenylbutyric acid (rac.) 1.441 2.370 2.370 /// 0.64 0.64 1.00 0.00 4550 4550 
TMB-Ala (rac.) 1.441 3.893 5.209 /// 1.70 2.61 1.54 4.98 4775 4713 
Bz-ACHSA (rac.) 1.441 5.289 5.678 /// 2.67 2.94 1.10 1.27 5107 5224 
MFQ.HCl (rac.) 1.441 1.401 1.401 /// -0.03 -0.03 1.00 0.00 1792 1792 
BOC-Gly 1.441 3.999 /// /// 1.78 /// /// /// 254 /// 
DNZ-Gly 1.441 8.081 /// /// 4.61 /// /// /// 5041 /// 
Vanillylmandelic acid (rac.) 1.441 5.583 5.583 /// 2.87 2.87 1.00 0.00 2105 2105 
Nitrophenylpropionic acid (rac.) 1.441 3.894 3.952 /// 1.70 1.74 1.02 0.32 7324 7672 
Hydroxyphenyllactic acid (rac.) 1.441 5.269 5.829 /// 2.66 3.05 1.15 1.73 4742 4618 
Tropic acid (rac.) 1.441 2.766 2.766 /// 0.92 0.92 1.00 0.00 4943 4943 
Fenoprofen (rac.) 1.441 3.187 3.187 /// 1.21 1.21 1.00 0.00 4000 4000 
Dichlorprop (rac.) 1.441 6.718 6.718 /// 3.66 3.66 1.00 0.00 4224 4224 
Hydroxymandelic acid (rac.) 1.441 5.494 5.494 /// 2.81 2.81 1.00 0.00 3455 3455 
Atrolactic acid (rac.) 1.441 4.875 4.875 /// 2.38 2.38 1.00 0.00 3243 3243 
Carprofen (rac.) 1.441 4.034 4.149 /// 1.80 1.88 1.04 0.54 6356 5591 
FMOC-Abu (rac.) 1.441 5.474 6.250 /// 2.80 3.34 1.19 2.07 3133 4656 
Flurbiprofen (rac.) 1.441 3.622 3.622 /// 1.51 1.51 1.00 0.00 2709 2709 
Bz-β-Phe (rac.) 1.441 3.682 4.138 /// 1.56 1.87 1.20 1.91 4246 4319 
Z-Leu (rac.) 1.441 3.867 3.867 /// 1.68 1.68 1.00 0.00 4627 4627 
Z-Arg (L>D) 1.441 2.053 2.053 /// 0.42 0.42 1.00 0.00 2335 2335 
Trp (rac.) 1.441 1.840 1.840 /// 0.28 0.28 1.00 0.00 1187 1187 
Tyr (rac.) 1.441 1.654 1.654 /// 0.15 0.15 1.00 0.00 2153 2153 
QN/QD (2:1) 1.441 1.585 1.585 /// 0.10 0.10 1.00 0.00 1578 1578 
Clenbuterol.HCl (rac.) 1.441 1.281 1.281 /// -0.11 -0.11 1.00 0.00 2025 2025 
PI-2-56-2 1.441 7.971 11.040 /// 4.53 6.66 1.47 4.54 3408 2912 
PI-2-4-3 1.441 11.452 11.596 /// 6.95 7.05 1.01 0.19 4375 2714 
PI-2-25-1 1.441 8.206 9.050 /// 4.69 5.28 1.12 1.59 4363 4104 
PI-2-34-1 1.441 4.369 5.477 /// 2.03 2.80 1.38 3.44 3851 3622 
PI-3-67-1 1.441 7.032 9.853 /// 3.88 5.84 1.50 5.68 4601 4631 
PI-1-89-1 1.441 7.342 8.181 /// 4.10 4.68 1.14 1.84 4673 4613 
PI-2-15-1 1.441 6.827 7.708 /// 3.74 4.35 1.16 2.00 4330 4340 
PI-2-38-1 1.441 4.165 5.314 /// 1.89 2.69 1.42 4.14 4753 4576 
PI-2-87-1 1.441 4.599 5.845 /// 2.19 3.06 1.39 4.06 4748 4517 
P-DML-ACHSA (S,S>R,R) 1.775 6.812 7.427 R,R 2.84 3.18 1.12 1.59 5480 5381 
P-DCL-ACHSA (S,S>R,R) 1.775 9.517 10.991 R,R 4.36 5.19 1.19 2.70 5692 5571 
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Table III: Column 3 (150x4 mm ID, 477 µmol/g, DHQN-type CSP; injection volume: 5 µL; sample 
concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; mobile 
phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C): different t0-
values derive from different positions of the column in the column compartment. 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
Bz-Leu (L>D) 1.334 3.643 4.186 D 1.73 2.14 1.24 1.23 1464 1072 
PFB-Leu (rac.) 1.334 3.397 3.397 /// 1.55 1.55 1.00 0.00 1492 1492 
A-DCL-Leu (rac.) 1.334 5.227 8.658 D 2.92 5.49 1.88 4.64 1709 1112 
DNB-Leu (rac.) 1.469 13.792 33.706 D 8.39 21.94 2.62 6.68 1291 739 
DCB-Leu (rac.) 1.334 5.890 9.718 D 3.42 6.28 1.84 4.89 1893 1288 
BTFMB-Leu (rac.) 1.334 2.947 4.030 D 1.21 2.02 1.67 3.63 2575 1811 
DNB-N-Me-Leu (rac.) 1.334 10.705 10.705 /// 7.02 7.02 1.00 0.00 692 692 
Ac-Phe (rac.) 1.334 5.433 6.567 D 3.07 3.92 1.28 1.69 1377 1195 
Z-Phe (rac.) 1.469 14.216 14.216 /// 8.68 8.68 1.00 0.00 1196 1196 
Phe (rac.) 1.469 1.500 1.500 /// 0.02 0.02 1.00 0.00 1738 1738 
DNZ-Phe (D>L) 1.469 2.133 2.407 D 0.45 0.64 1.41 1.64 2811 3061 
BOC-Phe (rac.) 1.469 7.311 7.716 D 3.98 4.25 1.07 0.61 2162 1936 
FMOC-β-Phe (rac.) 1.334 8.939 9.541 D 5.70 6.15 1.08 0.66 1981 1322 
Z-β-Phe (rac.) 1.334 5.908 5.908 /// 3.43 3.43 1.00 0.00 785 785 
Bz-Phe (D>L) 1.334 10.036 12.081 D 6.52 8.06 1.24 1.96 1855 1749 
Phenyl-Gly (rac.) 1.469 1.504 1.504 /// 0.02 0.02 1.00 0.00 2222 2222 
DNZ-Val (D>L) 1.469 17.772 23.674 D 11.10 15.12 1.36 2.46 1302 1089 
BOC-Tyr (rac.) 1.469 10.197 10.614 D 5.94 6.23 1.05 0.57 2752 3809 
Ac-Trp (rac.) 1.334 11.893 14.227 D 7.92 9.66 1.22 1.83 1618 1734 
FMOC-Asn (rac.) 1.469 17.534 18.099 D 10.94 11.32 1.04 0.36 2446 1626 
DNB-Pro (rac.) 1.469 16.237 16.237 /// 10.05 10.05 1.00 0.00 760 760 
FMOC-Ile (L>D) 1.334 9.265 10.844 D 5.95 7.13 1.20 1.58 1727 1500 
FMOC-Gln (rac.) 1.469 1.533 1.533 /// 0.04 0.04 1.00 0.00 2518 2518 
Z-Ser (rac.) 1.334 10.699 10.699 /// 7.02 7.02 1.00 0.00 944 944 
FMOC-Pro (L>D) 1.334 9.895 9.895 /// 6.42 6.42 1.00 0.00 931 931 
FMOC-Aze (rac.) 1.334 12.908 13.492 D 8.68 9.11 1.05 0.50 2585 1514 
DBTAMME (rac.) 1.469 17.555 20.878 S,S 10.95 13.21 1.21 1.48 1183 1168 
Trolox (rac.) 1.334 8.815 11.411 S 5.61 7.55 1.35 1.75 816 672 
Ibuprofen (rac) 1.334 3.576 3.576 /// 1.68 1.68 1.00 0.00 1871 1871 
Naproxen (rac.) 1.334 7.103 7.103 /// 4.32 4.32 1.00 0.00 1267 1267 
DNP-Mandelic acid (rac.) 1.469 97.687 109.533 R 65.50 73.56 1.12 0.85 947 824 
Acetylmandelic acid (rac.) 1.334 10.063 11.157 S 6.54 7.36 1.13 1.01 1612 1477 
Phenylbutyric acid (rac.) 1.334 3.464 3.464 /// 1.60 1.60 1.00 0.00 2610 2610 
TMB-Ala (rac.) 1.334 6.689 8.361 /// 4.01 5.27 1.31 2.05 1490 1227 
Bz-ACHSA (rac.) 1.334 12.861 12.861 /// 8.64 8.64 1.00 0.00 594 594 
MFQ.HCl (rac.) 1.334 1.143 1.143 /// -0.14 -0.14 1.00 0.00 1637 1637 
BOC-Gly 1.469 4.263 /// /// 1.90 /// /// /// 217 /// 
DNZ-Gly 1.469 31.486 /// /// 20.43 /// /// /// 1335 /// 
Vanillylmandelic acid (rac.) 1.334 11.763 11.763 /// 7.82 7.82 1.00 0.00 274 274 
Nitrophenylpropionic acid (rac.) 1.334 9.590 9.590 /// 6.19 6.19 1.00 0.00 956 956 
Hydroxyphenyllactic acid (rac.) 1.469 24.526 33.506 /// 15.70 21.81 1.39 2.82 1380 1277 
Tropic acid (rac.) 1.334 6.119 13.920 /// 3.59 9.43 2.63 4.63 339 794 
Fenoprofen (rac.) 1.334 5.316 5.407 /// 2.99 3.05 1.02 0.25 3279 3440 
Dichlorprop (rac.) 1.469 18.216 24.548 /// 11.40 15.71 1.38 2.62 1661 836 
Hydroxymandelic acid (rac.) 1.469 30.397 30.397 /// 19.69 19.69 1.00 0.00 2943 2943 
Atrolactic acid (rac.) 1.334 11.194 13.432 /// 7.39 9.07 1.23 1.30 255 1377 
Carprofen (rac.) 1.334 11.100 11.100 /// 7.32 7.32 1.00 0.00 801 801 
FMOC-Abu (rac.) 1.334 10.524 11.521 /// 6.89 7.64 1.11 0.96 1914 1673 
Flurbiprofen (rac.) 1.334 6.809 7.072 /// 4.10 4.30 1.05 0.50 3234 2367 
Bz-β-Phe (rac.) 1.334 7.073 7.546 /// 4.30 4.66 1.08 0.70 2127 1584 
Z-Leu (rac.) 1.334 5.987 5.987 /// 3.49 3.49 1.00 0.00 1462 1462 
Z-Arg (L>D) 1.334 1.958 1.958 /// 0.47 0.47 1.00 0.00 1873 1873 
Trp (rac.) 1.334 1.935 1.935 /// 0.45 0.45 1.00 0.00 1030 1030 
Tyr (rac.) 1.334 1.738 1.738 /// 0.30 0.30 1.00 0.00 1964 1964 
QN/QD (2:1) 1.334 1.239 1.239 /// -0.07 -0.07 1.00 0.00 1726 1726 
Clenbuterol.HCl (rac.) 1.334 1.089 1.089 /// -0.18 -0.18 1.00 0.00 2118 2118 
PI-2-56-2 1.334 4.374 4.374 /// 2.28 2.28 1.00 0.00 4552 4552 
PI-2-4-3 1.469 21.847 28.416 /// 13.87 18.34 1.32 2.01 1053 842 
PI-2-25-1 1.469 13.764 13.764 /// 8.37 8.37 1.00 0.00 676 676 
PI-2-34-1 1.334 6.064 6.896 /// 3.55 4.17 1.18 1.16 1478 1118 
PI-3-67-1 1.334 9.989 11.607 /// 6.49 7.70 1.19 1.42 1471 1385 
PI-1-89-1 1.334 12.756 13.866 /// 8.56 9.39 1.10 0.75 1286 1286 
PI-2-15-1 1.334 8.402 10.120 /// 5.30 6.59 1.24 1.75 1496 1354 
PI-2-38-1 1.334 6.138 7.244 /// 3.60 4.43 1.23 1.42 1377 989 
PI-2-87-1 1.334 6.134 7.024 /// 3.60 4.27 1.19 1.22 1463 1132 
P-DML-ACHSA (S,S>R,R) 1.469 11.684 11.684 /// 6.95 6.95 1.00 0.00 651 651 
P-DCL-ACHSA (S,S>R,R) 1.469 20.879 20.879 /// 13.21 13.21 1.00 0.00 1077 1077 
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Table IV: Column 4 (150x4 mm ID, 490 µmol/g, DHQD-type CSP; injection volume: 5 µL; sample 
concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; mobile 
phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C): different t0-
values derive from different positions of the column in the column compartment. 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
Bz-Leu (L>D) 1.287 3.294 4.105 L 1.56 2.19 1.40 2.04 1636 1143 
PFB-Leu (rac.) 1.287 3.354 3.354 /// 1.61 1.61 1.00 0.00 1487 1487 
A-DCL-Leu (rac.) 1.287 4.727 9.456 L 2.67 6.35 2.37 6.92 2147 1302 
DNB-Leu (rac.) 1.314 10.808 31.665 L 7.23 23.10 3.20 8.89 1621 999 
DCB-Leu (rac.) 1.287 5.380 10.439 L 3.18 7.11 2.24 6.99 2325 1495 
BTFMB-Leu (rac.) 1.287 2.706 4.331 L 1.10 2.37 2.15 5.74 3051 1891 
DNB-N-Me-Leu (rac.) 1.287 13.335 13.335 /// 9.36 9.36 1.00 0.00 671 671 
Ac-Phe (rac.) 1.287 5.209 6.842 L 3.05 4.32 1.42 3.12 2149 2081 
Z-Phe (rac.) 1.287 10.003 10.951 L 6.77 7.51 1.11 0.93 1773 1603 
Phe (rac.) 1.314 1.490 1.490 /// 0.13 0.13 1.00 0.00 1981 1981 
DNZ-Phe (D>L) 1.314 2.028 2.266 L 0.54 0.72 1.33 1.49 2819 2950 
BOC-Phe (rac.) 1.287 5.373 5.901 L 3.17 3.59 1.13 1.01 1954 1789 
FMOC-β-Phe (rac.) 1.287 7.774 9.615 L 5.04 6.47 1.28 2.08 1711 1390 
Z-β-Phe (rac.) 1.287 5.149 5.149 /// 3.00 3.00 1.00 0.00 1099 1099 
Bz-Phe (D>L) 1.287 9.044 11.589 L 6.03 8.00 1.33 2.29 1526 1233 
Phenyl-Gly (rac.) 1.314 1.492 1.492 /// 0.14 0.14 1.00 0.00 2258 2258 
DNZ-Val (D>L) 1.287 13.089 19.781 L 9.17 14.37 1.57 4.06 1842 1342 
BOC-Tyr (rac.) 1.287 7.192 8.014 L 4.59 5.23 1.14 1.07 1605 1503 
Ac-Trp (rac.) 1.287 9.793 12.633 L 6.61 8.82 1.33 2.22 1290 1169 
FMOC-Asn (rac.) 1.287 12.682 14.290 L 8.85 10.10 1.14 1.19 1713 1469 
DNB-Pro (rac.) 1.287 13.354 14.336 D 9.38 10.14 1.08 0.72 1823 1429 
FMOC-Ile (L>D) 1.287 7.743 10.233 L 5.02 6.95 1.39 2.93 1928 1654 
FMOC-Gln (rac.) 1.314 1.530 1.530 /// 0.16 0.16 1.00 0.00 2312 2312 
Z-Ser (rac.) 1.287 8.682 8.682 /// 5.75 5.75 1.00 0.00 1075 1075 
FMOC-Pro (L>D) 1.287 8.495 9.183 L 5.60 6.14 1.10 0.81 1732 1713 
FMOC-Aze (rac.) 1.287 10.985 11.933 L 7.54 8.27 1.10 0.86 1813 1612 
DBTAMME (rac.) 1.287 11.516 13.338 R,R 7.95 9.36 1.18 1.39 1444 1432 
Trolox (rac.) 1.287 6.373 7.519 R 3.95 4.84 1.23 1.54 1619 1162 
Ibuprofen (rac) 1.287 2.983 2.983 /// 1.32 1.32 1.00 0.00 1897 1897 
Naproxen (rac.) 1.287 5.784 5.784 /// 3.49 3.49 1.00 0.00 1788 1788 
DNP-Mandelic acid (rac.) 1.314 59.366 75.860 S 44.18 56.73 1.28 2.13 1268 1163 
Acetylmandelic acid (rac.) 1.314 9.256 9.256 /// 6.04 6.04 1.00 0.00 1152 1152 
Phenylbutyric acid (rac.) 1.287 2.992 2.992 /// 1.32 1.32 1.00 0.00 3257 3257 
TMB-Ala (rac.) 1.287 5.680 8.502 /// 3.41 5.61 1.64 3.81 1517 1421 
Bz-ACHSA (rac.) 1.314 13.464 13.464 /// 9.25 9.25 1.00 0.00 1220 1220 
MFQ.HCl (rac.) 1.287 1.142 1.142 /// -0.11 -0.11 1.00 0.00 1674 1674 
BOC-Gly 1.287 3.792 /// /// 1.95 /// /// /// 1251 /// 
DNZ-Gly 1.314 26.203 /// /// 18.94 /// /// /// 1722 /// 
Vanillylmandelic acid (rac.) 1.287 17.937 17.937 /// 12.94 12.94 1.00 0.00 1722 1722 
Nitrophenylpropionic acid (rac.) 1.287 8.584 8.584 /// 5.67 5.67 1.00 0.00 2387 2387 
Hydroxyphenyllactic acid (rac.) 1.287 16.140 17.668 /// 11.54 12.73 1.10 0.84 1478 1295 
Tropic acid (rac.) 1.287 4.695 4.695 /// 2.65 2.65 1.00 0.00 1955 1955 
Fenoprofen (rac.) 1.287 5.516 5.516 /// 3.29 3.29 1.00 0.00 4295 4295 
Dichlorprop (rac.) 1.287 13.331 15.489 /// 9.36 11.03 1.18 1.42 1876 1009 
Hydroxymandelic acid (rac.) 1.287 19.727 20.058 /// 14.33 14.59 1.02 0.20 2971 1584 
Atrolactic acid (rac.) 1.287 10.682 10.682 /// 7.30 7.30 1.00 0.00 1388 1388 
Carprofen (rac.) 1.287 8.464 8.464 /// 5.58 5.58 1.00 0.00 1395 1395 
FMOC-Abu (rac.) 1.287 8.938 10.578 /// 5.94 7.22 1.21 1.84 2040 1787 
Flurbiprofen (rac.) 1.287 5.994 5.994 /// 3.66 3.66 1.00 0.00 1938 1938 
Bz-β-Phe (rac.) 1.287 5.879 7.140 /// 3.57 4.55 1.27 1.97 1773 1520 
Z-Leu (rac.) 1.287 4.846 5.131 /// 2.77 2.99 1.08 0.76 2833 2796 
Z-Arg (L>D) 1.287 1.826 1.826 /// 0.42 0.42 1.00 0.00 2435 2435 
Trp (rac.) 1.287 1.911 1.911 /// 0.48 0.48 1.00 0.00 1651 1651 
Tyr (rac.) 1.287 1.701 1.701 /// 0.32 0.32 1.00 0.00 2208 2208 
QN/QD (2:1) 1.287 1.215 1.215 /// -0.06 -0.06 1.00 0.00 1348 1348 
Clenbuterol.HCl (rac.) 1.287 1.050 1.050 /// -0.18 -0.18 1.00 0.00 2126 2126 
PI-2-56-2 1.287 12.833 13.793 /// 8.97 9.72 1.08 0.58 1286 780 
PI-2-4-3 1.314 20.062 32.418 /// 14.27 23.67 1.66 4.12 1372 1081 
PI-2-25-1 1.287 10.308 11.624 /// 7.01 8.03 1.15 0.99 1135 1028 
PI-2-34-1 1.287 5.312 6.143 /// 3.13 3.77 1.21 1.40 1637 1331 
PI-3-67-1 1.287 8.503 10.140 /// 5.61 6.88 1.23 1.65 1491 1322 
PI-1-89-1 1.287 11.596 11.596 /// 8.01 8.01 1.00 0.00 1123 1123 
PI-2-15-1 1.287 7.213 10.331 /// 4.60 7.03 1.53 3.62 1797 1513 
PI-2-38-1 1.287 5.260 6.323 /// 3.09 3.91 1.27 1.70 1590 1145 
PI-2-87-1 1.287 5.393 6.215 /// 3.19 3.83 1.20 1.37 1650 1324 
P-DML-ACHSA (S,S>R,R) 1.314 10.899 11.517 S,S 7.29 7.76 1.06 0.57 1697 1757 
P-DCL-ACHSA (S,S>R,R) 1.314 18.773 18.773 /// 13.29 13.29 1.00 0.00 736 736 
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Table V: Column 5 (150x4 mm ID, 214 µmol/g, DHQN-type CSP; injection volume: 5 µL; sample 
concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; mobile 
phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C): different t0-
values derive from different positions of the column in the column compartment. 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
Bz-Leu (L>D) 1.499 3.190 3.850 D 1.13 1.57 1.39 3.26 4878 4785 
PFB-Leu (rac.) 1.499 3.082 3.082 /// 1.06 1.06 1.00 0.00 2432 2432 
A-DCL-Leu (rac.) 1.499 4.137 8.065 D 1.76 4.38 2.49 10.47 4497 3967 
DNB-Leu (rac.) 1.499 5.768 16.912 D 2.85 10.28 3.61 15.45 4339 3570 
DCB-Leu (rac.) 1.499 4.114 7.481 D 1.74 3.99 2.29 9.77 4811 4247 
BTFMB-Leu (rac.) 1.499 2.643 4.244 D 0.76 1.83 2.40 7.85 4725 4405 
DNB-N-Me-Leu (rac.) 1.499 6.522 6.836 D 3.35 3.56 1.06 0.74 3568 4421 
Ac-Phe (rac.) 1.499 3.871 4.789 D 1.58 2.19 1.39 3.72 4935 4908 
Z-Phe (rac.) 1.499 6.161 6.593 D 3.11 3.40 1.09 1.03 3455 3944 
Phe (rac.) 1.498 1.658 1.658 /// 0.11 0.11 1.00 0.00 2569 2569 
DNZ-Phe (D>L) 1.499 1.936 10.853 D 0.29 6.24 21.41 21.36 3457 4052 
BOC-Phe (rac.) 1.499 4.028 4.398 D 1.69 1.93 1.15 1.52 4734 4801 
FMOC-β-Phe (rac.) 1.499 4.969 5.569 D 2.31 2.72 1.17 1.80 4171 3848 
Z-β-Phe (rac.) 1.498 3.893 3.893 /// 1.60 1.60 1.00 0.00 4983 4983 
Bz-Phe (D>L) 1.499 5.474 7.041 D 2.65 3.70 1.39 4.22 4618 4455 
Phenyl-Gly (rac.) 1.499 1.705 1.705 /// 0.14 0.14 1.00 0.00 1551 1551 
DNZ-Val (D>L) 1.499 6.867 10.981 D 3.58 6.33 1.77 7.25 4265 3660 
BOC-Tyr (rac.) 1.499 4.412 4.773 D 1.94 2.18 1.12 1.29 4255 4372 
Ac-Trp (rac.) 1.499 5.709 7.101 D 2.81 3.74 1.33 3.49 4305 3969 
FMOC-Asn (rac.) 1.499 7.769 8.699 D 4.18 4.80 1.15 1.75 3914 3781 
DNB-Pro (rac.) 1.499 6.983 6.983 /// 3.66 3.66 1.00 0.00 2731 2731 
FMOC-Ile (L>D) 1.499 5.070 6.419 D 2.38 3.28 1.38 3.82 4290 4162 
FMOC-Gln (rac.) 1.498 1.685 1.685 /// 0.12 0.12 1.00 0.00 4241 4241 
Z-Ser (rac.) 1.499 5.047 5.047 /// 2.37 2.37 1.00 0.00 4781 4781 
FMOC-Pro (L>D) 1.499 5.580 5.717 D 2.72 2.81 1.03 0.41 5652 3396 
FMOC-Aze (rac.) 1.499 6.703 7.084 D 3.47 3.73 1.07 0.93 4296 4728 
DBTAMME (rac.) 1.499 7.556 8.687 S,S 4.04 4.80 1.19 2.31 4400 4407 
Trolox (rac.) 1.499 4.121 4.683 S 1.75 2.12 1.21 2.05 4137 4083 
Ibuprofen (rac) 1.499 2.469 2.469 /// 0.65 0.65 1.00 0.00 4235 4235 
Naproxen (rac.) 1.499 3.604 3.604 /// 1.40 1.40 1.00 0.00 2382 2382 
DNP-Mandelic acid (rac.) 1.498 26.503 33.850 R 16.69 21.60 1.29 3.46 3214 3264 
Acetylmandelic acid (rac.) 1.499 5.257 5.624 S 2.51 2.75 1.10 1.10 3921 4552 
Phenylbutyric acid (rac.) 1.499 2.345 2.345 /// 0.56 0.56 1.00 0.00 4349 4349 
TMB-Ala (rac.) 1.499 4.273 5.801 /// 1.85 2.87 1.55 4.83 3986 4129 
Bz-ACHSA (rac.) 1.499 6.035 6.035 /// 3.03 3.03 1.00 0.00 2079 2079 
MFQ.HCl (rac.) 1.499 1.376 1.376 /// -0.08 -0.08 1.00 0.00 1811 1811 
BOC-Gly 1.499 1.670 /// /// 0.11 /// /// /// 2739 /// 
DNZ-Gly 1.499 10.069 /// /// 5.72 /// /// /// 4225 /// 
Vanillylmandelic acid (rac.) 1.499 7.845 8.149 /// 4.23 4.44 1.05 0.67 4712 5335 
Nitrophenylpropionic acid (rac.) 1.499 4.251 4.336 /// 1.84 1.89 1.03 0.44 6063 9611 
Hydroxyphenyllactic acid (rac.) 1.499 7.122 8.808 /// 3.75 4.88 1.30 3.04 3506 3108 
Tropic acid (rac.) 1.499 3.006 3.006 /// 1.01 1.01 1.00 0.00 5299 5299 
Fenoprofen (rac.) 1.499 3.120 3.120 /// 1.08 1.08 1.00 0.00 2502 2502 
Dichlorprop (rac.) 1.499 6.765 7.290 /// 3.51 3.86 1.10 1.28 5140 4299 
Hydroxymandelic acid (rac.) 1.499 7.972 7.972 /// 4.32 4.32 1.00 0.00 3853 3853 
Atrolactic acid (rac.) 1.499 5.624 5.624 /// 2.75 2.75 1.00 0.00 5076 5076 
Carprofen (rac.) 1.499 4.276 4.400 /// 1.85 1.94 1.04 0.54 5045 6346 
FMOC-Abu (rac.) 1.499 5.337 6.121 /// 2.56 3.08 1.20 2.17 3810 4204 
Flurbiprofen (rac.) 1.499 3.549 3.655 /// 1.37 1.44 1.05 0.59 5820 7156 
Bz-β-Phe (rac.) 1.499 4.035 4.491 /// 1.69 2.00 1.18 1.76 4214 4425 
Z-Leu (rac.) 1.498 3.982 3.982 /// 1.66 1.66 1.00 0.00 5732 5732 
Z-Arg (L>D) 1.499 2.316 2.316 /// 0.55 0.55 1.00 0.00 4221 4221 
Trp (rac.) 1.499 1.903 1.958 D 0.27 0.31 1.14 0.48 5071 4041 
Tyr (rac.) 1.499 1.748 1.748 /// 0.17 0.17 1.00 0.00 3339 3339 
QN/QD (2:1) 1.499 1.665 1.665 /// 0.11 0.11 1.00 0.00 1913 1913 
Clenbuterol.HCl (rac.) 1.499 1.300 1.300 /// -0.13 -0.13 1.00 0.00 2902 2902 
PI-2-56-2 1.499 8.458 11.968 /// 4.64 6.98 1.50 4.16 2788 1893 
PI-2-4-3 1.499 10.649 14.634 /// 6.10 8.76 1.44 4.66 3664 3330 
PI-2-25-1 1.499 7.707 7.707 /// 4.14 4.14 1.00 0.00 3469 3469 
PI-2-34-1 1.499 4.366 5.154 /// 1.91 2.44 1.27 2.80 4738 4404 
PI-3-67-1 1.499 6.658 8.408 /// 3.44 4.61 1.34 3.92 4575 4525 
PI-1-89-1 1.499 7.795 8.422 /// 4.20 4.62 1.10 1.10 3148 3375 
PI-2-15-1 1.499 5.858 7.071 /// 2.91 3.72 1.28 2.97 4026 4005 
PI-2-38-1 1.499 4.301 5.209 /// 1.87 2.47 1.32 3.28 4984 4464 
PI-2-87-1 1.499 4.507 5.368 /// 2.01 2.58 1.29 3.02 4789 4783 
P-DML-ACHSA (S,S>R,R) 1.498 6.082 6.295 R,R 3.06 3.20 1.05 0.66 6722 5198 
P-DCL-ACHSA (S,S>R,R) 1.498 8.122 8.949 R,R 4.42 4.97 1.12 1.65 4468 4807 
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Table VI: Column 6 (150x4 mm ID, 232 µmol/g, DHQD-type CSP; injection volume: 5 µL; sample 
concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; mobile 
phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C): different t0-
values derive from different positions of the column in the column compartment. 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
Bz-Leu (L>D) 1.549 3.430 4.516 L 1.21 1.92 1.58 4.79 5496 4326 
PFB-Leu (rac.) 1.549 3.300 3.463 L 1.13 1.24 1.09 0.82 4027 5249 
A-DCL-Leu (rac.) 1.549 4.145 9.439 L 1.68 5.09 3.04 13.57 5154 4541 
DNB-Leu (rac.) 1.976 8.836 31.383 L 3.47 14.88 4.29 22.90 7061 6288 
DCB-Leu (rac.) 1.549 4.190 8.785 L 1.70 4.67 2.74 11.12 3104 4782 
BTFMB-Leu (rac.) 1.549 2.687 4.900 L 0.73 2.16 2.94 10.37 5236 4868 
DNB-N-Me-Leu (rac.) 1.549 9.183 9.183 /// 4.93 4.93 1.00 0.00 1144 1144 
Ac-Phe (rac.) 1.549 4.067 5.398 L 1.63 2.48 1.53 5.15 5157 5560 
Z-Phe (rac.) 1.549 6.413 7.243 L 3.14 3.68 1.17 2.22 5369 5276 
Phe (rac.) 1.976 2.228 2.228 /// 0.13 0.13 1.00 0.00 3047 3047 
DNZ-Phe (D>L) 1.976 2.921 11.830 L 0.48 4.99 10.43 20.01 3906 4875 
BOC-Phe (rac.) 1.549 4.186 4.694 L 1.70 2.03 1.19 2.11 5463 5440 
FMOC-β-Phe (rac.) 1.549 5.200 6.744 L 2.36 3.35 1.42 4.32 4629 4324 
Z-β-Phe (rac.) 1.549 3.772 3.975 L 1.44 1.57 1.09 0.96 5270 5496 
Bz-Phe (D>L) 1.549 5.948 8.164 L 2.84 4.27 1.50 5.64 5246 5084 
Phenyl-Gly (rac.) 1.549 1.765 1.765 /// 0.14 0.14 1.00 0.00 1775 1775 
DNZ-Val (D>L) 1.549 7.455 13.255 L 3.81 7.56 1.98 9.63 4974 4482 
BOC-Tyr (rac.) 1.549 4.514 5.078 L 1.91 2.28 1.19 2.09 5098 5002 
Ac-Trp (rac.) 1.549 5.887 7.826 L 2.80 4.05 1.45 4.88 4790 4724 
FMOC-Asn (rac.) 1.549 8.296 9.722 L 4.36 5.28 1.21 2.59 4527 4049 
DNB-Pro (rac.) 1.549 8.048 8.741 D 4.20 4.64 1.11 1.42 5037 4453 
FMOC-Ile (L>D) 1.549 5.351 7.570 L 2.45 3.89 1.58 6.03 5029 4837 
FMOC-Gln (rac.) 1.976 2.245 2.245 /// 0.14 0.14 1.00 0.00 5916 5916 
Z-Ser (rac.) 1.549 5.210 5.470 L 2.36 2.53 1.07 0.95 5744 6347 
FMOC-Pro (L>D) 1.549 6.038 6.477 L 2.90 3.18 1.10 1.22 4901 4746 
FMOC-Aze (rac.) 1.549 7.286 7.762 L 3.70 4.01 1.08 1.14 5043 5409 
DBTAMME (rac.) 1.549 7.776 8.764 R,R 4.02 4.66 1.16 2.18 5355 5261 
Trolox (rac.) 1.549 4.026 4.367 R 1.60 1.82 1.14 1.50 5489 5421 
Ibuprofen (rac) 1.549 2.535 2.535 /// 0.64 0.64 1.00 0.00 5022 5022 
Naproxen (rac.) 1.549 3.770 3.770 /// 1.43 1.43 1.00 0.00 5802 5802 
DNP-Mandelic acid (rac.) 1.976 28.402 42.205 S 13.37 20.36 1.52 6.38 4335 4174 
Acetylmandelic acid (rac.) 1.549 5.465 5.465 /// 2.53 2.53 1.00 0.00 6251 6251 
Phenylbutyric acid (rac.) 1.549 2.443 2.443 /// 0.58 0.58 1.00 0.00 5179 5179 
TMB-Ala (rac.) 1.549 4.424 6.999 /// 1.86 3.52 1.90 8.10 5516 4803 
Bz-ACHSA (rac.) 1.549 6.916 7.470 /// 3.46 3.82 1.10 1.44 5632 5607 
MFQ.HCl (rac.) 1.549 1.387 1.387 /// -0.10 -0.10 1.00 0.00 2941 2941 
BOC-Gly 1.549 1.776 /// /// 0.15 /// /// /// 3165 /// 
DNZ-Gly 1.549 11.000 /// /// 6.10 /// /// /// 5289 /// 
Vanillylmandelic acid (rac.) 1.549 8.305 8.305 /// 4.36 4.36 1.00 0.00 3683 3683 
Nitrophenylpropionic acid (rac.) 1.549 4.828 4.828 /// 2.12 2.12 1.00 0.00 6486 6486 
Hydroxyphenyllactic acid (rac.) 1.549 7.193 7.669 /// 3.64 3.95 1.08 1.18 5475 5293 
Tropic acid (rac.) 1.549 3.211 3.211 /// 1.07 1.07 1.00 0.00 6185 6185 
Fenoprofen (rac.) 1.549 3.269 3.269 /// 1.11 1.11 1.00 0.00 5920 5920 
Dichlorprop (rac.) 1.549 7.461 7.783 /// 3.82 4.02 1.05 0.85 5985 7074 
Hydroxymandelic acid (rac.) 1.549 8.080 8.080 /// 4.22 4.22 1.00 0.00 2031 2031 
Atrolactic acid (rac.) 1.549 5.906 5.906 /// 2.81 2.81 1.00 0.00 3496 3496 
Carprofen (rac.) 1.549 4.314 4.314 /// 1.79 1.79 1.00 0.00 2665 2665 
FMOC-Abu (rac.) 1.549 5.733 7.009 /// 2.70 3.52 1.30 3.30 3867 4809 
Flurbiprofen (rac.) 1.549 3.889 3.889 /// 1.51 1.51 1.00 0.00 3877 3877 
Bz-β-Phe (rac.) 1.549 4.233 5.184 /// 1.73 2.35 1.35 3.57 4972 5027 
Z-Leu (rac.) 1.549 3.808 4.058 /// 1.46 1.62 1.11 1.20 5597 5820 
Z-Arg (L>D) 1.549 2.063 2.063 /// 0.33 0.33 1.00 0.00 3541 3541 
Trp (rac.) 1.549 2.006 2.006 /// 0.30 0.30 1.00 0.00 1474 1474 
Tyr (rac.) 1.549 1.809 1.809 /// 0.17 0.17 1.00 0.00 3743 3743 
QN/QD (2:1) 1.549 1.640 1.640 /// 0.06 0.06 1.00 0.00 2260 2260 
Clenbuterol.HCl (rac.) 1.549 1.331 1.331 /// -0.14 -0.14 1.00 0.00 3561 3561 
PI-2-56-2 1.549 9.016 9.096 /// 4.82 4.87 1.01 0.17 5591 5651 
PI-2-4-3 1.976 16.341 28.279 /// 7.27 13.31 1.83 8.65 4423 3938 
PI-2-25-1 1.549 8.224 9.675 /// 4.31 5.25 1.22 2.70 4486 4421 
PI-2-34-1 1.549 4.811 5.533 /// 2.11 2.57 1.22 2.58 5543 5353 
PI-3-67-1 1.549 7.472 9.089 /// 3.82 4.87 1.27 3.54 5299 5188 
PI-1-89-1 1.549 8.936 8.936 /// 4.77 4.77 1.00 0.00 2160 2160 
PI-2-15-1 1.549 6.160 9.310 /// 2.98 5.01 1.68 7.03 4920 4611 
PI-2-38-1 1.549 4.621 5.500 /// 1.98 2.55 1.29 3.26 5826 5478 
PI-2-87-1 1.549 5.005 5.738 /// 2.23 2.70 1.21 2.51 5503 5353 
P-DML-ACHSA (S,S>R,R) 1.976 8.495 9.620 S,S 3.30 3.87 1.17 2.13 4840 4585 
P-DCL-ACHSA (S,S>R,R) 1.976 12.421 14.434 S,S 5.29 6.30 1.19 2.93 5873 6354 
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Table VII: Column 7 (150x4 mm ID, 238 µmol/g, DHQD-type CSP; injection volume: 5 µL; 
sample concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; 
mobile phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C). 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
PFB-Leu (rac.) 1.500 2.934 2.934 /// 0.96 0.96 1.00 0.00 1786 1786 
DCB-Leu (rac.) 1.500 3.853 6.870 L 1.57 3.58 2.28 5.33 1667 1199 
DNB-N-Me-Leu (rac.) 1.500 8.420 8.420 /// 4.61 4.61 1.00 0.00 568 568 
Ac-Phe (rac.) 1.500 3.521 4.408 L 1.35 1.94 1.44 2.25 1717 1526 
Z-Phe (rac.) 1.500 6.204 6.699 L 3.14 3.47 1.11 0.69 1533 1073 
Phe (rac.) 1.500 1.517 1.517 /// 0.01 0.01 1.00 0.00 957 957 
DNZ-Val (D>L) 1.500 7.714 11.356 L 4.14 6.57 1.59 3.34 1358 1096 
DNB-Pro (rac.) 1.500 7.740 8.356 D 4.16 4.57 1.10 0.72 1674 1123 
FMOC-Aze (rac.) 1.500 6.643 7.126 L 3.43 3.75 1.09 0.61 1346 1096 
DBTAMME (rac.) 1.500 6.946 7.982 R,R 3.63 4.32 1.19 1.10 1060 950 
DNZ-Gly 1.500 12.677 /// /// 7.45 /// /// /// 1307 /// 
Hydroxyphenyllactic acid (rac.) 1.500 9.077 9.938 /// 5.05 5.63 1.11 0.74 1255 890 
Flurbiprofen (rac.) 1.500 3.963 3.963 /// 1.64 1.64 1.00 0.00 1610 1610 
Trp (rac.) 1.500 1.655 1.655 /// 0.10 0.10 1.00 0.00 1894 1894 
QN/QD (2:1) 1.500 1.560 1.560 /// 0.04 0.04 1.00 0.00 2030 2030 
Clenbuterol.HCl (rac.) 1.500 1.378 1.378 /// -0.08 -0.08 1.00 0.00 2197 2197 
PI-2-56-2 1.500 8.540 9.260 /// 4.69 5.17 1.10 0.63 1030 905 
PI-2-15-1 1.500 4.773 6.627 /// 2.18 3.42 1.57 2.93 1375 1219 
P-DML-ACHSA (S,S>R,R) 1.500 5.619 5.806 S,S 2.75 2.87 1.05 0.33 1419 1862 
P-DCL-ACHSA (S,S>R,R) 1.500 9.106 9.473 S,S 5.07 5.32 1.05 0.40 1228 2090 
 
 
 
Table VIII: Column 8 (150x4 mm ID, 314 µmol/g, DHQD-type CSP; injection volume: 5 µL; 
sample concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; 
mobile phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C). 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
PFB-Leu (rac.) 1.602 4.952 5.155 L 2.09 2.22 1.06 0.79 5919 6613 
DCB-Leu (rac.) 1.602 6.523 14.131 L 3.07 7.82 2.55 13.73 5743 5374 
DNB-N-Me-Leu (rac.) 1.602 15.778 16.115 L 8.85 9.06 1.02 0.33 2854 4993 
Ac-Phe (rac.) 1.602 5.901 8.008 L 2.68 4.00 1.49 5.10 4493 4580 
Z-Phe (rac.) 1.602 10.543 11.859 L 5.58 6.40 1.15 2.04 4864 4828 
Phe (rac.) 1.602 1.779 1.779 /// 0.11 0.11 1.00 0.00 3211 3211 
DNZ-Val (D>L) 1.602 12.632 22.085 L 6.89 12.79 1.86 10.03 5629 5224 
DNB-Pro (rac.) 1.602 13.140 14.434 D 7.20 8.01 1.11 1.71 5646 4948 
FMOC-Aze (rac.) 1.602 11.819 12.681 L 6.38 6.92 1.08 1.32 5565 5675 
DBTAMME (rac.) 1.602 12.969 14.833 R,R 7.10 8.26 1.16 2.31 4759 4723 
DNZ-Gly 1.602 19.328 /// /// 11.07 /// /// /// 6006 /// 
Hydroxyphenyllactic acid (rac.) 1.602 12.296 13.337 /// 6.68 7.33 1.10 1.27 3962 3864 
Flurbiprofen (rac.) 1.602 5.852 5.852 /// 2.65 2.65 1.00 0.00 3771 3771 
Trp (rac.) 1.602 2.288 2.288 /// 0.43 0.43 1.00 0.00 1687 1687 
QN/QD (2:1) 1.602 1.599 1.599 /// 0.00 0.00 1.00 0.00 2408 2408 
Clenbuterol.HCl (rac.) 1.602 1.330 1.330 /// -0.17 -0.17 1.00 0.00 3843 3843 
PI-2-56-2 1.602 15.423 16.049 /// 8.63 9.02 1.05 0.42 2136 1354 
PI-2-15-1 1.602 9.372 14.383 /// 4.85 7.98 1.64 7.19 4681 4621 
P-DML-ACHSA (S,S>R,R) 1.602 9.815 11.058 S,S 5.13 5.90 1.15 2.20 5406 5499 
P-DCL-ACHSA (S,S>R,R) 1.602 15.278 17.624 S,S 8.54 10.00 1.17 2.67 5392 5802 
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Table IX: Column 9 (150x4 mm ID, 150 µmol/g, DHQD-type CSP; injection volume: 5 µL; sample 
concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; mobile 
phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C). 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
PFB-Leu (rac.) 1.669 3.218 3.364 L 0.93 1.02 1.09 0.58 2991 2471 
DCB-Leu (rac.) 1.669 3.821 7.708 L 1.29 3.62 2.81 8.16 2296 2391 
DNB-N-Me-Leu (rac.) 1.669 7.747 7.747 /// 3.64 3.64 1.00 0.00 1085 1085 
Ac-Phe (rac.) 1.669 3.567 4.614 L 1.14 1.77 1.55 2.95 2096 2169 
Z-Phe (rac.) 1.669 5.292 5.967 L 2.17 2.58 1.19 1.42 2246 2253 
Phe (rac.) 1.669 1.854 1.854 /// 0.11 0.11 1.00 0.00 768 768 
DNZ-Val (D>L) 1.669 5.871 10.426 L 2.52 5.25 2.08 7.15 3031 2199 
DNB-Pro (rac.) 1.669 6.326 6.846 D 2.79 3.10 1.11 0.99 3091 1937 
FMOC-Aze (rac.) 1.669 5.755 6.043 L 2.45 2.62 1.07 0.69 2828 3477 
DBTAMME (rac.) 1.669 6.488 7.182 R,R 2.89 3.30 1.14 1.39 2887 3104 
DNZ-Gly 1.669 7.909 /// /// 3.74 /// /// /// 3157 /// 
Hydroxyphenyllactic acid (rac.) 1.669 5.518 5.518 /// 2.31 2.31 1.00 0.00 812 812 
Flurbiprofen (rac.) 1.669 3.376 3.376 /// 1.02 1.02 1.00 0.00 2397 2397 
Trp (rac.) 1.669 2.091 2.091 /// 0.25 0.25 1.00 0.00 818 818 
QN/QD (2:1) 1.669 1.847 1.847 /// 0.11 0.11 1.00 0.00 1768 1768 
Clenbuterol.HCl (rac.) 1.669 1.457 1.457 /// -0.13 -0.13 1.00 0.00 1797 1797 
PI-2-56-2 1.669 7.267 7.267 /// 3.35 3.35 1.00 0.00 894 894 
PI-2-15-1 1.669 5.166 7.650 /// 2.10 3.58 1.71 4.93 2567 2617 
P-DML-ACHSA (S,S>R,R) 1.669 5.110 5.823 S,S 2.06 2.49 1.21 1.80 3038 3037 
P-DCL-ACHSA (S,S>R,R) 1.669 6.854 8.164 S,S 3.11 3.89 1.25 2.45 3103 3187 
 
 
 
 
Table X: Column 10 (150x4 mm ID, 138 µmol/g, DHQD-type CSP; injection volume: 5 µL; 
sample concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; 
mobile phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C). 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
PFB-Leu (rac.) 1.469 2.911 3.077 L 0.98 1.09 1.12 1.11 4761 8094 
DCB-Leu (rac.) 1.469 3.404 6.287 L 1.32 3.28 2.49 9.98 4812 4187 
DNB-N-Me-Leu (rac.) 1.469 6.543 6.543 /// 3.45 3.45 1.00 0.00 1305 1305 
Ac-Phe (rac.) 1.469 3.407 4.236 L 1.32 1.88 1.43 3.86 5018 5101 
Z-Phe (rac.) 1.469 4.822 5.340 L 2.28 2.64 1.15 1.78 4872 4930 
Phe (rac.) 1.469 1.734 1.734 /// 0.18 0.18 1.00 0.00 2724 2724 
DNZ-Val (D>L) 1.469 5.543 9.365 L 2.77 5.38 1.94 8.43 4598 4052 
DNB-Pro (rac.) 1.469 5.899 6.353 D 3.02 3.32 1.10 1.22 4452 4198 
FMOC-Aze (rac.) 1.469 5.213 5.481 L 2.55 2.73 1.07 0.87 4394 5229 
DBTAMME (rac.) 1.469 5.962 6.546 R,R 3.06 3.46 1.13 1.19 4718 445 
DNZ-Gly 1.469 7.757 /// /// 4.28 /// /// /// 4542 /// 
Hydroxyphenyllactic acid (rac.) 1.469 5.580 5.873 /// 2.80 3.00 1.07 0.68 3188 2543 
Flurbiprofen (rac.) 1.469 3.125 3.125 /// 1.13 1.13 1.00 0.00 4391 4391 
Trp (rac.) 1.469 1.915 1.915 /// 0.30 0.30 1.00 0.00 2453 2453 
QN/QD (2:1) 1.469 1.774 1.774 /// 0.21 0.21 1.00 0.00 3133 3133 
Clenbuterol.HCl (rac.) 1.469 1.555 1.555 /// 0.06 0.06 1.00 0.00 4052 4052 
PI-2-56-2 1.469 6.167 6.167 /// 3.20 3.20 1.00 0.00 1327 1327 
PI-2-15-1 1.469 4.223 6.025 /// 1.87 3.10 1.65 3.91 1990 1969 
P-DML-ACHSA (S,S>R,R) 1.469 4.594 5.093 S,S 2.13 2.47 1.16 1.23 2411 2176 
P-DCL-ACHSA (S,S>R,R) 1.469 6.068 7.012 S,S 3.13 3.77 1.21 1.69 2219 2176 
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Table XI: Column 11 (75x4 mm ID, 477 µmol/g, DHQN-type CSP; injection volume: 5 µL; sample 
concentration: 1 mg/mL MeOH; flow rate: 0.5 mL/min; detection wavelength: 254 nm; mobile 
phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C). 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
PFB-Leu (rac.) 1.430 4.466 4.466 /// 2.12 2.12 1.00 0.00 1510 1510 
DCB-Leu (rac.) 1.430 7.231 12.207 D 4.06 7.53 1.86 5.22 2048 1273 
DNB-N-Me-Leu (rac.) 1.430 12.657 12.657 /// 7.85 7.85 1.00 0.00 844 844 
Ac-Phe (rac.) 1.430 6.493 7.867 D 3.54 4.50 1.27 1.78 1303 1457 
Z-Phe (rac.) 1.430 13.564 13.564 /// 8.48 8.48 1.00 0.00 1153 1153 
Phe (rac.) 1.430 1.637 1.637 /// 0.14 0.14 1.00 0.00 1367 1367 
DNZ-Val (D>L) 1.430 15.907 21.791 D 10.12 14.23 1.41 2.73 1374 1080 
DNB-Pro (rac.) 1.430 14.948 14.948 /// 9.45 9.45 1.00 0.00 841 841 
FMOC-Aze (rac.) 1.430 13.675 14.280 D 8.56 8.98 1.05 0.52 3388 1209 
DBTAMME (rac.) 1.430 15.358 18.347 S,S 9.74 11.83 1.21 1.93 1816 1977 
DNZ-Gly 1.430 29.607 /// /// 19.70 /// /// /// 1971 /// 
Hydroxyphenyllactic acid (rac.) 1.430 23.298 31.504 /// 15.29 21.03 1.38 2.71 1364 1262 
Flurbiprofen (rac.) 1.430 7.254 7.537 /// 4.07 4.27 1.05 0.53 4029 2070 
Trp (rac.) 1.430 2.183 2.183 /// 0.53 0.53 1.00 0.00 771 771 
QN/QD (2:1) 1.430 1.349 1.349 /// -0.06 -0.06 1.00 0.00 1320 1320 
Clenbuterol.HCl (rac.) 1.430 1.243 1.243 /// -0.13 -0.13 1.00 0.00 1647 1647 
PI-2-56-2 1.430 19.965 19.965 /// 12.96 12.96 1.00 0.00 626 626 
PI-2-15-1 1.430 9.034 11.040 /// 5.32 6.72 1.26 1.86 1472 1296 
P-DML-ACHSA (S,S>R,R) 1.430 10.503 10.503 /// 6.34 6.34 1.00 0.00 1224 1224 
P-DCL-ACHSA (S,S>R,R) 1.430 17.498 17.498 /// 11.23 11.23 1.00 0.00 1222 1222 
 
 
 
 
Table XII: Column 11 (75x4 mm ID, 477 µmol/g, DHQN-type CSP; injection volume: 5 µL; 
sample concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; 
mobile phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C). 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
PFB-Leu (rac.) 0.702 2.435 2.435 /// 2.47 2.47 1.00 0.00 1130 1130 
DCB-Leu (rac.) 0.702 3.704 6.162 D 4.28 7.78 1.82 4.30 1389 994 
DNB-N-Me-Leu (rac.) 0.702 6.284 6.284 /// 7.96 7.96 1.00 0.00 696 696 
Ac-Phe (rac.) 0.702 3.145 3.788 D 3.48 4.40 1.26 1.63 1284 1191 
Z-Phe (rac.) 0.702 6.539 6.539 /// 8.32 8.32 1.00 0.00 939 939 
Phe (rac.) 0.702 0.811 0.811 /// 0.16 0.16 1.00 0.00 887 887 
DNZ-Val (D>L) 0.702 7.639 10.271 D 9.89 13.64 1.38 2.19 985 797 
DNB-Pro (rac.) 0.702 7.082 7.082 /// 9.09 9.09 1.00 0.00 681 681 
FMOC-Aze (rac.) 0.702 6.680 6.680 /// 8.52 8.52 1.00 0.00 510 510 
DBTAMME (rac.) 0.702 7.370 8.756 S,S 9.50 11.48 1.21 1.20 857 708 
DNZ-Gly 0.702 13.685 /// /// 18.50 /// /// /// 898 /// 
Hydroxyphenyllactic acid (rac.) 0.702 11.068 14.858 /// 14.77 20.18 1.37 2.06 859 732 
Flurbiprofen (rac.) 0.702 3.441 3.441 /// 3.90 3.90 1.00 0.00 548 548 
Trp (rac.) 0.702 1.030 1.030 /// 0.47 0.47 1.00 0.00 744 744 
QN/QD (2:1) 0.702 0.651 0.651 /// -0.07 -0.07 1.00 0.00 768 768 
Clenbuterol.HCl (rac.) 0.702 0.570 0.570 /// -0.19 -0.19 1.00 0.00 732 732 
PI-2-15-1 0.702 4.247 5.120 /// 5.05 6.30 1.25 1.45 1039 885 
P-DML-ACHSA (S,S>R,R) 0.702 5.097 5.097 /// 6.26 6.26 1.00 0.00 773 773 
P-DCL-ACHSA (S,S>R,R) 0.702 8.463 8.463 /// 11.06 11.06 1.00 0.00 903 903 
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Table XIII: Column 12 (75x4 mm ID, 490 µmol/g, DHQD-type CSP; injection volume: 5 µL; 
sample concentration: 1 mg/mL MeOH; flow rate: 0.5 mL/min; detection wavelength: 254 nm; 
mobile phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C). 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
PFB-Leu (rac.) 1.412 4.896 4.896 /// 2.47 2.47 1.00 0.00 1649 1649 
DCB-Leu (rac.) 1.412 6.801 13.404 L 3.82 8.49 2.23 6.48 1808 1338 
DNB-N-Me-Leu (rac.) 1.412 16.546 16.546 /// 10.72 10.72 1.00 0.00 618 618 
Ac-Phe (rac.) 1.412 6.405 8.436 L 3.54 4.97 1.41 2.77 1681 1607 
Z-Phe (rac.) 1.412 12.801 14.006 L 8.06 8.92 1.11 0.85 1469 1385 
Phe (rac.) 1.412 1.773 1.773 /// 0.26 0.26 1.00 0.00 729 729 
DNZ-Val (D>L) 1.412 15.438 23.387 L 9.93 15.56 1.57 3.73 1505 1144 
DNB-Pro (rac.) 1.412 15.760 16.960 D 10.16 11.01 1.08 0.68 1589 1182 
FMOC-Aze (rac.) 1.412 12.535 13.592 L 7.88 8.62 1.10 0.80 1664 1445 
DBTAMME (rac.) 1.412 16.306 18.905 R,R 10.55 12.39 1.17 1.58 1835 1812 
DNZ-Gly 1.412 28.428 /// /// 19.13 /// /// /// 1523 /// 
Hydroxyphenyllactic acid (rac.) 1.412 19.994 21.916 /// 13.16 14.52 1.10 0.81 1311 1181 
Flurbiprofen (rac.) 1.412 7.614 7.614 /// 4.39 4.39 1.00 0.00 1619 1619 
Trp (rac.) 1.412 2.377 2.377 /// 0.68 0.68 1.00 0.00 1212 1212 
QN/QD (2:1) 1.412 1.695 1.695 /// 0.20 0.20 1.00 0.00 1061 1061 
Clenbuterol.HCl (rac.) 1.412 1.387 1.387 /// -0.02 -0.02 1.00 0.00 1140 1140 
PI-2-56-2 1.412 17.502 18.835 /// 11.39 12.34 1.08 0.56 1066 830 
PI-2-15-1 1.412 10.197 14.674 /// 6.22 9.39 1.51 3.51 1625 1422 
P-DML-ACHSA (S,S>R,R) 1.412 10.505 11.120 S,S 6.44 6.87 1.07 0.60 1439 2179 
P-DCL-ACHSA (S,S>R,R) 1.412 17.645 18.402 S,S 11.49 12.03 1.05 0.42 1187 2012 
 
 
 
 
Table XIV: Column 12 (75x4 mm ID, 490 µmol/g, DHQD-type CSP; injection volume: 5 µL; 
sample concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; 
mobile phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C). 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
PFB-Leu (rac.) 0.705 2.385 2.385 /// 2.38 2.38 1.00 0.00 1144 1144 
DCB-Leu (rac.) 0.705 3.338 6.535 L 3.73 8.27 2.21 5.30 1211 936 
DNB-N-Me-Leu (rac.) 0.705 8.072 8.072 /// 10.45 10.45 1.00 0.00 500 500 
Ac-Phe (rac.) 0.705 3.026 3.983 L 3.29 4.65 1.41 2.29 1158 1100 
Z-Phe (rac.) 0.705 5.887 6.425 L 7.35 8.11 1.10 0.79 1363 1270 
Phe (rac.) 0.705 0.815 0.815 /// 0.16 0.16 1.00 0.00 642 642 
DNZ-Val (D>L) 0.705 7.536 11.353 L 9.69 15.10 1.56 3.13 1071 853 
DNB-Pro (rac.) 0.705 7.662 8.223 D 9.87 10.66 1.08 0.59 1328 922 
FMOC-Aze (rac.) 0.705 6.315 6.825 L 7.96 8.68 1.09 0.65 1266 1011 
DBTAMME (rac.) 0.705 6.796 7.878 R,R 8.64 10.17 1.18 1.24 1139 1107 
DNZ-Gly 0.705 13.213 /// /// 17.74 /// /// /// 1049 /// 
Hydroxyphenyllactic acid (rac.) 0.705 9.321 10.187 /// 12.22 13.45 1.10 0.68 991 883 
Flurbiprofen (rac.) 0.705 3.411 3.411 /// 3.84 3.84 1.00 0.00 1113 1113 
Trp (rac.) 0.705 1.043 1.043 /// 0.48 0.48 1.00 0.00 860 860 
QN/QD (2:1) 0.705 0.656 0.656 /// -0.07 -0.07 1.00 0.00 624 624 
Clenbuterol.HCl (rac.) 0.705 0.566 0.566 /// -0.20 -0.20 1.00 0.00 651 651 
PI-2-56-2 0.705 7.655 8.201 /// 9.86 10.63 1.08 0.48 929 630 
PI-2-15-1 0.705 4.173 5.995 /// 4.92 7.50 1.53 2.78 1016 909 
P-DML-ACHSA (S,S>R,R) 0.705 5.356 5.356 /// 6.60 6.60 1.00 0.00 557 557 
P-DCL-ACHSA (S,S>R,R) 0.705 9.065 9.065 /// 11.86 11.86 1.00 0.00 598 598 
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Table XV: Column 13 (150x4 mm ID, app. 340 µmol/g, QN-AX type CSP; injection volume: 5 µL; 
sample concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; 
mobile phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C): 
different t0-values derive from different positions of the column in the column compartment. 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
Bz-Leu (L>D) 1.431 3.787 7.650 D 1.65 4.35 2.64 10.59 3957 3906 
PFB-Leu (rac.) 1.431 3.640 5.550 D 1.54 2.88 1.86 6.52 4016 3851 
A-DCL-Leu (rac.) 1.426 4.628 34.770 D 2.25 23.38 10.41 26.28 3787 5654 
DNB-Leu (rac.) 1.426 5.898 75.109 D 3.14 51.67 16.48 24.87 3841 2940 
DCB-Leu (rac.) 1.426 4.889 31.016 D 2.43 20.75 8.54 21.36 3976 2919 
BTFMB-Leu (rac.) 1.426 3.178 17.217 D 1.23 11.07 9.01 21.22 3925 3680 
DNB-N-Me-Leu (rac.) 1.431 6.709 7.272 D 3.69 4.08 1.11 1.13 2639 3716 
Ac-Phe (rac.) 1.431 4.282 5.758 D 1.99 3.02 1.52 4.73 4142 4133 
Z-Phe (rac.) 1.431 6.844 8.236 D 3.78 4.76 1.26 2.60 3213 3137 
Phe (rac.) 1.431 1.632 1.632 /// 0.14 0.14 1.00 0.00 1124 1124 
DNZ-Phe (D>L) 1.426 1.733 1.823 D 0.22 0.28 1.29 0.87 3114 6432 
BOC-Phe (rac.) 1.431 4.424 5.255 D 2.09 2.67 1.28 2.76 4214 4073 
FMOC-β-Phe (rac.) 1.431 4.998 6.255 D 2.49 3.37 1.35 3.33 3570 3536 
Z-β-Phe (rac.) 1.431 3.731 4.066 D 1.61 1.84 1.15 1.32 3502 4103 
Bz-Phe (D>L) 1.431 6.053 10.457 D 3.23 6.31 1.95 8.38 4056 3844 
Phenyl-Gly (rac.) 1.431 1.631 1.631 /// 0.14 0.14 1.00 0.00 997 997 
DNZ-Val (D>L) 1.431 6.656 19.382 D 3.65 12.54 3.44 14.90 3962 3471 
BOC-Tyr (rac.) 1.431 4.919 6.051 D 2.44 3.23 1.32 2.78 2963 2843 
Ac-Trp (rac.) 1.431 6.381 10.614 D 3.46 6.42 1.86 7.37 3743 3270 
FMOC-Asn (rac.) 1.431 9.141 11.825 D 5.39 7.26 1.35 3.71 3403 3322 
DNB-Pro (rac.) 1.431 7.106 7.106 /// 3.97 3.97 1.00 0.00 2157 2157 
FMOC-Ile (L>D) 1.431 5.567 10.942 D 2.89 6.65 2.30 9.67 3639 3415 
FMOC-Gln (rac.) 1.431 1.529 1.529 /// 0.07 0.07 1.00 0.00 808 808 
Z-Ser (rac.) 1.431 6.267 7.338 D 3.38 4.13 1.22 2.51 4057 4062 
FMOC-Pro (L>D) 1.431 5.979 6.269 D 3.18 3.38 1.06 0.75 4390 3727 
FMOC-Aze (rac.) 1.431 7.207 7.207 /// 4.04 4.04 1.00 0.00 1954 1954 
DBTAMME (rac.) 1.431 6.766 7.210 S,S 3.73 4.04 1.08 1.01 3726 4370 
Trolox (rac.) 1.431 4.538 4.820 S 2.17 2.37 1.09 0.97 3830 4402 
Ibuprofen (rac) 1.431 2.637 2.637 /// 0.84 0.84 1.00 0.00 2359 2359 
Naproxen (rac.) 1.431 3.746 3.971 S 1.62 1.77 1.10 1.00 4428 4931 
DNP-Mandelic acid (rac.) 1.426 16.935 71.793 R 10.88 49.35 4.54 17.67 3741 2796 
Acetylmandelic acid (rac.) 1.431 5.919 6.332 S 3.14 3.42 1.09 1.15 4469 4864 
Phenylbutyric acid (rac.) 1.431 2.659 2.738 S 0.86 0.91 1.06 0.58 5001 7443 
TMB-Ala (rac.) 1.426 4.564 14.036 /// 2.20 8.84 4.02 15.15 3383 3693 
Bz-ACHSA (rac.) 1.431 5.272 8.853 /// 2.68 5.19 1.93 8.17 4239 4063 
MFQ.HCl (rac.) 1.431 1.292 1.292 /// -0.10 -0.10 1.00 0.00 1994 1994 
BOC-Gly 1.431 1.498 /// /// 0.05 /// /// /// 719 /// 
DNZ-Gly 1.431 11.356 /// /// 6.94 /// /// /// 3993 /// 
Vanillylmandelic acid (rac.) 1.431 9.477 9.477 /// 5.62 5.62 1.00 0.00 1859 1859 
Nitrophenylpropionic acid (rac.) 1.431 5.086 5.574 /// 2.55 2.90 1.13 1.59 4844 4854 
Hydroxyphenyllactic acid (rac.) 1.426 9.986 11.403 /// 6.00 7.00 1.17 1.24 1441 1362 
Tropic acid (rac.) 1.431 3.649 3.649 /// 1.55 1.55 1.00 0.00 2295 2295 
Fenoprofen (rac.) 1.431 3.397 3.484 /// 1.37 1.43 1.04 0.52 4759 8547 
Dichlorprop (rac.) 1.431 7.424 8.728 /// 4.19 5.10 1.22 2.75 4527 4727 
Hydroxymandelic acid (rac.) 1.431 10.953 10.953 /// 6.65 6.65 1.00 0.00 1719 1719 
Atrolactic acid (rac.) 1.431 7.756 9.281 /// 4.42 5.49 1.24 2.30 2685 2609 
Carprofen (rac.) 1.431 4.938 5.449 /// 2.45 2.81 1.15 1.52 3818 3798 
FMOC-Abu (rac.) 1.431 6.025 9.873 /// 3.21 5.90 1.84 6.98 3093 3558 
Flurbiprofen (rac.) 1.431 3.909 4.171 /// 1.73 1.91 1.11 1.04 3803 4406 
Bz-β-Phe (rac.) 1.431 3.935 5.672 /// 1.75 2.96 1.69 5.58 3818 3788 
Z-Leu (rac.) 1.431 4.101 4.935 /// 1.87 2.45 1.31 2.93 3924 4164 
Z-Arg (L>D) 1.431 2.005 2.186 D 0.40 0.53 1.32 1.17 2983 2855 
Trp (rac.) 1.431 1.852 2.115 D 0.29 0.48 1.62 1.46 2275 1617 
Tyr (rac.) 1.431 1.529 1.764 D 0.07 0.23 3.40 1.22 1009 1329 
QN/QD (2:1) 1.431 1.331 1.331 /// -0.07 -0.07 1.00 0.00 1511 1511 
Clenbuterol.HCl (rac.) 1.431 1.222 1.222 /// -0.15 -0.15 1.00 0.00 2145 2145 
PI-2-56-2 1.431 10.945 11.932 /// 6.65 7.34 1.10 0.88 1733 1616 
PI-2-4-3 1.431 8.979 17.953 /// 5.27 11.55 2.19 9.56 3425 3156 
PI-2-25-1 1.431 6.877 8.701 /// 3.81 5.08 1.33 3.33 3309 3169 
PI-2-34-1 1.431 5.193 5.441 /// 2.63 2.80 1.07 0.77 3757 4860 
PI-3-67-1 1.426 6.512 7.306 /// 3.57 4.12 1.16 1.48 2525 2791 
PI-1-89-1 1.431 8.113 9.945 /// 4.67 5.95 1.27 2.73 2887 2904 
PI-2-15-1 1.431 5.546 8.738 /// 2.88 5.11 1.78 6.47 3483 3215 
PI-2-38-1 1.431 5.298 5.767 /// 2.70 3.03 1.12 1.31 3744 3909 
PI-2-87-1 1.426 5.216 5.216 /// 2.66 2.66 1.00 0.00 2727 2727 
P-DML-ACHSA (S,S>R,R) 1.426 4.574 9.802 R,R 2.21 5.87 2.66 10.82 3472 3608 
P-DCL-ACHSA (S,S>R,R) 1.426 5.902 23.413 R,R 3.14 15.42 4.91 17.12 3832 2738 
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Table XVI: Column 14 (150x4 mm ID, app. 340 µmol/g, QD-AX type CSP; injection volume: 5 µL; 
sample concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; 
mobile phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C): 
different t0-values derive from different positions of the column in the column compartment. 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
Bz-Leu (L>D) 1.432 3.425 7.118 L 1.39 3.97 2.85 12.51 5099 5109 
PFB-Leu (rac.) 1.432 3.354 5.034 L 1.34 2.52 1.87 7.08 5058 4945 
A-DCL-Leu (rac.) 1.384 4.426 30.799 L 2.20 21.25 9.67 25.32 4482 4670 
DNB-Leu (rac.) 1.384 5.724 54.488 L 3.14 38.37 12.24 26.44 4735 3790 
DCB-Leu (rac.) 1.384 4.504 26.209 L 2.25 17.94 7.96 24.54 4600 5046 
BTFMB-Leu (rac.) 1.384 2.896 14.663 L 1.09 9.59 8.78 21.59 4263 4044 
DNB-N-Me-Leu (rac.) 1.432 7.492 7.894 L 4.23 4.51 1.07 0.78 4073 3111 
Ac-Phe (rac.) 1.432 3.889 5.580 L 1.72 2.90 1.69 6.52 5130 5543 
Z-Phe (rac.) 1.432 6.400 8.367 L 3.47 4.84 1.40 4.85 5337 5285 
Phe (rac.) 1.432 1.606 1.606 /// 0.12 0.12 1.00 0.00 1714 1714 
DNZ-Phe (D>L) 1.384 1.825 1.825 /// 0.32 0.32 1.00 0.00 3630 3630 
BOC-Phe (rac.) 1.432 4.181 5.281 L 1.92 2.69 1.40 4.12 5093 4960 
FMOC-β-Phe (rac.) 1.432 4.774 6.879 L 2.33 3.80 1.63 6.13 4717 4502 
Z-β-Phe (rac.) 1.432 3.576 4.269 L 1.50 1.98 1.32 3.10 4887 4965 
Bz-Phe (D>L) 1.432 5.587 10.260 L 2.90 6.16 2.12 10.62 5337 5039 
Phenyl-Gly (rac.) 1.432 1.593 1.593 /// 0.11 0.11 1.00 0.00 1107 1107 
DNZ-Val (D>L) 1.432 6.044 16.817 L 3.22 10.74 3.34 16.53 5188 4656 
BOC-Tyr (rac.) 1.432 4.451 5.685 L 2.11 2.97 1.41 4.17 4807 4590 
Ac-Trp (rac.) 1.432 5.577 8.467 L 2.89 4.91 1.70 6.93 4458 4620 
FMOC-Asn (rac.) 1.432 7.914 9.679 L 4.53 5.76 1.27 3.26 4050 4406 
DNB-Pro (rac.) 1.432 7.047 7.047 /// 3.92 3.92 1.00 0.00 2318 2318 
FMOC-Ile (L>D) 1.432 4.989 10.009 L 2.48 5.99 2.41 11.12 4575 4252 
FMOC-Gln (rac.) 1.432 1.543 1.543 /// 0.08 0.08 1.00 0.00 954 954 
Z-Ser (rac.) 1.432 5.626 7.000 L 2.93 3.89 1.33 3.96 5300 5277 
FMOC-Pro (L>D) 1.432 5.473 6.017 L 2.82 3.20 1.13 1.52 4382 3828 
FMOC-Aze (rac.) 1.432 6.600 7.156 L 3.61 4.00 1.11 1.38 4725 4587 
DBTAMME (rac.) 1.432 6.726 7.056 R,R 3.70 3.93 1.06 0.88 5900 4978 
Trolox (rac.) 1.432 4.003 4.227 S 1.80 1.95 1.09 0.99 5681 4930 
Ibuprofen (rac) 1.432 2.460 2.514 R,R 0.72 0.76 1.05 0.48 9898 5815 
Naproxen (rac.) 1.432 3.479 3.645 R,R 1.43 1.55 1.08 0.90 6639 5313 
DNP-Mandelic acid (rac.) 1.384 16.229 39.637 S 10.73 27.64 2.58 12.70 3701 3646 
Acetylmandelic acid (rac.) 1.384 5.360 5.360 /// 2.87 2.87 1.00 0.00 3172 3172 
Phenylbutyric acid (rac.) 1.432 2.433 2.503 R,R 0.70 0.75 1.07 0.60 8727 5661 
TMB-Ala (rac.) 1.384 4.236 13.261 /// 2.06 8.58 4.16 17.15 4520 4327 
Bz-ACHSA (rac.) 1.432 5.392 10.124 /// 2.77 6.07 2.19 11.41 5720 5480 
MFQ.HCl (rac.) 1.432 1.231 1.231 /// -0.14 -0.14 1.00 0.00 2677 2677 
BOC-Gly 1.432 1.466 /// /// 0.02 /// /// /// 749 /// 
DNZ-Gly 1.432 10.707 /// /// 6.48 /// /// /// 5439 /// 
Vanillylmandelic acid (rac.) 1.432 7.216 7.216 /// 4.04 4.04 1.00 0.00 1747 1747 
Nitrophenylpropionic acid (rac.) 1.432 4.841 5.093 /// 2.38 2.56 1.07 1.03 6877 6187 
Hydroxyphenyllactic acid (rac.) 1.432 6.980 7.540 /// 3.87 4.27 1.10 1.25 4360 3997 
Tropic acid (rac.) 1.432 3.370 3.524 /// 1.35 1.46 1.08 0.87 6855 5398 
Fenoprofen (rac.) 1.432 3.286 3.286 /// 1.29 1.29 1.00 0.00 2861 2861 
Dichlorprop (rac.) 1.432 6.792 8.569 /// 3.74 4.98 1.33 4.46 5976 5890 
Hydroxymandelic acid (rac.) 1.432 7.850 7.850 /// 4.48 4.48 1.00 0.00 2325 2325 
Atrolactic acid (rac.) 1.432 6.719 6.719 /// 3.69 3.69 1.00 0.00 2820 2820 
Carprofen (rac.) 1.432 4.595 4.951 /// 2.21 2.46 1.11 1.30 4951 4704 
FMOC-Abu (rac.) 1.432 5.433 8.980 /// 2.79 5.27 1.89 8.00 3937 4514 
Flurbiprofen (rac.) 1.384 3.854 4.040 /// 1.78 1.92 1.08 0.87 6158 4846 
Bz-β-Phe (rac.) 1.432 3.690 6.333 /// 1.58 3.42 2.17 9.25 4994 4856 
Z-Leu (rac.) 1.432 3.712 4.706 /// 1.59 2.29 1.44 4.20 5197 4927 
Z-Arg (L>D) 1.432 1.906 2.033 L 0.33 0.42 1.27 0.94 3626 3214 
Trp (rac.) 1.432 1.919 1.919 /// 0.34 0.34 1.00 0.00 1138 1138 
Tyr (rac.) 1.432 1.481 1.684 L 0.03 0.18 5.14 1.36 1417 2200 
QN/QD (2:1) 1.432 1.303 1.303 /// -0.09 -0.09 1.00 0.00 2016 2016 
Clenbuterol.HCl (rac.) 1.432 1.176 1.176 /// -0.18 -0.18 1.00 0.00 2426 2426 
PI-2-56-2 1.432 9.594 11.246 /// 5.70 6.85 1.20 2.10 2717 2896 
PI-2-4-3 1.432 9.849 20.274 /// 5.88 13.16 2.24 0.00 4458 4268 
PI-2-25-1 1.432 6.751 9.685 /// 3.71 5.76 1.55 5.74 4315 3963 
PI-2-34-1 1.432 4.829 5.593 /// 2.37 2.91 1.22 2.57 5028 4806 
PI-3-67-1 1.432 7.011 7.401 /// 3.90 4.17 1.07 0.92 4898 4441 
PI-1-89-1 1.432 8.753 11.074 /// 5.11 6.73 1.32 4.08 4927 4767 
PI-2-15-1 1.432 5.194 9.830 /// 2.63 5.86 2.23 10.19 4618 4105 
PI-2-38-1 1.432 4.876 5.645 /// 2.41 2.94 1.22 2.61 5152 5032 
PI-2-87-1 1.432 4.975 5.612 /// 2.47 2.92 1.18 2.12 5111 4803 
P-DML-ACHSA (S,S>R,R) 1.384 4.822 11.079 S,S 2.48 7.01 2.82 13.18 4553 4428 
P-DCL-ACHSA (S,S>R,R) 1.384 6.485 24.607 S,S 3.69 16.78 4.55 19.82 4466 4783 
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Table XVII: Column 16 (150x4 mm ID, 629 µmol/g, AzP-Silica type SP; injection volume: 5 µL; 
sample concentration: 1 mg/mL MeOH; flow rate: 1.0 mL/min; detection wavelength: 254 nm; 
mobile phase composition: MeOH/AcOH/NH4OAc 99/1/0.25 (v/v/w); temperature: 25°C). 
Analyte t0 [min.] tr1 [min.] tr2 [min.] EO k1 k2 α R N1 N2 
PFB-Leu (rac.) 1.650 1.417 1.417 /// -0.14 -0.14 1.00 0.00 4227 4227 
DCB-Leu (rac.) 1.650 1.458 1.458 /// -0.12 -0.12 1.00 0.00 4600 4600 
DNB-N-Me-Leu (rac.) 1.650 1.475 1.475 /// -0.11 -0.11 1.00 0.00 4307 4307 
Ac-Phe (rac.) 1.650 1.475 1.475 /// -0.11 -0.11 1.00 0.00 5188 5188 
Z-Phe (rac.) 1.650 1.544 1.544 /// -0.06 -0.06 1.00 0.00 5592 5592 
Phe (rac.) 1.650 1.502 1.502 /// -0.09 -0.09 1.00 0.00 3370 3370 
DNZ-Val (D>L) 1.650 1.478 1.478 /// -0.10 -0.10 1.00 0.00 3660 3660 
DNB-Pro (rac.) 1.650 1.486 1.486 /// -0.10 -0.10 1.00 0.00 4455 4455 
FMOC-Aze (rac.) 1.650 1.521 1.521 /// -0.08 -0.08 1.00 0.00 4206 4206 
DBTAMME (rac.) 1.650 1.465 1.465 /// -0.11 -0.11 1.00 0.00 3123 3123 
DNZ-Gly 1.650 1.484 1.484 /// -0.10 -0.10 1.00 0.00 4279 4279 
Hydroxyphenyllactic acid (rac.) 1.650 1.433 1.433 /// -0.13 -0.13 1.00 0.00 3324 3324 
Flurbiprofen (rac.) 1.650 1.579 1.579 /// -0.04 -0.04 1.00 0.00 5249 5249 
Trp (rac.) 1.650 1.540 1.540 /// -0.07 -0.07 1.00 0.00 3601 3601 
QN/QD (2:1) 1.650 1.874 1.874 /// 0.14 0.14 1.00 0.00 5263 5263 
Clenbuterol.HCl (rac.) 1.650 1.631 1.631 /// -0.01 -0.01 1.00 0.00 5644 5644 
PI-2-56-2 1.650 1.476 1.476 /// -0.11 -0.11 1.00 0.00 4154 4154 
PI-2-15-1 1.650 1.504 1.504 /// -0.09 -0.09 1.00 0.00 4652 4652 
P-DML-ACHSA (S.S>R.R) 1.650 1.499 1.499 /// -0.09 -0.09 1.00 0.00 4959 4959 
P-DCL-ACHSA (S.S>R.R) 1.650 1.475 1.475 /// -0.11 -0.11 1.00 0.00 4527 4527 
 
 
 
 
Table XVIII: Loading study Column 12 (75x4 mm ID, 490 µmol/g, DHQD-type CSP; injection 
volume: 5-100 µL (0.5-10 mg); sample concentration: 100 mg/mL Ac-Phe in MeOH; flow rate: 
0.5 mL/min; detection wavelength: 270 nm; mobile phase composition: MeOH/AcOH/NH4OAc 
99/1/0.25 (v/v/w); temperature: 25°C) and Column 15 (75x4 mm ID, app. 340 µmol/g, QD-AX type 
CSP); injection volume: 5-100 µL (0.5-10 mg); sample concentration: 100 mg/mL Ac-Phe in 
MeOH; flow rate: 0.5 mL/min; detection wavelength: 270 nm; mobile phase composition: 
MeOH/AcOH/NH4OAc 99.46/0.43/0.11 (v/v/w); temperature: 25°C). 
Column Inj. Vol. [µL] Inj. Mass [mg] t0 [min.] tr1 [min.] tr2 [min.] k1 k2 α R N1 N2 
12
 
5 0.5 1.459 6.260 8.049 3.29 4.52 1.373 2.012 1231 841 
8 0.8 1.459 6.171 7.900 3.23 4.42 1.367 1.745 983 631 
10 1.0 1.459 6.025 7.698 3.13 4.28 1.366 1.564 804 513 
12 1.2 1.459 6.016 7.683 3.12 4.27 1.366 1.472 714 456 
14 1.4 1.459 5.958 7.606 3.08 4.21 1.366 1.369 620 396 
16 1.6 1.459 5.889 7.511 3.04 4.15 1.366 1.285 552 349 
18 1.8 1.459 5.822 7.422 2.99 4.09 1.367 1.217 494 318 
20 2.0 1.459 5.758 7.337 2.95 4.03 1.367 1.146 439 283 
22 2.2 1.459 5.691 7.251 2.90 3.97 1.369 1.079 388 253 
24 2.4 1.459 5.634 7.187 2.86 3.93 1.372 1.034 352 231 
25 2.5 1.459 5.522 7.025 2.79 3.82 1.370 0.944 317 180 
30 3.0 1.459 5.475 6.966 2.75 3.78 1.371 0.788 264 82 
50 5.0 1.459 4.933 6.207 2.38 3.26 1.367 0.533 118 55 
60 6.0 1.459 4.742 5.923 2.25 3.06 1.360 0.472 104 42 
70 7.0 1.459 4.571 5.679 2.13 2.89 1.356 0.458 113 31 
80 8.0 1.459 4.382 5.383 2.00 2.69 1.342 0.451 131 23 
90 9.0 1.459 4.242 5.173 1.91 2.55 1.334 0.449 146 19 
100 10.0 1.459 4.109 4.970 1.82 2.41 1.325 0.449 162 17 
15
 
5 0.5 1.565 5.915 8.230 2.78 4.26 1.532 3.526 2532 1183 
10 1.0 1.565 5.689 7.835 2.64 4.01 1.520 2.276 1067 579 
20 2.0 1.565 5.288 7.296 2.38 3.66 1.539 1.418 356 276 
25 2.5 1.565 5.120 7.080 2.27 3.52 1.551 1.206 249 202 
30 3.0 1.565 4.977 6.897 2.18 3.41 1.563 1.051 187 151 
40 4.0 1.565 4.699 6.540 2.00 3.18 1.587 0.836 117 92 
50 5.0 1.565 4.450 6.240 1.84 2.99 1.620 0.693 78 59 
60 6.0 1.565 4.233 5.938 1.70 2.79 1.639 0.585 58 39 
70 7.0 1.565 4.220 5.602 1.70 2.58 1.521 0.462 57 29 
80 8.0 1.565 3.832 5.291 1.45 2.38 1.644 0.504 55 25 
90 9.0 1.565 3.658 4.882 1.34 2.12 1.585 0.442 60 16 
100 10.0 1.565 3.492 4.636 1.23 1.96 1.594 0.456 71 13 
 	  	  
